



COMPREHENSIVE FORMULARY

(List of Covered Drugs)

Formulary 25410 Version 18

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT
THE DRUGS WE COVER IN THIS PLAN**

2025



This formulary was updated on 02/19/2025. For more recent information or other questions, please contact Leon Health's Member Services at 1-844-969-5366 (TTY users should call 711). From October to March, we are open seven days a week from 8 a.m. to 8 p.m.. From April to September, we are open Monday – Friday from 8 a.m. to 8 p.m., or visit www.leonhealth.com.

H4286_2025FORMULARY_C

Leon Health, Inc.

Leon MediExtra, Leon MediDual, Leon MediMore, Leon

MediPlus, and Leon MediMax

2025 Formulary

List of Covered Drugs

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN**

Formulary ID 25410, Version 18

This formulary was updated on 02/19/2025. For more recent information or other questions, please contact Leon Health, Inc. Member Service at 844-9-MY-LEON (1-844-969-5366) or local at 305-541-LEON (305-541-5366) (TTY users should call 711), hours are from 8 a.m. to 8 p.m., seven days a week from October 1st through March 31st and Monday through Friday from April 1st through September 30th or visit www.leonhealth.com.

Note to existing members: This Formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this Drug List (Formulary) refers to “we,” “us”, or “our,” it means Leon Health, Inc. When it refers to “plan” or “our plan,” it means Leon Health, Inc.

This document includes a Drug List (formulary) for our plan which is current as of March 1, 2025. For an updated Drug List (formulary), please contact us. Our contact information, along with the date we last updated the Drug List (formulary), appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January, 2025, and from time to time during the year.

What is the Leon Health, Inc. Formulary?

In this document, we use the terms Drug List and formulary to mean the same thing. A formulary is a list of covered drugs selected by Leon Health, Inc. in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. Leon Health, Inc. will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at a Leon Health, Inc. network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

Can the formulary change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the formulary during the year, move them to different cost-sharing tiers, or add new restrictions. We must

follow the Medicare rules in making these changes. Updates to the formulary are posted monthly to our website here: <https://www.leonhealth.com/plans-and-benefits/prescription-drug-benefits/>.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **Immediate substitutions of certain new versions of brand name drugs and original biological products.** We may immediately remove a drug from our formulary if we replace it with a certain new version of that drug that will appear on the same or lower cost-sharing tier and with the same or fewer restrictions. When we add a new version of a drug to our formulary, we may decide to keep the brand name drug or original biological product on our formulary, but immediately move it to a different cost-sharing tier or add new restrictions.
 - We can make these immediate changes only if we are adding a new generic version of a brand name drug or adding certain new biosimilar versions of an original biological product, that was already on the formulary (for example, adding an interchangeable biosimilar that can be substituted for an original biological product by a pharmacy without a new prescription).
 - If you are currently taking the brand name drug or original biological product, we may not tell you in advance before we make an immediate change, but we will later provide you with information about the specific change(s) we have made.
 - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover for you the drug that is being changed. For more information, see the section below titled “How do I request an exception to the Leon Health, Inc. Formulary?”
 - Some of these drug types may be new to you. For more information, see the section below titled “What are original biological products and how are they related to biosimilars?”
- **Drugs removed from the market.** If a drug is withdrawn from sale by the manufacturer or the Food and Drug Administration (FDA) determines to be withdrawn for safety or effectiveness reasons, we may immediately remove the drug from our formulary and later provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may remove a brand name drug from the formulary when adding a generic equivalent or remove an original biological product when adding a biosimilar. We may also apply new restrictions to the brand name drug or original biological product, or move it to a different cost-sharing tier, or both. We may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug, or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective.

Alternatively, when a member requests a refill of the drug, they may receive a 30-day supply of the drug and notice of the change.

- If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand-name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Leon Health, Inc.’s Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2025 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2025 coverage year except as described above. This means these drugs will remain available at the same cost sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the formulary for the new benefit year for any changes to drugs.

The enclosed formulary is current as of March 2025. To get updated information about the drugs covered by Leon Health, Inc. please contact us. Our contact information appears on the front and back pages. If there are significant changes made to the printed drug list within the covered year, you may be notified by mail identifying the changes. Drug lists located on our website are reviewed and updated monthly. You can visit <https://www.leonhealth.com/plans-and-benefits/prescription-drug-benefits/>

How do I use the Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 12. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, cardiovascular agents. If you know what your drug is used for, look for the category name in the list that begins on page 10. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 145. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

Leon Health, Inc. covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs work just as well as and usually cost less than brand name drugs. There are generic drug substitutes available for many brand name drugs. Generic drugs usually can be substituted for the brand name drug at the pharmacy without needing a new prescription, depending on state laws

What are original biological products and how are they related to biosimilars?

On the formulary, when we refer to drugs, this could mean a drug or a biological product. Biological products are drugs that are more complex than typical drugs. Since biological products are more complex than typical drugs, instead of having a generic form, they have alternatives that are called biosimilars. Generally, biosimilars work just as well as the original biological product and may cost less. There are biosimilar alternatives for some original biological products. Some biosimilars are interchangeable biosimilars and, depending on state laws, may be substituted for the original biological product at the pharmacy without needing a new prescription, just like generic drugs can be substituted for brand name drugs.

- For discussion of drug types, please see the Evidence of Coverage, Chapter 5, Section 3.1, “The ‘Drug List’ tells which Part D drugs are covered.”

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization (PA):** Leon Health, Inc. requires you [or your prescriber] to get prior authorization for certain drugs. This means that you will need to get approval from Leon Health, Inc. before you fill your prescriptions. If you don't get approval, Leon Health, Inc. may not cover the drug.
- **Quantity Limits (QL):** For certain drugs, Leon Health, Inc. limits the amount of the drug that Leon Health, Inc. will cover. For example, Leon Health, Inc. provides 30 tablets every 30 days per prescription for atorvastatin. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy (ST):** In some cases, Leon Health, Inc. requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, Leon Health, Inc. may not cover Drug B unless you try Drug A first. If Drug A does not work for you, Leon Health, Inc. will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 12. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online documents that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask Leon Health, Inc. to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, “How do I request an exception to the Leon Health, Inc.'s formulary?” on page 5 for information about how to request an exception.

What are over-the-counter (OTC) drugs?

OTC drugs are non-prescription drugs that are not normally covered by a Medicare Prescription Drug Plan. Leon Health, Inc. pays for certain OTC drugs. Leon Health, Inc. will provide these OTC drugs at no cost to you. The cost to Leon Health, Inc. of these OTC drugs will not count toward your total Part D drug costs (that is, the cost of the OTC drugs does not count for the coverage gap).

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Member Services and ask if your drug is covered. If you learn that Leon Health, Inc. does not cover your drug, you have two options:

- You can ask Member Services for a list of similar drugs that are covered by Leon Health, Inc. When you receive the list, show it to your doctor and ask them to prescribe a similar drug that is covered by Leon Health, Inc.
- You can ask Leon Health, Inc. to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to Leon Health, Inc.'s Formulary?

You can ask Leon Health, Inc. to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, Leon Health, Inc. limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.
- You can ask us to cover a formulary drug at lower cost-sharing level unless the drug is on the specialty tier.

Generally, Leon Health, Inc. will only approve your request for an exception if the alternative drugs included on the plan's formulary, [the lower cost-sharing drug, or applying the restriction would not be as effective for you and/or would cause you to have adverse effects.

You or your prescriber should contact us to ask for a tiering or, formulary exception, including an exception to a coverage restriction. **When you request an exception, your prescriber will need to explain the medical reasons why you need the exception.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can ask for an expedited (fast) decision if you believe, and we agree, that your health could be seriously harmed by waiting up to 72 hours for a decision. If we agree, or if your prescriber asks for a fast decision, we must give you a decision no later than 24 hours after we get your prescriber's supporting statement.

What can I do if my drug is not on the formulary or has a restriction?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but has a coverage restriction, such as prior

authorization. You should talk to your prescriber about requesting a coverage decision to show that you meet the criteria for approval, switching to an alternative drug that we cover, or requesting a formulary exception so that we will cover the drug you take. While you and your doctor determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or has a coverage restriction, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30-day supply of medication. If coverage is not approved, after your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

Current members that need a one-time emergency fill or that are prescribed a non-formulary drug as a result of a level of care change will be placed in transition and we will allow a one-time 31-day supply (unless the prescription is written for fewer days). If you are admitted or readmitted into a Long-Term Care facility and you need a medication that is not on our drug list or has a limitation, you will be eligible to receive a 31-day emergency supply of that drug while you pursue a drug list exception or prior authorization.

For more information

For more detailed information about your Leon Health, Inc. prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about Leon Health, Inc., please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/7 days a week. TTY users should call 1-877-486-2048. Or, visit <http://www.medicare.gov>.

Leon Health, Inc. Formulary

The formulary below provides coverage information about the drugs covered by Leon Health, Inc. If you have trouble finding your drug in the list, turn to the Index that begins on page 145.

The first column of the chart lists the drug name. Brand-name drugs are capitalized (e.g., XIFAXAN) and generic drugs are listed in lower-case italics (e.g., *vancomycin*).

The information in the Requirements/Limits column tells you if Leon Health, Inc. has any special requirements for coverage of your drug.

Leon MediDual (HMO D-SNP) and Leon Medimax (HMO D-SNP)

| Tier | Preferred retail cost sharing (30-day supply) | Standard retail cost sharing (30-day supply) |
|-----------------------------------|---|--|
| Tier 1: Generic Drugs | \$0-\$4.90 copay | \$0-\$4.90 copay |
| Tier 2: Preferred Brand Drugs | \$0-\$12.15 copay | \$0-\$12.15 copay |
| Tier 3: Non-Preferred Brand Drugs | \$0-\$12.15 copay | \$0-\$12.15 copay |
| Tier 4: Specialty Tier | \$0-\$12.15 copay | \$0-\$12.15 copay |
| Tier 5: Supplemental Drugs | \$0 copay | \$10 copay |

You pay **\$0 - \$35** for a one-month supply of each covered insulin product regardless of the cost-sharing tier for preferred and standard retail pharmacies.

Leon MediExtra (HMO)

| Tier | Preferred retail cost sharing (30-day supply) | Standard retail cost sharing (30-day supply) |
|-----------------------------------|---|--|
| Tier 1: Generic Drugs | \$0 copay | \$5 copay |
| Tier 2: Preferred Brand Drugs | \$0 copay | \$20 copay |
| Tier 3: Non-Preferred Brand Drugs | \$40 copay | \$50 copay |
| Tier 4: Specialty Tier | 33% coinsurance | 33% coinsurance |
| Tier 5: Supplemental Drugs | \$0 copay | \$10 copay |

You pay no more than **\$35** for a one-month supply of each covered insulin product regardless of the cost-sharing tier for preferred and standard retail pharmacies.

Leon MediMore (HMO)

| Tier | Preferred retail cost sharing (30-day supply) | Standard retail cost sharing (30-day supply) |
|-----------------------------------|---|--|
| Tier 1: Generic Drugs | \$0 copay | \$10 copay |
| Tier 2: Preferred Brand Drugs | \$30 copay | \$40 copay |
| Tier 3: Non-Preferred Brand Drugs | \$40 copay | \$50 copay |
| Tier 4: Specialty Tier | 33% coinsurance | 33% coinsurance |
| Tier 5: Supplemental Drugs | \$0 copay | \$10 copay |

You pay no more than **\$35** for a one-month supply of each covered insulin product regardless of the cost-sharing tier for preferred and standard retail pharmacies.

Leon MediPlus (HMO)

| Tier | Preferred retail cost sharing (30-day supply) | Standard retail cost sharing (30-day supply) |
|-----------------------------------|---|--|
| Tier 1: Generic Drugs | \$0 copay | \$5 copay |
| Tier 2: Preferred Brand Drugs | \$40 copay | \$47 copay |
| Tier 3: Non-Preferred Brand Drugs | \$60 copay | \$70 copay |
| Tier 4: Specialty Tier | 33% coinsurance | 33% coinsurance |
| Tier 5: Supplemental Drugs | \$0 copay | \$10 copay |

You pay no more than **\$35** for a one-month supply of each covered insulin product regardless of the cost-sharing tier for preferred and standard retail pharmacies.

Leon Health, Inc. is an HMO with a Medicare contract. Enrollment in Leon Health, Inc. depends on contract renewal.

Leon Health, Inc. uses preferred network pharmacies. See your Provider and Pharmacy Directory or visit www.leonhealth.com to search for a preferred retail pharmacy near you.

Leon Health Inc.'s pharmacy network offers limited access to pharmacies with preferred cost sharing in Miami-Dade, FL. The lower costs advertised in our plan materials for these pharmacies may not be available at the pharmacy you use. For up-to-date information about our network pharmacies, including pharmacies with preferred cost sharing, please call 1-844-969-5366 (TTY: 711) or consult the online Provider and Pharmacy Directory at www.LeonHealth.com/

Symbols and Abbreviations:

- EX - This prescription drug is not normally covered in a Medicare Prescription Drug Plan. The amount you pay when you fill a prescription for this drug does not count towards your total drug costs (that is, the amount you pay does not help you qualify for catastrophic coverage). In addition, if you are receiving extra help to pay for your prescriptions, you will not get any extra help to pay for this drug.
- CB - Capped Benefit Limit (this drug has a specified limit amount per month and does not allow early refill).
- LA - This prescription may be available only at certain pharmacies. For more information consult your Pharmacy Directory or call Member Services at 1-844-969-5366 from 8 a.m. to 8 p.m., Monday through Friday, or visit www.leonhealth.com. TTY users should call 711.
- GC - We provide additional coverage of this prescription drug in the coverage gap. Please refer to our Evidence of Coverage for more information about this coverage.
- HI - This prescription drug may be covered under our medical benefit. For more information, call Member Services at 1-844-969-5366, or local at 305-541-LEON (305-541-5366) from 8 a.m. to 8 p.m., Monday through Friday. TTY users should call 711, seven days a week from October 1st through March 31st and Monday through Friday from April 1st through September 30th or visit www.leonhealth.com.
- PA NSO - New Starts Only (this would only apply to patients newly started on this drug).
- PA - This drug requires prior authorization.
- PA BvD - The decision process required determine whether or not a specific prescription should be covered as a Part B or a Part D benefit.
- QL - This drug has quantity limits.
- ST - This drug has step therapy requirements.
- NDS - Non-Extended Days' Supply.

Table of Contents

| | |
|--|----|
| Analgesics | 12 |
| Anesthetics | 15 |
| Anti-Addiction/Substance Abuse Treatment Agents | 15 |
| Antianxiety Agents | 16 |
| Antibacterials | 17 |
| Anticancer Agents | 22 |
| Anticonvulsants | 30 |
| Antidementia Agents | 33 |
| Antidepressants | 34 |
| Antidiabetic Agents | 36 |
| Antifungals | 40 |
| Antigout Agents | 42 |
| Antihistamines | 42 |
| Anti-Infectives (Skin And Mucous Membrane) | 42 |
| Antimigraine Agents | 42 |
| Antimycobacterials | 43 |
| Antinausea Agents | 44 |
| Antiparasite Agents | 44 |
| Antiparkinsonian Agents | 45 |
| Antipsychotic Agents | 46 |
| Antivirals (Systemic) | 50 |
| Blood Products/Modifiers/Volume Expanders | 54 |
| Caloric Agents | 57 |
| Cardiovascular Agents | 58 |
| Central Nervous System Agents | 66 |
| Contraceptives | 69 |
| Cough And Cold Products | 73 |

| | |
|---|-----|
| Dental And Oral Agents | 73 |
| Dermatological Agents | 73 |
| Devices | 77 |
| Enzyme Replacement/Modifiers | 112 |
| Eye, Ear, Nose, Throat Agents | 113 |
| Gastrointestinal Agents | 116 |
| Genitourinary Agents | 119 |
| Heavy Metal Antagonists | 120 |
| Hormonal Agents, Stimulant/Replacement/Modifying | 120 |
| Immunological Agents | 124 |
| Inflammatory Bowel Disease Agents | 132 |
| Metabolic Bone Disease Agents | 133 |
| Miscellaneous Therapeutic Agents | 134 |
| Ophthalmic Agents | 135 |
| Replacement Preparations | 136 |
| Respiratory Tract Agents | 137 |
| Skeletal Muscle Relaxants | 141 |
| Sleep Disorder Agents | 141 |
| Vasodilating Agents | 142 |
| Vitamins And Minerals | 142 |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| Analgesics | | |
| Analgesics, Miscellaneous | | |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | 1 | QL (4500 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg</i> | 1 | QL (360 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i> | 1 | QL (180 per 30 days) |
| <i>ascomp with codeine oral capsule 30-50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>buprenorphine transdermal patch weekly 10 mcg/hour, 15 mcg/hour, 20 mcg/hour, 5 mcg/hour, 7.5 mcg/hour</i> | 1 | QL (4 per 28 days) |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg</i> | 1 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen oral tablet 50-325 mg</i> | 1 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen-caff oral capsule 50-300-40 mg, 50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>butalbital-aspirin-caffeine oral capsule 50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>butorphanol nasal spray, non-aerosol 10 mg/ml</i> | 1 | QL (5 per 28 days) |
| <i>codeine sulfate oral tablet 60 mg</i> | 1 | QL (180 per 30 days) |
| <i>codeine-butalbital-asa-caff oral capsule 30-50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>endocet oral tablet 10-325 mg</i> | 1 | QL (180 per 30 days) |
| <i>endocet oral tablet 2.5-325 mg, 5-325 mg</i> | 1 | QL (360 per 30 days) |
| <i>endocet oral tablet 7.5-325 mg</i> | 1 | QL (240 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg</i> | 4 | PA; NDS; QL (120 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg</i> | 1 | PA; QL (120 per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | 1 | QL (10 per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i> | 1 | QL (2700 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------|
| <i>hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 7.5-300 mg, 7.5-325 mg</i> | 1 | QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 5-300 mg, 5-325 mg</i> | 1 | QL (240 per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg</i> | 1 | QL (150 per 30 days) |
| <i>hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml</i> | 1 | |
| <i>hydromorphone oral liquid 1 mg/ml</i> | 1 | QL (1200 per 30 days) |
| <i>hydromorphone oral tablet 2 mg, 4 mg, 8 mg</i> | 1 | QL (180 per 30 days) |
| <i>methadone oral tablet 10 mg</i> | 1 | QL (120 per 30 days) |
| <i>methadone oral tablet 5 mg</i> | 1 | QL (180 per 30 days) |
| <i>morphine concentrate oral solution 100 mg/5 ml (20 mg/ml)</i> | 1 | PA; QL (180 per 30 days) |
| <i>morphine oral solution 10 mg/5 ml</i> | 1 | QL (700 per 30 days) |
| <i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i> | 1 | QL (300 per 30 days) |
| MORPHINE ORAL TABLET 15 MG | 3 | NDS; QL (180 per 30 days) |
| MORPHINE ORAL TABLET 30 MG | 3 | NDS; QL (120 per 30 days) |
| <i>morphine oral tablet extended release 100 mg, 200 mg, 60 mg</i> | 1 | QL (60 per 30 days) |
| <i>morphine oral tablet extended release 15 mg, 30 mg</i> | 1 | QL (90 per 30 days) |
| <i>oxycodone oral capsule 5 mg</i> | 1 | QL (180 per 30 days) |
| <i>oxycodone oral concentrate 20 mg/ml</i> | 1 | PA; QL (120 per 30 days) |
| <i>oxycodone oral solution 5 mg/5 ml</i> | 1 | QL (1300 per 30 days) |
| <i>oxycodone oral tablet 10 mg, 5 mg</i> | 1 | QL (180 per 30 days) |
| <i>oxycodone oral tablet 15 mg, 20 mg, 30 mg</i> | 1 | QL (120 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i> | 1 | QL (180 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg</i> | 1 | QL (360 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 7.5-325 mg</i> | 1 | QL (240 per 30 days) |
| <i>oxymorphone oral tablet 10 mg</i> | 1 | QL (120 per 30 days) |
| <i>oxymorphone oral tablet 5 mg</i> | 1 | QL (180 per 30 days) |
| <i>tramadol oral tablet 50 mg</i> | 1 | QL (240 per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | 1 | QL (300 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 13.5 MG, 18 MG, 9 MG | 2 | QL (60 per 30 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 27 MG | 2 | QL (120 per 30 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 36 MG | 4 | NDS; QL (240 per 30 days) |
| Nonsteroidal Anti-Inflammatory Agents | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> | 1 | QL (60 per 30 days) |
| <i>diclofenac potassium oral tablet 50 mg</i> | 1 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet extended release 24 hr 100 mg</i> | 1 | QL (60 per 30 days) |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 25 mg</i> | 1 | QL (150 per 30 days) |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 50 mg</i> | 1 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 75 mg</i> | 1 | QL (60 per 30 days) |
| <i>diclofenac sodium topical drops 1.5 %</i> | 1 | QL (300 per 30 days) |
| <i>diclofenac sodium topical gel 3 %</i> | 1 | PA; QL (100 per 28 days) |
| <i>diclofenac sodium topical solution in metered-dose pump 20 mg/gram /actuation(2 %)</i> | 4 | PA; NDS; QL (224 per 28 days) |
| <i>diclofenac-misoprostol oral tablet,ir, delayed rel,biphasic 50-200 mg-mcg, 75-200 mg-mcg</i> | 1 | |
| <i>diflunisal oral tablet 500 mg</i> | 1 | |
| <i>ec-naproxen dr 500 mg tablet</i> | 1 | |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 1 | |
| <i>etodolac oral tablet 400 mg, 500 mg</i> | 1 | |
| <i>fenoprofen oral tablet 600 mg</i> | 1 | |
| <i>flurbiprofen oral tablet 100 mg</i> | 1 | |
| <i>ibu oral tablet 600 mg, 800 mg</i> | 1 | |
| <i>ibuprofen oral suspension 100 mg/5 ml</i> | 1 | |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | 1 | |
| <i>indomethacin oral capsule 25 mg</i> | 1 | QL (240 per 30 days) |
| <i>indomethacin oral capsule 50 mg</i> | 1 | QL (120 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------|
| <i>indomethacin oral capsule, extended release 75 mg</i> | 1 | QL (60 per 30 days) |
| <i>ketoprofen oral capsule 50 mg</i> | 1 | |
| <i>ketoprofen oral capsule,ext rel. pellets 24 hr 200 mg</i> | 1 | |
| <i>ketorolac oral tablet 10 mg</i> | 1 | QL (20 per 30 days) |
| <i>mefenamic acid oral capsule 250 mg</i> | 1 | |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | 1 | |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 1 | |
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i> | 1 | |
| <i>naproxen oral tablet,delayed release (dr/ec) 375 mg, 500 mg</i> | 1 | |
| <i>piroxicam oral capsule 10 mg, 20 mg</i> | 1 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 1 | |
| Anesthetics | | |
| Local Anesthetics | | |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | 1 | PA |
| <i>lidocaine topical adhesive patch,medicated 5 %</i> | 1 | PA; QL (90 per 30 days) |
| <i>lidocaine topical ointment 5 %</i> | 1 | PA; QL (90 per 30 days) |
| <i>lidocaine viscous mucous membrane solution 2 %</i> | 1 | |
| <i>lidocaine-prilocaine topical cream 2.5-2.5 %</i> | 1 | PA; QL (30 per 30 days) |
| Anti-Addiction/Substance Abuse Treatment Agents | | |
| Anti-Addiction/Substance Abuse Treatment Agents | | |
| <i>acamprosate oral tablet,delayed release (dr/ec) 333 mg</i> | 1 | |
| <i>buprenorphine hcl sublingual tablet 2 mg, 8 mg</i> | 1 | QL (90 per 30 days) |
| <i>buprenorphine-naloxone sublingual film 12-3 mg</i> | 1 | QL (60 per 30 days) |
| <i>buprenorphine-naloxone sublingual film 2-0.5 mg, 4-1 mg, 8-2 mg</i> | 1 | QL (90 per 30 days) |
| <i>buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg</i> | 1 | QL (90 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------|
| <i>bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg</i> | 1 | |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>naloxone injection solution 0.4 mg/ml</i> | 1 | |
| <i>naloxone injection syringe 0.4 mg/ml, 1 mg/ml</i> | 1 | |
| <i>naloxone nasal spray,non-aerosol 4 mg/actuation</i> | 1 | QL (4 per 30 days) |
| <i>naltrexone oral tablet 50 mg</i> | 1 | |
| NICOTROL INHALATION CARTRIDGE 10 MG | 3 | NDS |
| <i>varenicline tartrate oral tablet 0.5 mg, 1 mg, 1 mg (56 pack)</i> | 1 | QL (336 per 365 days) |
| <i>varenicline tartrate oral tablets,dose pack 0.5 mg (11)- 1 mg (42)</i> | 1 | |
| Antianxiety Agents | | |
| Benzodiazepines | | |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg</i> | 1 | QL (120 per 30 days) |
| <i>alprazolam oral tablet 2 mg</i> | 1 | QL (150 per 30 days) |
| <i>alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg</i> | 1 | QL (120 per 30 days) |
| <i>alprazolam oral tablet extended release 24 hr 3 mg</i> | 1 | QL (90 per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 1 | QL (120 per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> | 1 | QL (90 per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> | 1 | QL (300 per 30 days) |
| <i>clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 1 | QL (90 per 30 days) |
| <i>clonazepam oral tablet,disintegrating 2 mg</i> | 1 | QL (300 per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 1 | QL (180 per 30 days) |
| <i>diazepam intensol oral concentrate 5 mg/ml</i> | 1 | QL (1200 per 30 days) |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i> | 1 | QL (1200 per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i> | 1 | QL (120 per 30 days) |
| <i>estazolam oral tablet 1 mg</i> | 1 | QL (60 per 30 days) |
| <i>estazolam oral tablet 2 mg</i> | 1 | QL (30 per 30 days) |
| <i>lorazepam 2 mg/ml oral concent</i> | 1 | QL (150 per 30 days) |
| <i>lorazepam intensol oral concentrate 2 mg/ml</i> | 1 | QL (150 per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i> | 1 | QL (90 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| <i>lorazepam oral tablet 2 mg</i> | 1 | QL (150 per 30 days) |
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | 1 | QL (120 per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> | 1 | QL (30 per 30 days) |
| <i>triazolam oral tablet 0.125 mg</i> | 1 | QL (120 per 30 days) |
| <i>triazolam oral tablet 0.25 mg</i> | 1 | QL (60 per 30 days) |
| Antibacterials | | |
| Aminoglycosides | | |
| <i>amikacin injection solution 500 mg/2 ml</i> | 3 | NDS |
| ARIKAYCE INHALATION SUSPENSION FOR NEBULIZATION 590 MG/8.4 ML | 3 | NDS; QL (252 per 30 days) |
| <i>gentamicin injection solution 40 mg/ml</i> | 1 | |
| <i>neomycin oral tablet 500 mg</i> | 1 | |
| <i>streptomycin intramuscular recon soln 1 gram</i> | 4 | NDS |
| TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE 28 MG | 4 | NDS; QL (224 per 28 days) |
| <i>tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml</i> | 4 | PA BvD; NDS |
| <i>tobramycin sulfate injection solution 40 mg/ml</i> | 1 | |
| Antibacterials, Miscellaneous | | |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg</i> | 1 | |
| <i>clindamycin in 5 % dextrose intravenous piggyback 300 mg/50 ml</i> | 1 | PA BvD; HI |
| <i>clindamycin pediatric oral recon soln 75 mg/5 ml</i> | 1 | |
| <i>clindamycin phosphate injection solution 150 mg/ml</i> | 1 | PA BvD; HI |
| <i>colistin (colistimethate na) injection recon soln 150 mg</i> | 4 | PA BvD; HI; NDS |
| <i>daptomycin intravenous recon soln 500 mg</i> | 4 | NDS |
| <i>fosfomicin tromethamine oral packet 3 gram</i> | 1 | |
| <i>linezolid in dextrose 5% intravenous piggyback 600 mg/300 ml</i> | 1 | PA BvD; HI |
| <i>linezolid oral suspension for reconstitution 100 mg/5 ml</i> | 4 | NDS; QL (1800 per 30 days) |
| <i>linezolid oral tablet 600 mg</i> | 1 | |
| <i>methenamine hippurate oral tablet 1 gram</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| <i>metronidazole in nacl (iso-os) intravenous piggyback 500 mg/100 ml</i> | 1 | PA BvD; HI |
| <i>metronidazole oral tablet 125 mg, 250 mg, 500 mg</i> | 1 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | QL (120 per 30 days) |
| <i>nitrofurantoin monohyd/m-cryst oral capsule 100 mg</i> | 1 | QL (60 per 30 days) |
| <i>polymyxin b sulfate injection recon soln 500,000 unit</i> | 1 | PA BvD; HI |
| <i>trimethoprim oral tablet 100 mg</i> | 1 | |
| <i>vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg</i> | 1 | |
| <i>vancomycin oral capsule 125 mg</i> | 1 | QL (56 per 14 days) |
| <i>vancomycin oral capsule 250 mg</i> | 1 | QL (112 per 14 days) |
| <i>vancomycin oral recon soln 25 mg/ml</i> | 3 | NDS |
| XIFAXAN ORAL TABLET 200 MG | 3 | PA; NDS; QL (9 per 30 days) |
| XIFAXAN ORAL TABLET 550 MG | 4 | PA; NDS; QL (90 per 30 days) |
| Cephalosporins | | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>cefaclor oral suspension for reconstitution 250 mg/5 ml</i> | 1 | |
| <i>cefaclor oral tablet extended release 12 hr 500 mg</i> | 1 | |
| <i>cefadroxil oral capsule 500 mg</i> | 1 | |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml</i> | 1 | |
| <i>cefadroxil oral tablet 1 gram</i> | 1 | |
| <i>cefazolin injection recon soln 1 gram, 10 gram, 500 mg</i> | 1 | |
| <i>cefdinir oral capsule 300 mg</i> | 1 | |
| <i>cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 1 | |
| <i>cefepime injection recon soln 1 gram, 2 gram</i> | 1 | |
| <i>cefixime oral capsule 400 mg</i> | 1 | |
| <i>cefixime oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> | 1 | |
| <i>cefoxitin intravenous recon soln 1 gram, 10 gram, 2 gram</i> | 1 | PA BvD; HI |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------|
| <i>cefepodoxime oral suspension for reconstitution 100 mg/5 ml, 50 mg/5 ml</i> | 1 | |
| <i>cefepodoxime oral tablet 100 mg, 200 mg</i> | 1 | |
| <i>cefprozil oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 1 | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>ceftazidime injection recon soln 1 gram, 2 gram, 6 gram</i> | 1 | |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i> | 1 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>cefuroxime sodium injection recon soln 750 mg</i> | 1 | PA BvD; HI |
| <i>cefuroxime sodium intravenous recon soln 1.5 gram</i> | 1 | PA BvD; HI |
| <i>cephalexin oral capsule 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 1 | |
| <i>cephalexin oral tablet 250 mg, 500 mg</i> | 1 | |
| TEFLARO INTRAVENOUS RECON SOLN 400 MG, 600 MG | 4 | PA BvD; HI; NDS |
| Macrolides | | |
| <i>azithromycin intravenous recon soln 500 mg</i> | 1 | PA BvD; HI |
| <i>azithromycin oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> | 1 | |
| <i>azithromycin oral tablet 250 mg, 250 mg (6 pack), 500 mg, 500 mg (3 pack), 600 mg</i> | 1 | |
| <i>clarithromycin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 1 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>clarithromycin oral tablet extended release 24 hr 500 mg</i> | 1 | |
| DIFICID ORAL SUSPENSION FOR RECONSTITUTION 40 MG/ML | 4 | NDS; QL (136 per 10 days) |
| DIFICID ORAL TABLET 200 MG | 4 | NDS; QL (20 per 10 days) |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml, 400 mg/5 ml</i> | 1 | |
| <i>erythromycin oral tablet 250 mg, 500 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Miscellaneous B-Lactam Antibiotics | | |
| <i>aztreonam injection recon soln 1 gram</i> | 1 | PA BvD; HI |
| <i>aztreonam injection recon soln 2 gram</i> | 4 | NDS |
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML | 4 | PA; NDS |
| <i>ertapenem injection recon soln 1 gram</i> | 1 | |
| <i>imipenem-cilastatin intravenous recon soln 250 mg, 500 mg</i> | 1 | |
| <i>meropenem intravenous recon soln 1 gram, 500 mg</i> | 1 | |
| Penicillins | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml</i> | 1 | |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet extended release 12 hr 1,000-62.5 mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet, chewable 200-28.5 mg, 400-57 mg</i> | 1 | |
| <i>ampicillin oral capsule 500 mg</i> | 1 | |
| <i>ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg</i> | 1 | PA BvD; HI |
| <i>ampicillin-sulbactam injection recon soln 1.5 gram, 15 gram, 3 gram</i> | 1 | |
| BICILLIN L-A INTRAMUSCULAR SYRINGE 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML | 3 | NDS |
| <i>dicloxacillin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>nafcillin injection recon soln 1 gram</i> | 1 | PA BvD; HI |
| <i>nafcillin injection recon soln 10 gram</i> | 4 | PA BvD; HI; NDS |
| <i>nafcillin injection recon soln 2 gram</i> | 3 | NDS |
| <i>penicillin g potassium injection recon soln 20 million unit</i> | 1 | PA BvD; HI |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>penicillin v potassium oral recon soln 125 mg/5 ml, 250 mg/5 ml</i> | 1 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram</i> | 1 | |
| Quinolones | | |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml</i> | 1 | PA BvD; HI |
| <i>levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml</i> | 1 | |
| <i>levofloxacin oral solution 250 mg/10 ml</i> | 1 | |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>moxifloxacin 400 mg/250 ml bag</i> | 3 | PA BvD; HI; NDS |
| <i>moxifloxacin oral tablet 400 mg</i> | 1 | |
| <i>moxifloxacin-sod.chloride(iso) intravenous piggyback 400 mg/250 ml</i> | 3 | PA BvD; HI; NDS |
| Sulfonamides | | |
| <i>sulfadiazine oral tablet 500 mg</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | 1 | |
| Tetracyclines | | |
| <i>demeclocycline oral tablet 150 mg, 300 mg</i> | 1 | |
| <i>doxy-100 intravenous recon soln 100 mg</i> | 1 | PA BvD; HI |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i> | 1 | |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i> | 1 | |
| <i>doxycycline monohydrate oral capsule 100 mg, 150 mg, 50 mg, 75 mg</i> | 1 | |
| <i>doxycycline monohydrate oral suspension for reconstitution 25 mg/5 ml</i> | 1 | |
| <i>doxycycline monohydrate oral tablet 100 mg, 150 mg, 50 mg, 75 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| <i>minocycline oral capsule 100 mg, 50 mg, 75 mg</i> | 1 | |
| <i>minocycline oral tablet 100 mg, 50 mg, 75 mg</i> | 1 | |
| <i>tetracycline oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>tigecycline intravenous recon soln 50 mg</i> | 4 | PA BvD; HI; NDS |
| Anticancer Agents | | |
| Anticancer Agents | | |
| <i>abiraterone oral tablet 250 mg, 500 mg</i> | 4 | PA NSO; NDS; QL (120 per 30 days) |
| AKEEGA ORAL TABLET 100-500 MG, 50-500 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG | 4 | PA NSO; NDS; QL (240 per 30 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| ALUNBRIG ORAL TABLETS,DOSE PACK 90 MG (7)- 180 MG (23) | 4 | PA NSO; NDS |
| <i>anastrozole oral tablet 1 mg</i> | 1 | |
| AUGTYRO ORAL CAPSULE 160 MG, 40 MG | 4 | PA NSO; NDS; QL (240 per 30 days) |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| BALVERSA ORAL TABLET 3 MG | 4 | PA NSO; NDS; QL (84 per 28 days) |
| BALVERSA ORAL TABLET 4 MG | 4 | PA NSO; NDS; QL (56 per 28 days) |
| BALVERSA ORAL TABLET 5 MG | 4 | PA NSO; NDS; QL (28 per 28 days) |
| <i>bexarotene oral capsule 75 mg</i> | 4 | PA NSO; NDS |
| <i>bexarotene topical gel 1 %</i> | 4 | PA NSO; NDS; QL (240 per 30 days) |
| <i>bicalutamide oral tablet 50 mg</i> | 1 | |
| BOSULIF ORAL CAPSULE 100 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| BOSULIF ORAL CAPSULE 50 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| BOSULIF ORAL TABLET 100 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 60 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| CABOMETYX ORAL TABLET 40 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| CALQUENCE (ACALABRUTINIB MAL) ORAL TABLET 100 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| CALQUENCE ORAL CAPSULE 100 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 100 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------------------|
| CAPRELSA ORAL TABLET 300 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1) | 4 | PA NSO; NDS; QL (56 per 28 days) |
| COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3) | 4 | PA NSO; NDS; QL (112 per 28 days) |
| COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY) | 4 | PA NSO; NDS; QL (84 per 28 days) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 4 | PA NSO; NDS; QL (56 per 28 days) |
| COTELLIC ORAL TABLET 20 MG | 4 | PA NSO; LA; NDS; QL (63 per 28 days) |
| <i>cyclophosphamide oral capsule 25 mg</i> | 3 | PA BvD; NDS |
| <i>cyclophosphamide oral capsule 50 mg</i> | 3 | PA BvD; ST; NDS |
| <i>cyclophosphamide oral tablet 25 mg, 50 mg</i> | 2 | PA BvD; ST |
| DANZITEN ORAL TABLET 71 MG, 95 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| <i>dasatinib oral tablet 100 mg, 140 mg, 50 mg, 70 mg, 80 mg</i> | 4 | PA NSO; NDS; QL (30 per 30 days) |
| <i>dasatinib oral tablet 20 mg</i> | 4 | PA NSO; NDS; QL (90 per 30 days) |
| DAURISMO ORAL TABLET 100 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| DAURISMO ORAL TABLET 25 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| ELIGARD (3 MONTH) SUBCUTANEOUS SYRINGE 22.5 MG | 3 | PA NSO; NDS |
| ELIGARD (4 MONTH) SUBCUTANEOUS SYRINGE 30 MG | 3 | PA NSO; NDS |
| ELIGARD (6 MONTH) SUBCUTANEOUS SYRINGE 45 MG | 3 | PA NSO; NDS |
| ELIGARD SUBCUTANEOUS SYRINGE 7.5 MG (1 MONTH) | 3 | PA NSO; NDS |
| ERIVEDGE ORAL CAPSULE 150 MG | 4 | PA NSO; NDS; QL (28 per 28 days) |
| ERLEADA ORAL TABLET 240 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| <i>erlotinib oral tablet 100 mg, 25 mg</i> | 4 | PA NSO; NDS; QL (60 per 30 days) |
| <i>erlotinib oral tablet 150 mg</i> | 4 | PA NSO; NDS; QL (90 per 30 days) |
| <i>everolimus (antineoplastic) oral tablet 10 mg</i> | 4 | PA NSO; NDS; QL (56 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | 4 | PA NSO; NDS; QL (28 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg</i> | 4 | PA NSO; NDS; QL (112 per 28 days) |
| <i>exemestane oral tablet 25 mg</i> | 1 | |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG | 4 | PA NSO; NDS; QL (4 per 365 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG | 3 | PA NSO; NDS |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG | 4 | PA NSO; NDS; QL (21 per 28 days) |
| FRUZAQLA ORAL CAPSULE 1 MG | 4 | PA NSO; NDS; QL (84 per 21 days) |
| FRUZAQLA ORAL CAPSULE 5 MG | 4 | PA NSO; NDS; QL (21 per 21 days) |
| GAVRETO ORAL CAPSULE 100 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| <i>gefitinib oral tablet 250 mg</i> | 4 | PA NSO; NDS |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| GLEOSTINE ORAL CAPSULE 10 MG | 3 | NDS |
| GLEOSTINE ORAL CAPSULE 100 MG, 40 MG | 4 | NDS |
| <i>hydroxyurea oral capsule 500 mg</i> | 1 | |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 4 | PA NSO; NDS; QL (21 per 28 days) |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 4 | PA NSO; NDS; QL (21 per 28 days) |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| IDHIFA ORAL TABLET 100 MG, 50 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| <i>imatinib oral tablet 100 mg</i> | 4 | PA NSO; NDS; QL (180 per 30 days) |
| <i>imatinib oral tablet 400 mg</i> | 4 | PA NSO; NDS; QL (60 per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| IMBRUVICA ORAL CAPSULE 70 MG | 4 | PA NSO; NDS; QL (28 per 28 days) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML | 4 | PA NSO; NDS; QL (240 per 30 days) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG | 4 | PA NSO; NDS; QL (28 per 28 days) |
| IMKELDI ORAL SOLUTION 80 MG/ML | 4 | PA NSO; NDS |
| INLYTA ORAL TABLET 1 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| INLYTA ORAL TABLET 5 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| INQOVI ORAL TABLET 35-100 MG | 4 | PA NSO; NDS; QL (5 per 28 days) |
| INREBIC ORAL CAPSULE 100 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| ITOVEBI ORAL TABLET 3 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| ITOVEBI ORAL TABLET 9 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| IWILFIN ORAL TABLET 192 MG | 4 | PA NSO; NDS; QL (240 per 30 days) |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 100 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------------|
| JAYPIRCA ORAL TABLET 50 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG | 4 | PA NSO; NDS; QL (49 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG | 4 | PA NSO; NDS; QL (70 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG | 4 | PA NSO; NDS; QL (91 per 28 days) |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) | 4 | PA NSO; NDS; QL (21 per 28 days) |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) | 4 | PA NSO; NDS; QL (42 per 28 days) |
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) | 4 | PA NSO; NDS; QL (63 per 28 days) |
| KOSELUGO ORAL CAPSULE 10 MG | 4 | PA NSO; NDS; QL (300 per 30 days) |
| KOSELUGO ORAL CAPSULE 25 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| KRAZATI ORAL TABLET 200 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| <i>lapatinib oral tablet 250 mg</i> | 4 | PA NSO; NDS |
| LAZCLUZE ORAL TABLET 240 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| LAZCLUZE ORAL TABLET 80 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg</i> | 4 | PA NSO; NDS; QL (28 per 28 days) |
| LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2) | 4 | PA NSO; NDS |
| <i>letrozole oral tablet 2.5 mg</i> | 1 | |
| LEUKERAN ORAL TABLET 2 MG | 4 | NDS |
| <i>leuprolide (3 month) intramuscular suspension for reconstitution 22.5 mg</i> | 3 | PA NSO; NDS |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i> | 3 | PA NSO; NDS |
| LONSURF ORAL TABLET 15-6.14 MG | 4 | PA NSO; NDS; QL (100 per 28 days) |
| LONSURF ORAL TABLET 20-8.19 MG | 4 | PA NSO; NDS; QL (80 per 28 days) |
| LORBRENA ORAL TABLET 100 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| LUMAKRAS ORAL TABLET 120 MG, 320 MG | 4 | PA NSO; NDS; QL (240 per 30 days) |
| LUMAKRAS ORAL TABLET 240 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 22.5 MG | 4 | PA NSO; NDS |
| LUPRON DEPOT (4 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG | 4 | PA NSO; NDS |
| LUPRON DEPOT (6 MONTH) INTRAMUSCULAR SYRINGE KIT 45 MG | 4 | PA NSO; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 7.5 MG | 4 | PA NSO; NDS |
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 4 | NDS |
| LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) | 4 | PA NSO; NDS; QL (140 per 28 days) |
| MATULANE ORAL CAPSULE 50 MG | 4 | NDS |
| <i>megestrol oral tablet 20 mg, 40 mg</i> | 1 | |
| MEKINIST ORAL RECON SOLN 0.05 MG/ML | 4 | NDS; QL (1260 per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| MEKTOVI ORAL TABLET 15 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| <i>mercaptopurine oral tablet 50 mg</i> | 1 | |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | 1 | |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | 1 | |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 1 | |
| NERLYNX ORAL TABLET 40 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| <i>nilutamide oral tablet 150 mg</i> | 4 | NDS |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 4 | PA NSO; NDS; QL (3 per 28 days) |
| NUBEQA ORAL TABLET 300 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 4 | PA NSO; LA; NDS |
| OGSIVEO ORAL TABLET 100 MG, 150 MG | 4 | PA NSO; NDS; QL (56 per 28 days) |
| OGSIVEO ORAL TABLET 50 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| OJEMDA ORAL SUSPENSION FOR RECONSTITUTION 25 MG/ML | 4 | PA NSO; NDS; QL (96 per 28 days) |
| OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6) | 4 | PA NSO; NDS; QL (24 per 28 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| ONUREG ORAL TABLET 200 MG, 300 MG | 4 | PA NSO; NDS; QL (14 per 28 days) |
| ORSERDU ORAL TABLET 345 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| ORSERDU ORAL TABLET 86 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| <i>pazopanib oral tablet 200 mg</i> | 4 | PA NSO; NDS; QL (120 per 30 days) |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1) | 4 | PA NSO; NDS; QL (28 per 28 days) |
| PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | 4 | PA NSO; NDS; QL (56 per 28 days) |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 4 | PA NSO; NDS; QL (21 per 28 days) |
| PURIXAN ORAL SUSPENSION 20 MG/ML | 4 | NDS |
| QINLOCK ORAL TABLET 50 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| RETEVMO ORAL TABLET 80 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| REVUFORJ ORAL TABLET 110 MG, 160 MG | 4 | PA NSO; NDS |
| REZLIDHIA ORAL CAPSULE 150 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| ROZLYTREK ORAL CAPSULE 100 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| ROZLYTREK ORAL PELLETS IN PACKET 50 MG | 4 | PA NSO; NDS; QL (360 per 30 days) |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| RYDAPT ORAL CAPSULE 25 MG | 4 | PA NSO; NDS; QL (224 per 28 days) |
| SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG | 4 | PA NSO; NDS |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML | 4 | NDS |
| <i>sorafenib oral tablet 200 mg</i> | 4 | PA NSO; NDS; QL (120 per 30 days) |
| SPRYCEL ORAL TABLET 100 MG, 140 MG, 50 MG, 70 MG, 80 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| SPRYCEL ORAL TABLET 20 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------------|
| STIVARGA ORAL TABLET 40 MG | 4 | PA NSO; NDS; QL (84 per 28 days) |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | 4 | PA NSO; NDS; QL (28 per 28 days) |
| TABLOID ORAL TABLET 40 MG | 3 | NDS |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 4 | PA NSO; NDS; QL (112 per 28 days) |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| TAFINLAR ORAL TABLET FOR SUSPENSION 10 MG | 4 | NDS; QL (900 per 30 days) |
| TAGRISSO ORAL TABLET 40 MG, 80 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i> | 1 | |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG | 4 | PA NSO; NDS; QL (112 per 28 days) |
| TASIGNA ORAL CAPSULE 50 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 4 | PA NSO; NDS; QL (240 per 30 days) |
| TEPMETKO ORAL TABLET 225 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| TIBSOVO ORAL TABLET 250 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| <i>toremifene oral tablet 60 mg</i> | 4 | NDS |
| <i>torpenz oral tablet 10 mg</i> | 4 | PA NSO; NDS; QL (60 per 30 days) |
| <i>torpenz oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | 4 | PA NSO; NDS; QL (30 per 30 days) |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG, 22.5 MG, 3.75 MG | 3 | PA NSO; NDS |
| <i>tretinoin (antineoplastic) oral capsule 10 mg</i> | 4 | NDS |
| TRUQAP ORAL TABLET 160 MG, 200 MG | 4 | PA NSO; NDS; QL (64 per 28 days) |
| TUKYSA ORAL TABLET 150 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| TUKYSA ORAL TABLET 50 MG | 4 | PA NSO; NDS; QL (300 per 30 days) |
| TURALIO ORAL CAPSULE 125 MG | 4 | NDS |
| VANFLYTA ORAL TABLET 17.7 MG, 26.5 MG | 4 | PA NSO; NDS; QL (56 per 28 days) |
| VENCLEXTA ORAL TABLET 10 MG | 2 | PA NSO; LA; QL (60 per 30 days) |
| VENCLEXTA ORAL TABLET 100 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------------|
| VENCLEXTA STARTING PACK ORAL TABLETS,DOSE PACK 10 MG-50 MG- 100 MG | 4 | PA NSO; LA; NDS; QL (42 per 28 days) |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 4 | PA NSO; NDS; QL (56 per 28 days) |
| VITRAKVI ORAL CAPSULE 100 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 4 | PA NSO; NDS; QL (300 per 30 days) |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| VONJO ORAL CAPSULE 100 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| VORANIGO ORAL TABLET 10 MG, 40 MG | 4 | PA NSO; NDS |
| WELIREG ORAL TABLET 40 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| XALKORI ORAL PELLETT 150 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| XALKORI ORAL PELLETT 20 MG | 4 | PA NSO; NDS; QL (240 per 30 days) |
| XALKORI ORAL PELLETT 50 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 3 | ST; NDS |
| XOSPATA ORAL TABLET 40 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2) | 4 | PA NSO; NDS; QL (8 per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) | 4 | PA NSO; NDS; QL (4 per 28 days) |
| XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK) | 4 | PA NSO; NDS; QL (24 per 28 days) |
| XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK) | 4 | PA NSO; NDS; QL (32 per 28 days) |
| XTANDI ORAL CAPSULE 40 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 40 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 80 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| YONSA ORAL TABLET 125 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 4 | PA NSO; NDS; QL (240 per 30 days) |
| ZOLINZA ORAL CAPSULE 100 MG | 4 | NDS |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 4 | PA NSO; NDS; QL (84 per 28 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| Anticonvulsants | | |
| Anticonvulsants | | |
| APTIOM ORAL TABLET 200 MG, 400 MG | 4 | ST; NDS; QL (30 per 30 days) |
| APTIOM ORAL TABLET 600 MG, 800 MG | 4 | ST; NDS; QL (60 per 30 days) |
| BRIVIACT ORAL SOLUTION 10 MG/ML | 4 | NDS; QL (600 per 30 days) |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | 4 | NDS; QL (60 per 30 days) |
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i> | 1 | |
| <i>carbamazepine oral suspension 100 mg/5 ml</i> | 1 | |
| <i>carbamazepine oral tablet 200 mg</i> | 1 | |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> | 1 | |
| <i>carbamazepine oral tablet, chewable 100 mg</i> | 1 | |
| <i>clobazam oral suspension 2.5 mg/ml</i> | 1 | QL (480 per 30 days) |
| <i>clobazam oral tablet 10 mg, 20 mg</i> | 1 | QL (60 per 30 days) |
| DIACOMIT ORAL CAPSULE 250 MG | 4 | PA NSO; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL CAPSULE 500 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 250 MG | 4 | PA NSO; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 500 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg</i> | 3 | NDS |
| DILANTIN ORAL CAPSULE 30 MG | 3 | NDS |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i> | 1 | |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> | 1 | |
| <i>divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> | 1 | |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 4 | PA NSO; NDS |
| <i>epitol oral tablet 200 mg</i> | 1 | |
| EPRONTIA ORAL SOLUTION 25 MG/ML | 3 | ST; NDS; QL (480 per 30 days) |
| <i>ethosuximide oral capsule 250 mg</i> | 1 | |
| <i>ethosuximide oral solution 250 mg/5 ml</i> | 1 | |
| <i>felbamate oral suspension 600 mg/5 ml</i> | 3 | NDS |
| <i>felbamate oral tablet 400 mg, 600 mg</i> | 1 | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | 4 | NDS |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML | 4 | ST; NDS; QL (720 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 8 MG | 4 | ST; NDS; QL (30 per 30 days) |
| FYCOMPA ORAL TABLET 2 MG | 3 | ST; NDS; QL (30 per 30 days) |
| FYCOMPA ORAL TABLET 4 MG, 6 MG | 4 | ST; NDS; QL (60 per 30 days) |
| <i>gabapentin oral capsule 100 mg, 300 mg</i> | 1 | QL (360 per 30 days) |
| <i>gabapentin oral capsule 400 mg</i> | 1 | QL (270 per 30 days) |
| <i>gabapentin oral solution 250 mg/5 ml</i> | 1 | QL (2160 per 30 days) |
| <i>gabapentin oral tablet 600 mg</i> | 1 | QL (180 per 30 days) |
| <i>gabapentin oral tablet 800 mg</i> | 1 | QL (120 per 30 days) |
| <i>lacosamide oral solution 10 mg/ml</i> | 3 | NDS; QL (1200 per 30 days) |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 1 | QL (60 per 30 days) |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | |
| <i>lamotrigine oral tablet disintegrating, dose pk 25 mg (21) -50 mg (7), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg (42) -100 mg (14)</i> | 1 | |
| <i>lamotrigine oral tablet extended release 24hr 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | 1 | |
| <i>lamotrigine oral tablet, chewable dispersible 25 mg, 5 mg</i> | 1 | |
| <i>lamotrigine oral tablet, disintegrating 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>levetiracetam oral solution 100 mg/ml</i> | 1 | |
| <i>levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg</i> | 1 | |
| <i>levetiracetam oral tablet for suspension 250 mg</i> | 1 | |
| LIBERVANT BUCCAL FILM 10 MG, 12.5 MG, 15 MG, 5 MG, 7.5 MG | 4 | NDS; QL (10 per 30 days) |
| <i>methsuximide oral capsule 300 mg</i> | 3 | NDS |
| NAYZILAM NASAL SPRAY, NON-AEROSOL 5 MG/SPRAY (0.1 ML) | 3 | NDS; QL (10 per 30 days) |
| <i>oxcarbazepine oral suspension 300 mg/5 ml (60 mg/ml)</i> | 1 | |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i> | 1 | |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 1 | |
| PHENYTEK ORAL CAPSULE 200 MG, 300 MG | 2 | |
| <i>phenytoin oral suspension 125 mg/5 ml</i> | 1 | |
| <i>phenytoin oral tablet, chewable 50 mg</i> | 1 | |
| <i>phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg</i> | 1 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i> | 1 | QL (90 per 30 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> | 1 | QL (60 per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> | 1 | QL (900 per 30 days) |
| <i>primidone oral tablet 125 mg, 250 mg, 50 mg</i> | 1 | |
| <i>rufinamide oral suspension 40 mg/ml</i> | 4 | NDS |
| <i>rufinamide oral tablet 200 mg</i> | 1 | |
| <i>rufinamide oral tablet 400 mg</i> | 4 | NDS |
| SPRITAM ORAL TABLET FOR SUSPENSION 1,000 MG | 3 | ST; NDS; QL (60 per 30 days) |
| SPRITAM ORAL TABLET FOR SUSPENSION 250 MG, 500 MG, 750 MG | 3 | ST; NDS; QL (120 per 30 days) |
| <i>subvenite oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | |
| SYMPAZAN ORAL FILM 10 MG, 20 MG, 5 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| <i>tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 1 | |
| <i>topiramate oral capsule, sprinkle 15 mg, 25 mg</i> | 1 | |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | 1 | |
| <i>valproic acid oral capsule 250 mg</i> | 1 | |
| VALTOCO NASAL SPRAY, NON-AEROSOL 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) | 4 | NDS |
| <i>vigabatrin oral powder in packet 500 mg</i> | 4 | PA NSO; NDS; QL (180 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------------|
| <i>vigabatrin oral tablet 500 mg</i> | 4 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigadrone oral powder in packet 500 mg</i> | 4 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigadrone oral tablet 500 mg</i> | 4 | PA NSO; NDS; QL (180 per 30 days) |
| VIGAFYDE ORAL SOLUTION 100 MG/ML | 4 | PA NSO; NDS |
| <i>vigpoder oral powder in packet 500 mg</i> | 4 | PA NSO; NDS; QL (180 per 30 days) |
| XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) | 4 | ST; NDS; QL (56 per 28 days) |
| XCOPRI ORAL TABLET 100 MG, 50 MG | 4 | ST; NDS; QL (30 per 30 days) |
| XCOPRI ORAL TABLET 150 MG, 200 MG | 4 | ST; NDS; QL (60 per 30 days) |
| XCOPRI ORAL TABLET 25 MG | 4 | NDS; QL (30 per 30 days) |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14) | 3 | NDS; QL (28 per 28 days) |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) | 4 | NDS; QL (28 per 28 days) |
| ZONISADE ORAL SUSPENSION 100 MG/5 ML | 4 | NDS |
| <i>zonisamide oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | |
| ZTALMY ORAL SUSPENSION 50 MG/ML | 4 | PA NSO; NDS; QL (1080 per 30 days) |
| Antidementia Agents | | |
| Antidementia Agents | | |
| <i>donepezil oral tablet 10 mg, 23 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>donepezil oral tablet, disintegrating 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>ergoloid oral tablet 1 mg</i> | 2 | |
| <i>galantamine oral capsule, ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg</i> | 1 | QL (30 per 30 days) |
| <i>galantamine oral solution 4 mg/ml</i> | 1 | QL (200 per 30 days) |
| <i>galantamine oral tablet 12 mg, 4 mg, 8 mg</i> | 1 | QL (60 per 30 days) |
| <i>memantine oral capsule, sprinkle, er 24hr 14 mg, 21 mg, 28 mg, 7 mg</i> | 1 | QL (30 per 30 days) |
| <i>memantine oral solution 2 mg/ml</i> | 1 | QL (300 per 30 days) |
| <i>memantine oral tablet 10 mg, 5 mg</i> | 1 | QL (60 per 30 days) |
| NAMZARIC ORAL CAP, SPRINKLE, ER 24HR DOSE PACK 7/14/21/28 MG-10 MG | 3 | NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------|
| NAMZARIC ORAL CAPSULE,SPRINKLE,ER 24HR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG | 3 | NDS; QL (30 per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 1 | QL (60 per 30 days) |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour</i> | 1 | QL (30 per 30 days) |
| Antidepressants | | |
| Antidepressants | | |
| <i>amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 1 | |
| AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 45-105 MG | 4 | ST; NDS |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | 1 | |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg, 300 mg</i> | 1 | |
| <i>bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg</i> | 1 | |
| <i>citalopram oral solution 10 mg/5 ml</i> | 1 | QL (600 per 30 days) |
| <i>citalopram oral tablet 10 mg</i> | 1 | QL (120 per 30 days) |
| <i>citalopram oral tablet 20 mg, 40 mg</i> | 1 | QL (30 per 30 days) |
| <i>clomipramine oral capsule 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>desipramine oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg</i> | 1 | QL (30 per 30 days) |
| <i>doxepin oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>doxepin oral concentrate 10 mg/ml</i> | 1 | |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG | 3 | NDS; QL (60 per 30 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 30 mg, 60 mg</i> | 1 | QL (60 per 30 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 40 mg</i> | 1 | QL (30 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR | 4 | ST; NDS; QL (30 per 30 days) |
| <i>escitalopram oxalate oral solution 5 mg/5 ml</i> | 1 | |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | |
| FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) | 3 | ST; NDS |
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG | 3 | ST; NDS; QL (30 per 30 days) |
| <i>fluoxetine oral capsule 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>fluoxetine oral solution 20 mg/5 ml (4 mg/ml)</i> | 1 | |
| <i>fluvoxamine oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 1 | |
| <i>imipramine pamoate oral capsule 100 mg, 125 mg, 150 mg, 75 mg</i> | 1 | |
| MARPLAN ORAL TABLET 10 MG | 3 | NDS |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg, 7.5 mg</i> | 1 | |
| <i>mirtazapine oral tablet, disintegrating 15 mg, 30 mg, 45 mg</i> | 1 | |
| <i>nefazodone oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 1 | |
| <i>nortriptyline oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>nortriptyline oral solution 10 mg/5 ml</i> | 1 | |
| <i>paroxetine hcl oral suspension 10 mg/5 ml</i> | 1 | |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 | |
| <i>paroxetine hcl oral tablet extended release 24 hr 12.5 mg, 25 mg, 37.5 mg</i> | 1 | |
| <i>perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg</i> | 1 | |
| <i>phenelzine oral tablet 15 mg</i> | 1 | |
| <i>protriptyline oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>sertraline oral concentrate 20 mg/ml</i> | 1 | |
| <i>sertraline oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>tranylcypromine oral tablet 10 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| <i>trazodone oral tablet 100 mg, 150 mg, 300 mg, 50 mg</i> | 1 | |
| <i>trimipramine oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 2 | QL (30 per 30 days) |
| <i>venlafaxine besylate oral tablet extended release 24hr 112.5 mg</i> | 3 | NDS; QL (30 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 150 mg</i> | 1 | QL (30 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 37.5 mg, 75 mg</i> | 1 | QL (90 per 30 days) |
| <i>venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 1 | |
| <i>venlafaxine oral tablet extended release 24hr 150 mg, 225 mg, 37.5 mg</i> | 1 | QL (30 per 30 days) |
| <i>venlafaxine oral tablet extended release 24hr 75 mg</i> | 1 | QL (90 per 30 days) |
| <i>vilazodone oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | QL (30 per 30 days) |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG | 4 | PA NSO; NDS; QL (28 per 14 days) |
| ZURZUVAE ORAL CAPSULE 30 MG | 4 | PA NSO; NDS; QL (14 per 14 days) |
| Antidiabetic Agents | | |
| Antidiabetic Agents, Miscellaneous | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | QL (90 per 30 days) |
| <i>alogliptin oral tablet 12.5 mg, 25 mg, 6.25 mg</i> | 1 | |
| <i>alogliptin-metformin oral tablet 12.5-1,000 mg, 12.5-500 mg</i> | 1 | |
| <i>alogliptin-pioglitazone oral tablet 12.5-30 mg, 25-15 mg, 25-30 mg, 25-45 mg</i> | 1 | |
| <i>dapaglifloz propaned-metformin oral tablet, ir - er, biphasic 24hr 10-1,000 mg</i> | 1 | QL (30 per 30 days) |
| <i>dapaglifloz propaned-metformin oral tablet, ir - er, biphasic 24hr 5-1,000 mg</i> | 1 | QL (60 per 30 days) |
| <i>dapagliflozin propanediol oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG | 2 | QL (30 per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 2 | QL (30 per 30 days) |
| JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG | 2 | QL (60 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG | 2 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | 2 | QL (30 per 30 days) |
| <i>metformin oral solution 500 mg/5 ml</i> | 1 | QL (765 per 30 days) |
| <i>metformin oral tablet 1,000 mg</i> | 1 | QL (75 per 30 days) |
| <i>metformin oral tablet 500 mg</i> | 1 | QL (150 per 30 days) |
| <i>metformin oral tablet 850 mg</i> | 1 | QL (90 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 500 mg</i> | 1 | QL (120 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 750 mg</i> | 1 | QL (60 per 30 days) |
| <i>mifepristone oral tablet 300 mg</i> | 4 | PA; NDS; QL (112 per 28 days) |
| <i>miglitol oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | QL (90 per 30 days) |
| MOUNJARO SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML | 2 | PA NSO; QL (2 per 28 days) |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 1 | QL (90 per 30 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 0.25 MG OR 0.5 MG(2 MG/1.5 ML), 1 MG/DOSE (2 MG/1.5 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | 2 | PA NSO; QL (3 per 28 days) |
| <i>pioglitazone oral tablet 15 mg, 30 mg, 45 mg</i> | 1 | QL (30 per 30 days) |
| <i>pioglitazone-metformin oral tablet 15-500 mg, 15-850 mg</i> | 1 | QL (90 per 30 days) |
| <i>repaglinide oral tablet 0.5 mg, 1 mg</i> | 1 | QL (120 per 30 days) |
| <i>repaglinide oral tablet 2 mg</i> | 1 | QL (240 per 30 days) |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG | 2 | PA NSO; QL (30 per 30 days) |
| SYNJARDY ORAL TABLET 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG | 2 | QL (60 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 25-1,000 MG | 2 | QL (30 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-1,000 MG, 5-1,000 MG | 2 | QL (60 per 30 days) |
| TRADJENTA ORAL TABLET 5 MG | 2 | QL (30 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--|
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG | 2 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG | 2 | QL (60 per 30 days) |
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML | 2 | PA NSO; QL (2 per 28 days) |
| Insulins | | |
| FIASP FLEXTOUCH U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 2 | max \$35 copay per month supply; QL (30 per 28 days) |
| FIASP PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (3 ML) | 2 | max \$35 copay per month supply; QL (30 per 28 days) |
| FIASP U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 2 | max \$35 copay per month supply; QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML | 2 | max \$35 copay per month supply; QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) | 2 | max \$35 copay per month supply; QL (24 per 28 days) |
| <i>insulin asp prt-insulin aspart subcutaneous insulin pen 100 unit/ml (70-30)</i> | 1 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin asp prt-insulin aspart subcutaneous solution 100 unit/ml (70-30)</i> | 1 | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin aspart u-100 subcutaneous cartridge 100 unit/ml</i> | 1 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous insulin pen 100 unit/ml (3 ml)</i> | 1 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous solution 100 unit/ml</i> | 1 | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin degludec subcutaneous insulin pen 100 unit/ml (3 ml), 200 unit/ml (3 ml)</i> | 2 | max \$35 copay per month supply |
| <i>insulin degludec subcutaneous solution 100 unit/ml</i> | 2 | max \$35 copay per month supply |
| <i>insulin glargine u-300 conc subcutaneous insulin pen 300 unit/ml (1.5 ml)</i> | 2 | max \$35 copay per month supply; QL (13.5 per 28 days) |
| <i>insulin glargine u-300 conc subcutaneous insulin pen 300 unit/ml (3 ml)</i> | 2 | max \$35 copay per month supply; QL (18 per 28 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--|
| <i>insulin glargine-yfgn subcutaneous insulin pen 100 unit/ml (3 ml)</i> | 2 | max \$35 copay per month supply |
| <i>insulin glargine-yfgn subcutaneous solution 100 unit/ml</i> | 2 | max \$35 copay per month supply |
| <i>insulin lispro protamin-lispro subcutaneous insulin pen 100 unit/ml (75-25)</i> | 2 | max \$35 copay per month supply |
| <i>insulin lispro subcutaneous insulin pen 100 unit/ml</i> | 2 | max \$35 copay per month supply |
| <i>insulin lispro subcutaneous insulin pen, half-unit 100 unit/ml</i> | 2 | max \$35 copay per month supply |
| <i>insulin lispro subcutaneous solution 100 unit/ml</i> | 2 | max \$35 copay per month supply |
| NOVOLIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) | 2 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN 70-30 FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | 2 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN N FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 2 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 2 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN R FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 2 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN R REGULAR U100 INSULIN INJECTION SOLUTION 100 UNIT/ML | 2 | max \$35 copay per month supply; QL (40 per 28 days) |
| SEMGLEE(INSULIN GLARGINE-YFGN) SUBCUTANEOUS SOLUTION 100 UNIT/ML | 2 | max \$35 copay per month supply; QL (40 per 28 days) |
| SEMGLEE(INSULIN GLARG-YFGN)PEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 2 | max \$35 copay per month supply; QL (30 per 28 days) |
| SOLIQUA 100/33 SUBCUTANEOUS INSULIN PEN 100 UNIT-33 MCG/ML | 2 | max \$35 copay per month supply; QL (30 per 30 days) |
| TOUJEO MAX U-300 SOLOSTAR SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (3 ML) | 2 | max \$35 copay per month supply; QL (18 per 28 days) |
| TOUJEO SOLOSTAR U-300 INSULIN SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (1.5 ML) | 2 | max \$35 copay per month supply; QL (13.5 per 28 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---|
| XULTOPHY 100/3.6 SUBCUTANEOUS INSULIN PEN 100 UNIT-3.6 MG /ML (3 ML) | 2 | max \$35 copay per month supply; QL (15 per 28 days) |
| Sulfonylureas | | |
| <i>glimepiride oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | |
| <i>glipizide oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>glipizide oral tablet extended release 24hr 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>glipizide-metformin oral tablet 2.5-250 mg, 2.5-500 mg, 5-500 mg</i> | 1 | |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg</i> | 1 | |
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | 1 | |
| Antifungals | | |
| Antifungals | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 3 | PA BvD; HI; NDS |
| <i>amphotericin b injection recon soln 50 mg</i> | 1 | PA BvD; HI |
| <i>amphotericin b liposome intravenous suspension for reconstitution 50 mg</i> | 4 | PA BvD; NDS |
| <i>casprofungin intravenous recon soln 50 mg</i> | 3 | NDS |
| <i>casprofungin intravenous recon soln 70 mg</i> | 3 | PA BvD; HI; NDS |
| <i>ciclopirox topical cream 0.77 %</i> | 1 | QL (180 per 30 days) |
| <i>ciclopirox topical gel 0.77 %</i> | 1 | QL (300 per 30 days) |
| <i>ciclopirox topical shampoo 1 %</i> | 1 | |
| <i>ciclopirox topical solution 8 %</i> | 1 | QL (19.8 per 30 days) |
| <i>ciclopirox topical suspension 0.77 %</i> | 1 | QL (180 per 30 days) |
| <i>clotrimazole mucous membrane troche 10 mg</i> | 1 | |
| <i>clotrimazole topical cream 1 %</i> | 1 | QL (45 per 30 days) |
| <i>clotrimazole topical solution 1 %</i> | 1 | |
| <i>clotrimazole-betamethasone topical cream 1-0.05 %</i> | 1 | QL (90 per 30 days) |
| <i>clotrimazole-betamethasone topical lotion 1-0.05 %</i> | 1 | QL (90 per 30 days) |
| <i>econazole nitrate topical cream 1 %</i> | 1 | QL (170 per 30 days) |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | 1 | PA BvD; HI |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------|
| <i>fluconazole oral suspension for reconstitution 10 mg/ml, 40 mg/ml</i> | 1 | |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 1 | |
| <i>flucytosine oral capsule 250 mg, 500 mg</i> | 4 | NDS |
| <i>griseofulvin microsize oral suspension 125 mg/5 ml</i> | 1 | |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 1 | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i> | 1 | |
| <i>itraconazole oral capsule 100 mg</i> | 1 | |
| <i>itraconazole oral solution 10 mg/ml</i> | 4 | PA; NDS |
| <i>ketoconazole oral tablet 200 mg</i> | 1 | |
| <i>ketoconazole topical cream 2 %</i> | 1 | QL (180 per 30 days) |
| <i>ketoconazole topical foam 2 %</i> | 1 | ST; QL (100 per 30 days) |
| <i>ketoconazole topical shampoo 2 %</i> | 1 | QL (360 per 30 days) |
| <i>miconazole-3 vaginal suppository 200 mg</i> | 1 | |
| NOXAFIL ORAL SUSP, DELAYED RELEASE FOR RECON 300 MG | 4 | PA; NDS |
| <i>nyamyc topical powder 100,000 unit/gram</i> | 1 | QL (60 per 30 days) |
| <i>nystatin oral suspension 100,000 unit/ml</i> | 1 | QL (900 per 30 days) |
| <i>nystatin oral tablet 500,000 unit</i> | 1 | |
| <i>nystatin topical cream 100,000 unit/gram</i> | 1 | QL (60 per 30 days) |
| <i>nystatin topical ointment 100,000 unit/gram</i> | 1 | QL (60 per 30 days) |
| <i>nystatin topical powder 100,000 unit/gram</i> | 1 | QL (60 per 30 days) |
| <i>nystatin-triamcinolone topical cream 100,000-0.1 unit/g-%</i> | 1 | |
| <i>nystatin-triamcinolone topical ointment 100,000-0.1 unit/gram-%</i> | 1 | |
| <i>nystop topical powder 100,000 unit/gram</i> | 1 | QL (60 per 30 days) |
| <i>posaconazole oral suspension 200 mg/5 ml (40 mg/ml)</i> | 4 | PA; NDS |
| <i>posaconazole oral tablet, delayed release (dr/ec) 100 mg</i> | 4 | PA; NDS |
| <i>terbinafine hcl oral tablet 250 mg</i> | 1 | |
| <i>voriconazole intravenous recon soln 200 mg</i> | 4 | PA BvD; HI; NDS |
| <i>voriconazole oral suspension for reconstitution 200 mg/5 ml (40 mg/ml)</i> | 4 | PA; NDS |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------|
| Antigout Agents | | |
| Antigout Agents, Other | | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | 1 | |
| <i>colchicine oral capsule 0.6 mg</i> | 1 | QL (60 per 30 days) |
| <i>colchicine oral tablet 0.6 mg</i> | 1 | QL (120 per 30 days) |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | 1 | ST; QL (30 per 30 days) |
| <i>probenecid oral tablet 500 mg</i> | 1 | |
| <i>probenecid-colchicine oral tablet 500-0.5 mg</i> | 1 | |
| Antihistamines | | |
| Antihistamines | | |
| <i>carbinoxamine maleate oral liquid 4 mg/5 ml</i> | 1 | |
| <i>carbinoxamine maleate oral tablet 4 mg, 6 mg</i> | 1 | |
| <i>clemastine oral tablet 2.68 mg</i> | 1 | |
| <i>cyproheptadine oral syrup 2 mg/5 ml</i> | 1 | |
| <i>cyproheptadine oral tablet 4 mg</i> | 1 | |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> | 1 | |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 1 | |
| <i>levocetirizine oral solution 2.5 mg/5 ml</i> | 1 | |
| <i>levocetirizine oral tablet 5 mg</i> | 1 | |
| <i>promethazine oral syrup 6.25 mg/5 ml</i> | 1 | |
| Anti-Infectives (Skin And Mucous Membrane) | | |
| Anti-Infectives (Skin And Mucous Membrane) | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> | 1 | |
| <i>metronidazole vaginal gel 0.75 % (37.5mg/5 gram)</i> | 1 | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 1 | |
| <i>terconazole vaginal suppository 80 mg</i> | 1 | |
| Antimigraine Agents | | |
| Antimigraine Agents | | |
| AJOVY AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 225 MG/1.5 ML | 2 | PA; QL (1.5 per 30 days) |
| AJOVY SYRINGE SUBCUTANEOUS SYRINGE 225 MG/1.5 ML | 2 | PA; QL (1.5 per 30 days) |
| <i>dihydroergotamine nasal spray, non-aerosol 0.5 mg/pump act. (4 mg/ml)</i> | 4 | NDS; QL (8 per 28 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------|
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML | 2 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML | 2 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3) | 2 | PA; QL (3 per 30 days) |
| <i>naratriptan oral tablet 1 mg, 2.5 mg</i> | 1 | QL (9 per 30 days) |
| NURTEC ODT ORAL TABLET,DISINTEGRATING 75 MG | 2 | PA; QL (18 per 30 days) |
| QULIPTA ORAL TABLET 10 MG, 30 MG, 60 MG | 2 | PA; QL (30 per 30 days) |
| <i>rizatriptan oral tablet 10 mg, 5 mg</i> | 1 | QL (12 per 30 days) |
| <i>rizatriptan oral tablet,disintegrating 10 mg, 5 mg</i> | 1 | QL (12 per 30 days) |
| <i>sumatriptan nasal spray,non-aerosol 20 mg/actuation</i> | 1 | QL (12 per 30 days) |
| <i>sumatriptan nasal spray,non-aerosol 5 mg/actuation</i> | 1 | QL (18 per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg</i> | 1 | QL (9 per 30 days) |
| <i>sumatriptan succinate oral tablet 25 mg, 50 mg</i> | 1 | QL (18 per 30 days) |
| <i>sumatriptan succinate subcutaneous cartridge 6 mg/0.5 ml</i> | 3 | NDS; QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml</i> | 3 | NDS; QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml</i> | 1 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5 ml</i> | 1 | QL (4 per 28 days) |
| <i>sumatriptan-naproxen oral tablet 85-500 mg</i> | 1 | QL (9 per 27 days) |
| UBRELVY ORAL TABLET 100 MG, 50 MG | 2 | PA; QL (16 per 30 days) |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> | 1 | QL (6 per 30 days) |
| <i>zolmitriptan oral tablet,disintegrating 2.5 mg, 5 mg</i> | 1 | QL (6 per 30 days) |
| Antimycobacterials | | |
| Antimycobacterials | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 1 | |
| <i>ethambutol oral tablet 100 mg, 400 mg</i> | 1 | |
| <i>isoniazid oral solution 50 mg/5 ml</i> | 1 | |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------|
| PRETOMANID ORAL TABLET 200 MG | 3 | NDS; QL (30 per 30 days) |
| PRIFTIN ORAL TABLET 150 MG | 3 | NDS |
| <i>pyrazinamide oral tablet 500 mg</i> | 1 | |
| <i>rifabutin oral capsule 150 mg</i> | 1 | |
| <i>rifampin intravenous recon soln 600 mg</i> | 1 | PA BvD; HI |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 1 | |
| SIRTURO ORAL TABLET 100 MG, 20 MG | 4 | PA; NDS |
| TRECTOR ORAL TABLET 250 MG | 3 | NDS |
| Antinausea Agents | | |
| Antinausea Agents | | |
| <i>aprepitant oral capsule 125 mg</i> | 4 | PA BvD; NDS; QL (2 per 28 days) |
| <i>aprepitant oral capsule 40 mg</i> | 1 | PA BvD; QL (1 per 28 days) |
| <i>aprepitant oral capsule 80 mg</i> | 3 | PA BvD; NDS; QL (4 per 28 days) |
| <i>aprepitant oral capsule, dose pack 125 mg (1)- 80 mg (2)</i> | 1 | PA BvD |
| <i>compro rectal suppository 25 mg</i> | 1 | |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> | 1 | PA; QL (60 per 30 days) |
| EMEND ORAL SUSPENSION FOR RECONSTITUTION 125 MG (25 MG/ ML FINAL CONC.) | 3 | PA BvD; NDS; QL (6 per 28 days) |
| <i>granisetron hcl oral tablet 1 mg</i> | 1 | PA BvD |
| <i>meclizine oral tablet 12.5 mg, 25 mg</i> | 1 | |
| <i>ondansetron hcl oral solution 4 mg/5 ml</i> | 1 | PA BvD |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 1 | PA BvD |
| <i>ondansetron oral tablet, disintegrating 4 mg, 8 mg</i> | 1 | PA BvD |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>prochlorperazine rectal suppository 25 mg</i> | 1 | |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>promethazine rectal suppository 12.5 mg, 25 mg</i> | 1 | |
| <i>promethegan rectal suppository 25 mg, 50 mg</i> | 1 | |
| <i>scopolamine base transdermal patch 3 day 1 mg over 3 days</i> | 1 | QL (10 per 30 days) |
| Antiparasite Agents | | |
| Antiparasite Agents | | |
| <i>albendazole oral tablet 200 mg</i> | 4 | NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| <i>atovaquone oral suspension 750 mg/5 ml</i> | 1 | |
| <i>atovaquone-proguanil oral tablet 250-100 mg, 62.5-25 mg</i> | 1 | |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 1 | |
| COARTEM ORAL TABLET 20-120 MG | 3 | NDS |
| <i>hydroxychloroquine oral tablet 200 mg</i> | 1 | QL (90 per 30 days) |
| IMPAVIDO ORAL CAPSULE 50 MG | 4 | PA; NDS; QL (84 per 28 days) |
| <i>ivermectin oral tablet 3 mg</i> | 1 | PA |
| KRINTAFEL ORAL TABLET 150 MG | 3 | NDS |
| <i>mefloquine oral tablet 250 mg</i> | 1 | |
| <i>nitazoxanide oral tablet 500 mg</i> | 4 | NDS; QL (60 per 30 days) |
| <i>pentamidine inhalation recon soln 300 mg</i> | 1 | PA BvD |
| <i>pentamidine injection recon soln 300 mg</i> | 1 | PA BvD; HI |
| <i>praziquantel oral tablet 600 mg</i> | 3 | NDS |
| PRIMAQUINE ORAL TABLET 26.3 MG (15 MG BASE) | 3 | NDS |
| <i>pyrimethamine oral tablet 25 mg</i> | 4 | PA; NDS |
| <i>quinine sulfate oral capsule 324 mg</i> | 1 | PA; QL (42 per 7 days) |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | 1 | |
| Antiparkinsonian Agents | | |
| Antiparkinsonian Agents | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 1 | |
| <i>amantadine hcl oral solution 50 mg/5 ml</i> | 1 | |
| <i>amantadine hcl oral tablet 100 mg</i> | 1 | |
| <i>apomorphine subcutaneous cartridge 10 mg/ml</i> | 4 | PA; NDS; QL (60 per 30 days) |
| <i>benztropine oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | |
| <i>bromocriptine oral capsule 5 mg</i> | 1 | |
| <i>bromocriptine oral tablet 2.5 mg</i> | 1 | |
| <i>cabergoline oral tablet 0.5 mg</i> | 1 | |
| <i>carbidopa oral tablet 25 mg</i> | 1 | |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> | 1 | |
| <i>carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg</i> | 1 | |
| <i>carbidopa-levodopa oral tablet, disintegrating 10-100 mg, 25-100 mg, 25-250 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 2 | |
| <i>entacapone oral tablet 200 mg</i> | 1 | |
| INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE 42 MG | 4 | PA; NDS; QL (300 per 30 days) |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR | 2 | QL (30 per 30 days) |
| <i>pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 1 | |
| <i>rasagiline oral tablet 0.5 mg, 1 mg</i> | 1 | |
| <i>ropinirole oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 1 | |
| <i>ropinirole oral tablet extended release 24 hr 12 mg, 2 mg, 4 mg, 6 mg, 8 mg</i> | 1 | |
| RYTARY ORAL CAPSULE, EXTENDED RELEASE 23.75-95 MG, 36.25-145 MG, 48.75-195 MG, 61.25-245 MG | 2 | |
| <i>selegiline hcl oral capsule 5 mg</i> | 1 | |
| <i>selegiline hcl oral tablet 5 mg</i> | 1 | |
| <i>trihexyphenidyl oral elixir 0.4 mg/ml</i> | 1 | |
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i> | 1 | |
| Antipsychotic Agents | | |
| Antipsychotic Agents | | |
| ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 720 MG/2.4 ML, 960 MG/3.2 ML | 4 | NDS |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG | 4 | NDS; QL (1 per 28 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 300 MG, 400 MG | 4 | NDS; QL (1 per 28 days) |
| <i>aripiprazole oral solution 1 mg/ml</i> | 1 | |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg</i> | 1 | |
| <i>aripiprazole oral tablet 2 mg</i> | 1 | QL (60 per 30 days) |
| <i>aripiprazole oral tablet,disintegrating 10 mg</i> | 4 | ST; NDS; QL (90 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| <i>aripiprazole oral tablet, disintegrating 15 mg</i> | 3 | ST; NDS; QL (60 per 30 days) |
| ARISTADA INITIO INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 675 MG/2.4 ML | 4 | NDS; QL (4.8 per 365 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 1,064 MG/3.9 ML | 4 | NDS; QL (3.9 per 56 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 441 MG/1.6 ML | 4 | NDS; QL (1.6 per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 662 MG/2.4 ML | 4 | NDS; QL (2.4 per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 882 MG/3.2 ML | 4 | NDS; QL (3.2 per 28 days) |
| <i>asenapine maleate sublingual tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | QL (60 per 30 days) |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG | 4 | ST; NDS; QL (30 per 30 days) |
| <i>chlorpromazine oral concentrate 100 mg/ml, 30 mg/ml</i> | 1 | |
| <i>chlorpromazine oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>clozapine oral tablet, disintegrating 100 mg, 12.5 mg, 25 mg</i> | 1 | ST; QL (90 per 30 days) |
| <i>clozapine oral tablet, disintegrating 150 mg</i> | 1 | ST; QL (180 per 30 days) |
| <i>clozapine oral tablet, disintegrating 200 mg</i> | 3 | ST; NDS; QL (120 per 30 days) |
| COBENFY ORAL CAPSULE 100-20 MG, 125-30 MG, 50-20 MG | 4 | ST; NDS; QL (60 per 30 days) |
| COBENFY STARTER PACK ORAL CAPSULE, DOSE PACK 50 MG-20 MG /100 MG-20 MG | 4 | ST; NDS |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 4 | ST; NDS; QL (60 per 30 days) |
| FANAPT ORAL TABLETS, DOSE PACK 1MG(2)-2MG(2)- 4MG(2)-6MG(2) | 3 | ST; NDS |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 1 | |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 1 | |
| <i>fluphenazine hcl oral elixir 2.5 mg/5 ml</i> | 1 | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml (1 ml), 50 mg/ml, 50 mg/ml(1ml)</i> | 1 | |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 1 | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 1 | |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 1 | |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML | 4 | NDS; QL (3.5 per 180 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML | 4 | NDS; QL (5 per 180 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 4 | NDS; QL (0.75 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML | 4 | NDS; QL (1 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 4 | NDS; QL (1.5 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 2 | QL (0.25 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 4 | NDS; QL (0.5 per 28 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML | 4 | NDS; QL (0.88 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML | 4 | NDS; QL (1.32 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML | 4 | NDS; QL (1.75 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML | 4 | NDS; QL (2.63 per 84 days) |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 1 | |
| <i>lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i> | 3 | NDS; QL (30 per 30 days) |
| <i>lurasidone oral tablet 80 mg</i> | 3 | NDS; QL (60 per 30 days) |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| <i>molindone oral tablet 10 mg</i> | 1 | QL (240 per 30 days) |
| <i>molindone oral tablet 25 mg</i> | 1 | QL (270 per 30 days) |
| <i>molindone oral tablet 5 mg</i> | 4 | NDS; QL (120 per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| NUPLAZID ORAL TABLET 10 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| <i>olanzapine intramuscular recon soln 10 mg</i> | 1 | QL (30 per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg</i> | 1 | |
| <i>olanzapine oral tablet, disintegrating 10 mg, 15 mg, 20 mg, 5 mg</i> | 1 | |
| <i>paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg</i> | 1 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 6 mg</i> | 1 | QL (60 per 30 days) |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | 1 | |
| PERSERIS SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 120 MG, 90 MG | 4 | NDS; QL (1 per 30 days) |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 1 | |
| <i>quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> | 1 | |
| <i>quetiapine oral tablet 150 mg</i> | 1 | QL (30 per 30 days) |
| <i>quetiapine oral tablet extended release 24 hr 150 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> | 1 | |
| REXULTI ORAL TABLET 0.25 MG | 4 | NDS; QL (120 per 30 days) |
| REXULTI ORAL TABLET 0.5 MG | 4 | NDS; QL (60 per 30 days) |
| REXULTI ORAL TABLET 1 MG, 2 MG, 3 MG, 4 MG | 4 | NDS; QL (30 per 30 days) |
| <i>risperidone oral solution 1 mg/ml</i> | 1 | |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | |
| <i>risperidone oral tablet, disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR | 4 | ST; NDS; QL (30 per 30 days) |
| <i>thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | |
| <i>trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 100 MG/0.28 ML | 4 | NDS; QL (0.28 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 125 MG/0.35 ML | 4 | NDS; QL (0.35 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 150 MG/0.42 ML | 4 | NDS; QL (0.42 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 200 MG/0.56 ML | 4 | NDS; QL (0.56 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 250 MG/0.7 ML | 4 | NDS; QL (0.7 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 50 MG/0.14 ML | 4 | NDS; QL (0.14 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 75 MG/0.21 ML | 4 | NDS; QL (0.21 per 28 days) |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 4 | ST; NDS; QL (540 per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG | 4 | ST; NDS; QL (30 per 30 days) |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> | 1 | |
| <i>ziprasidone mesylate intramuscular recon soln 20 mg/ml (final conc.)</i> | 1 | QL (6 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG | 3 | NDS; QL (2 per 28 days) |
| Antivirals (Systemic) | | |
| Antiretrovirals | | |
| <i>abacavir oral solution 20 mg/ml</i> | 1 | |
| <i>abacavir oral tablet 300 mg</i> | 1 | |
| <i>abacavir-lamivudine oral tablet 600-300 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------|
| APTIVUS ORAL CAPSULE 250 MG | 4 | NDS |
| <i>atazanavir oral capsule 150 mg, 200 mg, 300 mg</i> | 1 | |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG | 4 | NDS; QL (30 per 30 days) |
| CIMDUO ORAL TABLET 300-300 MG | 4 | NDS |
| COMPLERA ORAL TABLET 200-25-300 MG | 4 | NDS |
| <i>darunavir oral tablet 600 mg</i> | 4 | NDS; QL (60 per 30 days) |
| <i>darunavir oral tablet 800 mg</i> | 4 | NDS; QL (30 per 30 days) |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 4 | NDS |
| DESCOVY ORAL TABLET 120-15 MG, 200-25 MG | 4 | NDS |
| DOVATO ORAL TABLET 50-300 MG | 4 | NDS |
| EDURANT ORAL TABLET 25 MG | 4 | NDS |
| <i>efavirenz oral tablet 600 mg</i> | 1 | |
| <i>efavirenz-emtricitabin-tenofovir oral tablet 600-200-300 mg</i> | 4 | NDS |
| <i>efavirenz-lamivudine-tenofovir disoproxil fumarate oral tablet 400-300-300 mg, 600-300-300 mg</i> | 4 | NDS |
| <i>emtricitabine oral capsule 200 mg</i> | 1 | |
| <i>emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 133-200 mg, 167-250 mg</i> | 4 | NDS; QL (30 per 30 days) |
| <i>emtricitabine-tenofovir (tdf) oral tablet 200-300 mg</i> | 3 | NDS; QL (30 per 30 days) |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 3 | NDS |
| <i>etravirine oral tablet 100 mg, 200 mg</i> | 4 | NDS |
| EVOTAZ ORAL TABLET 300-150 MG | 4 | NDS |
| <i>fosamprenavir oral tablet 700 mg</i> | 4 | NDS |
| FUZEON SUBCUTANEOUS RECON SOLN 90 MG | 4 | NDS |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 4 | NDS |
| INTELENCE ORAL TABLET 25 MG | 3 | NDS |
| ISENTRESS HD ORAL TABLET 600 MG | 4 | NDS |
| ISENTRESS ORAL POWDER IN PACKET 100 MG | 4 | NDS |
| ISENTRESS ORAL TABLET 400 MG | 4 | NDS |
| ISENTRESS ORAL TABLET,CHEWABLE 100 MG | 4 | NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------|
| ISENTRESS ORAL TABLET,CHEWABLE 25 MG | 3 | NDS |
| JULUCA ORAL TABLET 50-25 MG | 4 | NDS |
| <i>lamivudine oral solution 10 mg/ml</i> | 1 | |
| <i>lamivudine oral tablet 100 mg, 150 mg, 300 mg</i> | 1 | |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | 1 | |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5 ml</i> | 1 | QL (480 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> | 1 | QL (300 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> | 3 | NDS; QL (120 per 30 days) |
| <i>maraviroc oral tablet 150 mg, 300 mg</i> | 4 | NDS |
| <i>nevirapine oral suspension 50 mg/5 ml</i> | 1 | |
| <i>nevirapine oral tablet 200 mg</i> | 1 | |
| <i>nevirapine oral tablet extended release 24 hr 400 mg</i> | 1 | |
| NORVIR ORAL POWDER IN PACKET 100 MG | 3 | NDS |
| ODEFSEY ORAL TABLET 200-25-25 MG | 4 | NDS |
| PIFELTRO ORAL TABLET 100 MG | 4 | NDS |
| PREZCOBIX ORAL TABLET 800-150 MG-MG | 4 | NDS |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 4 | NDS; QL (400 per 30 days) |
| PREZISTA ORAL TABLET 150 MG | 4 | NDS; QL (240 per 30 days) |
| PREZISTA ORAL TABLET 75 MG | 4 | NDS; QL (480 per 30 days) |
| REYATAZ ORAL POWDER IN PACKET 50 MG | 4 | NDS |
| <i>ritonavir oral tablet 100 mg</i> | 1 | |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG | 4 | NDS |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 4 | NDS |
| SELZENTRY ORAL TABLET 25 MG | 2 | |
| SELZENTRY ORAL TABLET 75 MG | 4 | NDS |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 4 | NDS |
| SUNLENCA ORAL TABLET 300 MG | 4 | NDS; QL (10 per 365 days) |
| SUNLENCA ORAL TABLET 300 MG (4-TABLET PACK) | 4 | NDS; QL (8 per 365 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| SYMITUZA ORAL TABLET 800-150-200-10 MG | 4 | NDS |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | 1 | |
| TIVICAY ORAL TABLET 10 MG | 3 | NDS |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 4 | NDS |
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG | 4 | NDS |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 4 | NDS; QL (30 per 30 days) |
| TRIUMEQ PD ORAL TABLET FOR SUSPENSION 60-5-30 MG | 3 | NDS |
| VEMLIDY ORAL TABLET 25 MG | 4 | NDS; QL (30 per 30 days) |
| VIRACEPT ORAL TABLET 250 MG, 625 MG | 4 | NDS |
| VIREAD ORAL POWDER 40 MG/SCOOP (40 MG/GRAM) | 4 | NDS |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 4 | NDS |
| <i>zidovudine oral capsule 100 mg</i> | 1 | |
| <i>zidovudine oral syrup 10 mg/ml</i> | 1 | |
| <i>zidovudine oral tablet 300 mg</i> | 1 | |
| Antivirals, Miscellaneous | | |
| LIVTENCITY ORAL TABLET 200 MG | 4 | PA; NDS |
| <i>oseltamivir oral capsule 30 mg</i> | 1 | QL (84 per 180 days) |
| <i>oseltamivir oral capsule 45 mg</i> | 1 | QL (48 per 180 days) |
| <i>oseltamivir oral capsule 75 mg</i> | 1 | QL (42 per 180 days) |
| <i>oseltamivir oral suspension for reconstitution 6 mg/ml</i> | 1 | QL (540 per 180 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 150-100 MG, 300 MG (150 MG X 2)-100 MG | 1 | |
| PREVYMIS ORAL PELLETS IN PACKET 120 MG, 20 MG | 4 | PA; NDS |
| PREVYMIS ORAL TABLET 240 MG, 480 MG | 4 | PA; NDS; QL (28 per 28 days) |
| RELENZA DISKHALER INHALATION BLISTER WITH DEVICE 5 MG/ACTUATION | 3 | NDS; QL (60 per 180 days) |
| <i>rimantadine oral tablet 100 mg</i> | 1 | |
| XOFLUZA ORAL TABLET 40 MG, 80 MG | 3 | NDS |
| Hcv Antivirals | | |
| EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG | 4 | PA NSO; NDS; QL (28 per 28 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| EPCLUSA ORAL PELLETS IN PACKET 200-50 MG | 4 | PA NSO; NDS; QL (56 per 28 days) |
| EPCLUSA ORAL TABLET 200-50 MG | 4 | PA NSO; NDS; QL (56 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 33.75-150 MG | 4 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 45-200 MG | 4 | PA; NDS; QL (56 per 28 days) |
| <i>ledipasvir-sofosbuvir oral tablet 90-400 mg</i> | 4 | PA; NDS; QL (28 per 28 days) |
| MAVYRET ORAL PELLETS IN PACKET 50-20 MG | 4 | PA; NDS |
| MAVYRET ORAL TABLET 100-40 MG | 4 | PA; NDS; QL (84 per 28 days) |
| <i>sofosbuvir-velpatasvir oral tablet 400-100 mg</i> | 4 | PA NSO; NDS; QL (30 per 30 days) |
| VOSEVI ORAL TABLET 400-100-100 MG | 4 | PA; NDS; QL (28 per 28 days) |
| Interferons | | |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 4 | NDS |
| PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML | 4 | NDS |
| Nucleosides And Nucleotides | | |
| <i>acyclovir oral capsule 200 mg</i> | 1 | |
| <i>acyclovir oral suspension 200 mg/5 ml</i> | 1 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 1 | |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 1 | PA BvD; HI |
| <i>adefovir oral tablet 10 mg</i> | 1 | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> | 1 | |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 1 | |
| <i>ribavirin oral capsule 200 mg</i> | 1 | |
| <i>ribavirin oral tablet 200 mg</i> | 1 | |
| <i>valacyclovir oral tablet 1 gram, 500 mg</i> | 1 | |
| <i>valganciclovir oral recon soln 50 mg/ml</i> | 4 | NDS |
| <i>valganciclovir oral tablet 450 mg</i> | 1 | |
| Blood Products/Modifiers/Volume Expanders | | |
| Anticoagulants | | |
| <i>dabigatran etexilate oral capsule 110 mg</i> | 1 | |
| <i>dabigatran etexilate oral capsule 150 mg, 75 mg</i> | 1 | QL (60 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------|
| ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS) | 2 | QL (74 per 30 days) |
| ELIQUIS ORAL TABLET 2.5 MG | 2 | QL (60 per 30 days) |
| ELIQUIS ORAL TABLET 5 MG | 2 | QL (74 per 30 days) |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 150 mg/ml</i> | 1 | QL (60 per 30 days) |
| <i>enoxaparin subcutaneous syringe 120 mg/0.8 ml, 80 mg/0.8 ml</i> | 1 | QL (48 per 30 days) |
| <i>enoxaparin subcutaneous syringe 30 mg/0.3 ml</i> | 1 | QL (18 per 30 days) |
| <i>enoxaparin subcutaneous syringe 40 mg/0.4 ml</i> | 1 | QL (24 per 30 days) |
| <i>enoxaparin subcutaneous syringe 60 mg/0.6 ml</i> | 1 | QL (36 per 30 days) |
| <i>fondaparinux subcutaneous syringe 10 mg/0.8 ml</i> | 4 | NDS; QL (24 per 30 days) |
| <i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml</i> | 1 | QL (15 per 30 days) |
| <i>fondaparinux subcutaneous syringe 5 mg/0.4 ml</i> | 4 | NDS; QL (12 per 30 days) |
| <i>fondaparinux subcutaneous syringe 7.5 mg/0.6 ml</i> | 4 | NDS; QL (18 per 30 days) |
| <i>heparin (porcine) injection solution 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml</i> | 1 | PA BvD; HI |
| <i>jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | |
| <i>warfarin oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | |
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)-20 MG (9) | 2 | QL (51 per 30 days) |
| XARELTO ORAL SUSPENSION FOR RECONSTITUTION 1 MG/ML | 2 | QL (600 per 30 days) |
| XARELTO ORAL TABLET 10 MG, 20 MG | 2 | QL (30 per 30 days) |
| XARELTO ORAL TABLET 15 MG, 2.5 MG | 2 | QL (60 per 30 days) |
| Blood Formation Modifiers | | |
| CINRYZE INTRAVENOUS RECON SOLN 500 UNIT (5 ML) | 4 | PA BvD; NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| DOPTELET (10 TAB PACK) ORAL TABLET 20 MG | 4 | PA; NDS; QL (60 per 30 days) |
| DOPTELET (15 TAB PACK) ORAL TABLET 20 MG | 4 | PA; NDS; QL (60 per 30 days) |
| DOPTELET (30 TAB PACK) ORAL TABLET 20 MG | 4 | PA; NDS; QL (60 per 30 days) |
| FULPHILA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 4 | PA; NDS |
| HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT | 4 | PA; NDS; QL (30 per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 3,000 UNIT | 4 | PA; NDS; QL (20 per 30 days) |
| LEUKINE INJECTION RECON SOLN 250 MCG | 4 | NDS |
| NEULASTA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 4 | PA; NDS |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 4 | PA; NDS |
| NIVESTYM SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 4 | PA; NDS |
| NYVEPRIA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 4 | PA; NDS |
| PROMACTA ORAL POWDER IN PACKET 12.5 MG | 4 | PA; NDS; QL (90 per 30 days) |
| PROMACTA ORAL POWDER IN PACKET 25 MG | 4 | PA; NDS; QL (180 per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG | 4 | PA; NDS; QL (90 per 30 days) |
| PROMACTA ORAL TABLET 25 MG | 4 | PA; NDS; QL (30 per 30 days) |
| PROMACTA ORAL TABLET 50 MG, 75 MG | 4 | PA; NDS; QL (60 per 30 days) |
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | 2 | PA; QL (12 per 28 days) |
| RETACRIT INJECTION SOLUTION 40,000 UNIT/ML | 2 | PA; QL (4 per 28 days) |
| UDENYCA AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 6 MG/0.6 ML | 4 | PA; NDS |
| UDENYCA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 4 | PA; NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| ZARXIO INJECTION SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 4 | PA; NDS |
| Hematologic Agents, Miscellaneous | | |
| <i>anagrelide oral capsule 0.5 mg, 1 mg</i> | 1 | |
| CABLIVI INJECTION KIT 11 MG | 4 | PA; NDS; QL (30 per 30 days) |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 3 | NDS |
| <i>tranexamic acid oral tablet 650 mg</i> | 1 | |
| Platelet-Aggregation Inhibitors | | |
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | 1 | QL (60 per 30 days) |
| BRILINTA ORAL TABLET 60 MG, 90 MG | 2 | |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 1 | |
| <i>clopidogrel oral tablet 75 mg</i> | 1 | |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>pentoxifylline oral tablet extended release 400 mg</i> | 1 | |
| <i>prasugrel hcl oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| Caloric Agents | | |
| Caloric Agents | | |
| CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 3 | PA BvD; HI; NDS |
| CLINIMIX 4.25%/D10W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 3 | PA BvD; HI; NDS |
| CLINIMIX 4.25%/D5W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 3 | PA BvD; HI; NDS |
| CLINIMIX 5%-D20W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 5 % | 3 | PA BvD; HI; NDS |
| CLINIMIX E 2.75%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 2.75 % | 3 | PA BvD; HI; NDS |
| CLINIMIX E 4.25%/D10W SUL FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 3 | PA BvD; HI; NDS |
| CLINIMIX E 4.25%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 3 | PA BvD; HI; NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| CLINIMIX E 5%/D15W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 3 | PA BvD; HI; NDS |
| CLINIMIX E 5%/D20W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 3 | PA BvD; HI; NDS |
| <i>dextrose 10 % in water (d10w) intravenous parenteral solution 10 %</i> | 1 | PA BvD; HI |
| <i>dextrose 5 % in water (d5w) intravenous parenteral solution</i> | 1 | PA BvD; HI |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | 3 | PA BvD; HI; NDS |
| NUTRILIPID INTRAVENOUS EMULSION 20 % | 3 | PA BvD; HI; NDS |
| PROSOL 20 % INTRAVENOUS PARENTERAL SOLUTION | 3 | PA BvD; HI; NDS |
| TRAVASOL 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 3 | PA BvD; HI; NDS |
| TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 3 | PA BvD; HI; NDS |
| Cardiovascular Agents | | |
| Alpha-Adrenergic Agents | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 1 | |
| <i>clonidine transdermal patch weekly 0.1 mg/24 hr, 0.2 mg/24 hr</i> | 1 | QL (4 per 28 days) |
| <i>clonidine transdermal patch weekly 0.3 mg/24 hr</i> | 1 | QL (8 per 28 days) |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | 1 | |
| <i>droxidopa oral capsule 100 mg, 200 mg, 300 mg</i> | 4 | PA; NDS; QL (180 per 30 days) |
| <i>guanfacine oral tablet 1 mg, 2 mg</i> | 1 | |
| <i>midodrine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> | 1 | |
| Angiotensin II Receptor Antagonists | | |
| <i>candesartan oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 1 | |
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | 1 | |
| EDARBI ORAL TABLET 40 MG, 80 MG | 2 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------|
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG | 2 | |
| ENTRESTO ORAL TABLET 24-26 MG | 2 | QL (180 per 30 days) |
| ENTRESTO ORAL TABLET 49-51 MG, 97-103 MG | 2 | QL (60 per 30 days) |
| ENTRESTO SPRINKLE ORAL PELLETT 15-16 MG, 6-6 MG | 2 | |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | 1 | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | 1 | |
| <i>losartan oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | 1 | |
| <i>olmesartan oral tablet 20 mg, 40 mg, 5 mg</i> | 1 | |
| <i>olmesartan-amlodipin-hcthiiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | 1 | |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | 1 | |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | 1 | |
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | 1 | |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> | 1 | |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | 1 | |
| Angiotensin-Converting Enzyme Inhibitors | | |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | 1 | |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>enalapril maleate oral solution 1 mg/ml</i> | 1 | ST; QL (1200 per 30 days) |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 1 | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>fosinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg</i> | 1 | |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | 1 | |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 1 | |
| <i>moexipril oral tablet 15 mg, 7.5 mg</i> | 1 | |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 1 | |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 1 | |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | |
| <i>trandolapril-verapamil oral tablet, ir - er, biphasic 24hr 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg</i> | 1 | |
| Antiarrhythmic Agents | | |
| <i>amiodarone oral tablet 100 mg, 200 mg, 400 mg</i> | 1 | |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> | 1 | |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> | 1 | |
| <i>flecainide oral tablet 100 mg, 150 mg, 50 mg</i> | 1 | |
| <i>mexiletine oral capsule 150 mg, 200 mg, 250 mg</i> | 1 | |
| MULTAQ ORAL TABLET 400 MG | 2 | |
| <i>pacerone oral tablet 100 mg, 200 mg, 400 mg</i> | 1 | |
| <i>propafenone oral capsule, extended release 12 hr 225 mg, 325 mg, 425 mg</i> | 1 | |
| <i>propafenone oral tablet 150 mg, 225 mg, 300 mg</i> | 1 | |
| <i>quinidine gluconate oral tablet extended release 324 mg</i> | 1 | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| Beta-Adrenergic Blocking Agents | | |
| <i>acebutolol oral capsule 200 mg, 400 mg</i> | 1 | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | 1 | |
| <i>betaxolol oral tablet 10 mg, 20 mg</i> | 1 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 1 | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | 1 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | 1 | |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>metoprolol ta-hydrochlorothiaz oral tablet 100-25 mg, 100-50 mg, 50-25 mg</i> | 1 | |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | |
| <i>nebivolol oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 1 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>propranolol oral capsule, extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> | 1 | |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | 1 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 1 | |
| <i>sorine oral tablet 120 mg, 160 mg</i> | 1 | |
| <i>sotalol af oral tablet 120 mg, 160 mg, 80 mg</i> | 1 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 1 | |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | |
| Calcium-Channel Blocking Agents | | |
| <i>cartia xt oral capsule, extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | 1 | |
| <i>diltiazem hcl oral capsule, extended release 12 hr 120 mg, 60 mg, 90 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg, 420 mg</i> | 1 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | 1 | |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | 1 | |
| <i>dilt-xr oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> | 1 | |
| <i>matzim la oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 1 | |
| <i>tiadylt er oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 1 | |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> | 1 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg</i> | 1 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 360 mg</i> | 3 | NDS |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | |
| <i>verapamil oral tablet extended release 120 mg, 180 mg, 240 mg</i> | 1 | |
| Cardiovascular Agents, Miscellaneous | | |
| CORLANOR ORAL SOLUTION 5 MG/5 ML | 2 | QL (600 per 30 days) |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> | 1 | |
| <i>epinephrine injection auto-injector 0.15 mg/0.3 ml, 0.3 mg/0.3 ml</i> | 1 | QL (4 per 30 days) |
| <i>hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>icatibant subcutaneous syringe 30 mg/3 ml</i> | 4 | PA; NDS; QL (18 per 30 days) |
| <i>ivabradine oral tablet 5 mg, 7.5 mg</i> | 1 | QL (60 per 30 days) |
| <i>metyrosine oral capsule 250 mg</i> | 4 | NDS |
| <i>ranolazine oral tablet extended release 12 hr 1,000 mg</i> | 1 | QL (60 per 30 days) |
| <i>ranolazine oral tablet extended release 12 hr 500 mg</i> | 1 | QL (120 per 30 days) |
| <i>sajazir subcutaneous syringe 30 mg/3 ml</i> | 4 | PA; NDS; QL (18 per 30 days) |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG | 3 | PA; NDS; QL (30 per 30 days) |
| VYNDAMAX ORAL CAPSULE 61 MG | 4 | PA; NDS; QL (30 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Dihydropyridines | | |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | 1 | |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> | 1 | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | 1 | |
| <i>amlodipine-valsartan-hcthiazyd oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | 1 | |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>isradipine oral capsule 2.5 mg, 5 mg</i> | 1 | |
| <i>nicardipine oral capsule 20 mg, 30 mg</i> | 1 | |
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | 1 | |
| <i>nifedipine oral tablet extended release 24hr 30 mg, 60 mg, 90 mg</i> | 1 | |
| <i>nifedipine oral tablet extended release 30 mg, 60 mg, 90 mg</i> | 1 | |
| Diuretics | | |
| <i>amiloride oral tablet 5 mg</i> | 1 | |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 1 | |
| <i>bumetanide injection solution 0.25 mg/ml</i> | 1 | |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 1 | |
| <i>furosemide injection solution 10 mg/ml</i> | 1 | |
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i> | 1 | |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------|
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | 1 | |
| <i>torse mide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 1 | |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | 1 | |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | |
| Dyslipidemics | | |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg</i> | 1 | |
| <i>amlodipine-atorvastatin oral tablet 10-20 mg, 10-40 mg, 10-80 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | 1 | QL (30 per 30 days) |
| <i>atorvastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 1 | QL (30 per 30 days) |
| <i>cholestyramine (with sugar) oral powder in packet 4 gram</i> | 1 | |
| <i>cholestyramine light oral powder in packet 4 gram</i> | 1 | |
| <i>colesevelam oral powder in packet 3.75 gram</i> | 1 | |
| <i>colesevelam oral tablet 625 mg</i> | 1 | |
| <i>colestipol oral packet 5 gram</i> | 1 | |
| <i>colestipol oral tablet 1 gram</i> | 1 | |
| <i>ezetimibe oral tablet 10 mg</i> | 1 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg</i> | 1 | QL (30 per 30 days) |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 43 mg, 67 mg</i> | 1 | |
| <i>fenofibrate nanocrystallized oral tablet 145 mg, 48 mg</i> | 1 | |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i> | 1 | |
| <i>fenofibric acid (choline) oral capsule, delayed release(dr/ec) 135 mg, 45 mg</i> | 1 | |
| <i>fluvastatin oral capsule 20 mg, 40 mg</i> | 1 | QL (60 per 30 days) |
| <i>fluvastatin oral tablet extended release 24 hr 80 mg</i> | 1 | |
| <i>gemfibrozil oral tablet 600 mg</i> | 1 | |
| <i>icosapent ethyl oral capsule 0.5 gram</i> | 1 | QL (240 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------|
| <i>icosapent ethyl oral capsule 1 gram</i> | 1 | QL (120 per 30 days) |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | |
| NEXLETOL ORAL TABLET 180 MG | 2 | QL (30 per 30 days) |
| NEXLIZET ORAL TABLET 180-10 MG | 2 | QL (30 per 30 days) |
| <i>niacin oral tablet 500 mg</i> | 1 | |
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 500 mg, 750 mg</i> | 1 | |
| <i>niacor oral tablet 500 mg</i> | 1 | |
| <i>omega-3 acid ethyl esters oral capsule 1 gram</i> | 1 | QL (120 per 30 days) |
| <i>pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | |
| <i>pravastatin oral tablet 10 mg, 80 mg</i> | 1 | |
| <i>pravastatin oral tablet 20 mg, 40 mg</i> | 1 | QL (30 per 30 days) |
| <i>prevalite oral powder in packet 4 gram</i> | 1 | |
| REPATHA PUSHTRONEX SUBCUTANEOUS WEARABLE INJECTOR 420 MG/3.5 ML | 2 | QL (7 per 28 days) |
| REPATHA SURECLICK SUBCUTANEOUS PEN INJECTOR 140 MG/ML | 2 | QL (6 per 28 days) |
| REPATHA SYRINGE SUBCUTANEOUS SYRINGE 140 MG/ML | 2 | QL (6 per 28 days) |
| <i>rosuvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg</i> | 1 | QL (30 per 30 days) |
| Renin-Angiotensin-Aldosterone System Inhibitors | | |
| <i>aliskiren oral tablet 150 mg, 300 mg</i> | 1 | |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> | 1 | |
| KERENDIA ORAL TABLET 10 MG, 20 MG | 2 | PA; QL (30 per 30 days) |
| Vasodilators | | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i> | 1 | |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 1 | |
| <i>isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg</i> | 1 | |
| <i>isosorbide-hydralazine oral tablet 20-37.5 mg</i> | 1 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| <i>nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg</i> | 1 | |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 1 | |
| Central Nervous System Agents | | |
| Central Nervous System Agents | | |
| <i>atomoxetine oral capsule 10 mg, 18 mg, 25 mg, 40 mg</i> | 1 | QL (60 per 30 days) |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i> | 1 | QL (30 per 30 days) |
| AUSTEDO ORAL TABLET 12 MG, 9 MG | 4 | PA; NDS; QL (120 per 30 days) |
| AUSTEDO ORAL TABLET 6 MG | 4 | PA; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 18 MG | 4 | PA; NDS; QL (90 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 24 MG | 4 | PA; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 30 MG, 36 MG, 42 MG, 48 MG | 4 | PA; NDS; QL (30 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 6 MG | 4 | PA; NDS; QL (210 per 30 days) |
| AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG, 6 MG (14)-12 MG (14)-24 MG (14) | 4 | PA; NDS; QL (84 per 30 days) |
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT 30 MCG/0.5 ML | 4 | PA; NDS; QL (1 per 28 days) |
| AVONEX INTRAMUSCULAR SYRINGE KIT 30 MCG/0.5 ML | 4 | PA; NDS; QL (1 per 28 days) |
| AVONEX PEN 30 MCG/0.5 ML | 4 | PA; NDS; QL (1 per 28 days) |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 4 | PA; NDS; QL (15 per 30 days) |
| <i>clonidine hcl oral tablet extended release 12 hr 0.1 mg</i> | 1 | |
| <i>dalfampridine oral tablet extended release 12 hr 10 mg</i> | 1 | PA; QL (60 per 30 days) |
| <i>dexmethylphenidate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | QL (60 per 30 days) |
| <i>dextroamphetamine sulfate oral capsule, extended release 10 mg, 15 mg, 5 mg</i> | 1 | QL (120 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10 mg</i> | 1 | QL (180 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| <i>dextroamphetamine sulfate oral tablet 15 mg, 5 mg</i> | 1 | QL (90 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 20 mg, 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule,extended release 24hr 10 mg, 15 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule,extended release 24hr 20 mg, 25 mg, 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> | 1 | QL (60 per 30 days) |
| <i>dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg</i> | 4 | PA; NDS; QL (14 per 7 days) |
| <i>dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg (14)- 240 mg (46)</i> | 4 | PA; NDS |
| <i>dimethyl fumarate oral capsule,delayed release(dr/ec) 240 mg</i> | 4 | PA; NDS; QL (60 per 30 days) |
| <i>fingolimod oral capsule 0.5 mg</i> | 4 | PA; NDS; QL (30 per 30 days) |
| GILENYA ORAL CAPSULE 0.25 MG | 4 | PA; NDS; QL (60 per 30 days) |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i> | 4 | PA; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i> | 4 | PA; NDS; QL (12 per 28 days) |
| <i>glatopa subcutaneous syringe 20 mg/ml</i> | 4 | PA; NDS; QL (30 per 30 days) |
| <i>glatopa subcutaneous syringe 40 mg/ml</i> | 4 | PA; NDS; QL (12 per 28 days) |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | |
| INGREZZA INITIATION PK(TARDIV) ORAL CAPSULE,DOSE PACK 40 MG (7)- 80 MG (21) | 4 | PA; NDS |
| INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG | 4 | PA; NDS; QL (30 per 30 days) |
| KESIMPTA PEN SUBCUTANEOUS PEN INJECTOR 20 MG/0.4 ML | 4 | PA; NDS; QL (1.2 per 28 days) |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | |
| <i>lithium carbonate oral tablet 300 mg</i> | 1 | |
| <i>lithium carbonate oral tablet extended release 300 mg, 450 mg</i> | 1 | |
| <i>lithium citrate oral solution 8 meq/5 ml</i> | 2 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| MAVENCLAD (10 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; NDS |
| MAVENCLAD (4 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; NDS |
| MAVENCLAD (5 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; NDS |
| MAVENCLAD (6 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; NDS |
| MAVENCLAD (7 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; NDS |
| MAVENCLAD (8 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; NDS |
| MAVENCLAD (9 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; NDS |
| MAYZENT ORAL TABLET 0.25 MG | 4 | PA; NDS; QL (112 per 28 days) |
| MAYZENT ORAL TABLET 1 MG, 2 MG | 4 | PA; NDS; QL (30 per 30 days) |
| MAYZENT STARTER(FOR 1MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (7 TABS) | 3 | PA; NDS |
| MAYZENT STARTER(FOR 2MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (12 TABS) | 4 | PA; NDS |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 10 mg, 20 mg, 40 mg, 50 mg, 60 mg</i> | 1 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 10 mg, 20 mg, 40 mg, 60 mg</i> | 1 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral solution 10 mg/5 ml, 5 mg/5 ml</i> | 1 | QL (900 per 30 days) |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 10 mg, 20 mg</i> | 1 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 18 mg (bx rating), 27 mg, 27 mg (bx rating), 54 mg, 54 mg (bx rating)</i> | 1 | QL (30 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| <i>methylphenidate hcl oral tablet extended release 24hr 36 mg, 36 mg (bx rating)</i> | 1 | QL (60 per 30 days) |
| RADICAVA ORS STARTER KIT SUSP ORAL SUSPENSION 105 MG/5 ML | 4 | PA; NDS; QL (150 per 30 days) |
| <i>riluzole oral tablet 50 mg</i> | 1 | QL (60 per 30 days) |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | 2 | QL (60 per 30 days) |
| SAVELLA ORAL TABLETS,DOSE PACK 12.5 MG (5)-25 MG(8)-50 MG(42) | 2 | |
| <i>teriflunomide oral tablet 14 mg, 7 mg</i> | 4 | PA; NDS; QL (30 per 30 days) |
| <i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> | 4 | PA; NDS; QL (112 per 28 days) |
| VUMERITY ORAL CAPSULE,DELAYED RELEASE(DR/EC) 231 MG | 4 | PA; NDS; QL (120 per 30 days) |
| Contraceptives | | |
| Contraceptives | | |
| <i>altavera (28) oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>alyacen 1/35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| <i>amethia oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| <i>apri oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>aranelle (28) oral tablet 0.5/1/0.5-35 mg-mcg</i> | 1 | |
| <i>ashlyna oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| <i>aubra eq oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>aviane oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>balziva (28) oral tablet 0.4-35 mg-mcg</i> | 1 | |
| <i>blisovi 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>blisovi fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1 | |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i> | 1 | |
| <i>camila oral tablet 0.35 mg</i> | 1 | |
| <i>cryselle (28) oral tablet 0.3-30 mg-mcg</i> | 1 | |
| <i>cyred eq oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>deblitane oral tablet 0.35 mg</i> | 1 | |
| <i>desog-e.estradiol/e.estradiol oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 1 | |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.03 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg</i> | 1 | |
| <i>eluryng vaginal ring 0.12-0.015 mg/24 hr</i> | 1 | QL (1 per 28 days) |
| <i>enpresse oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 1 | |
| <i>enskyce oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>errin oral tablet 0.35 mg</i> | 1 | |
| <i>estarylla oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i> | 1 | |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr</i> | 1 | QL (1 per 28 days) |
| <i>falmina (28) oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>hailey 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>haloette vaginal ring 0.12-0.015 mg/24 hr</i> | 1 | QL (1 per 28 days) |
| <i>iclevia oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 1 | QL (91 per 84 days) |
| <i>incassia oral tablet 0.35 mg</i> | 1 | |
| <i>isibloom oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>jasmiel (28) oral tablet 3-0.02 mg</i> | 1 | |
| <i>juleber oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>junel 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 1 | |
| <i>junel 1/20 (21) oral tablet 1-20 mg-mcg</i> | 1 | |
| <i>junel fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1 | |
| <i>junel fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>junel fe 24 oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>kariva (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 1 | |
| <i>kelnor 1/35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| <i>kelnor 1/50 (28) oral tablet 1-50 mg-mcg</i> | 1 | |
| <i>kurvelo (28) oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>l norgest/e.estradiol-e.estradiol oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7), 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| <i>larin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>larin 1/20 (21) oral tablet 1-20 mg-mcg</i> | 1 | |
| <i>larin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1 | |
| <i>larin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>lessina oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>levonest (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 1 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-0.03 mg</i> | 1 | |
| <i>levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 1 | QL (91 per 84 days) |
| <i>levonorg-eth estrad triphasic oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 1 | |
| <i>levora-28 oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>loryna (28) oral tablet 3-0.02 mg</i> | 1 | |
| <i>low-ogestrel (28) oral tablet 0.3-30 mg-mcg</i> | 1 | |
| <i>lutera (28) oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>lyleq oral tablet 0.35 mg</i> | 1 | |
| <i>lyza oral tablet 0.35 mg</i> | 1 | |
| <i>marlissa (28) oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>merzee oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>microgestin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>mili oral tablet 0.25-35 mg-mcg</i> | 1 | |
| MIRENA INTRAUTERINE INTRAUTERINE DEVICE 21 MCG/24HR (UP TO 8 YRS) 52 MG | 2 | |
| <i>necon 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i> | 1 | |
| NEXPLANON SUBDERMAL IMPLANT 68 MG | 2 | |
| <i>nikki (28) oral tablet 3-0.02 mg</i> | 1 | |
| <i>norethindrone (contraceptive) oral tablet 0.35 mg</i> | 1 | |
| <i>norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7), 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | 1 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-25 mcg, 0.18/0.215/0.25 mg-35 mcg (28), 0.25-35 mg-mcg</i> | 1 | |
| <i>nortrel 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i> | 1 | |
| <i>nortrel 1/35 (21) oral tablet 1-35 mg-mcg (21)</i> | 1 | |
| <i>nortrel 1/35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| <i>nortrel 7/7/7 (28) oral tablet 0.5/0.75/1 mg-35 mcg</i> | 1 | |
| <i>nylia 1/35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| <i>nylia 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 1 | |
| <i>nymyo oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>pimtreea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 1 | |
| <i>portia 28 oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>reclipsen (28) oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>setlakin oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 1 | QL (91 per 84 days) |
| <i>sharobel oral tablet 0.35 mg</i> | 1 | |
| <i>sprintec (28) oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>sronyx oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>syeda oral tablet 3-0.03 mg</i> | 1 | |
| <i>tarina 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>tarina fe 1-20 eq (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>tri-estarylla oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |
| <i>tri-legest fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | 1 | |
| <i>tri-lo-estarylla oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-mili oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>tri-nymyo oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |
| <i>tri-sprintec (28) oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |
| <i>trivora (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 1 | |
| <i>tri-vylibra lo oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-vylibra oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |
| <i>tyblume oral tablet, chewable 0.1 mg- 20 mcg</i> | 3 | NDS |
| <i>velivet triphasic regimen (28) oral tablet 0.1/.125/.15-25 mg-mcg</i> | 1 | |
| <i>vestura (28) oral tablet 3-0.02 mg</i> | 1 | |
| <i>vienva oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>vyfemla (28) oral tablet 0.4-35 mg-mcg</i> | 1 | |
| <i>vylibra oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>xulane transdermal patch weekly 150-35 mcg/24 hr</i> | 1 | QL (3 per 28 days) |
| <i>zafemy transdermal patch weekly 150-35 mcg/24 hr</i> | 1 | QL (3 per 28 days) |
| <i>zovia 1-35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| Cough And Cold Products | | |
| Cough And Cold Products | | |
| <i>benzonatate oral capsule 100 mg, 200 mg</i> | 5 | NDS; EX |
| Dental And Oral Agents | | |
| Dental And Oral Agents | | |
| <i>cevimeline oral capsule 30 mg</i> | 1 | |
| <i>chlorhexidine gluconate mucous membrane mouthwash 0.12 %</i> | 1 | |
| <i>periogard mucous membrane mouthwash 0.12 %</i> | 1 | |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> | 1 | |
| <i>triamcinolone acetonide dental paste 0.1 %</i> | 1 | |
| Dermatological Agents | | |
| Dermatological Agents, Other | | |
| <i>accutane oral capsule 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | 1 | |
| <i>acyclovir topical ointment 5 %</i> | 1 | QL (30 per 30 days) |
| <i>ammonium lactate topical cream 12 %</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| <i>ammonium lactate topical lotion 12 %</i> | 1 | |
| <i>calcipotriene scalp solution 0.005 %</i> | 1 | QL (120 per 30 days) |
| <i>calcipotriene topical cream 0.005 %</i> | 1 | QL (120 per 30 days) |
| <i>calcipotriene topical ointment 0.005 %</i> | 1 | QL (120 per 30 days) |
| <i>fluorouracil topical cream 0.5 %</i> | 4 | NDS; QL (30 per 30 days) |
| <i>fluorouracil topical cream 5 %</i> | 1 | QL (40 per 30 days) |
| <i>fluorouracil topical solution 2 %, 5 %</i> | 1 | |
| <i>imiquimod topical cream in packet 5 %</i> | 1 | QL (24 per 30 days) |
| <i>methoxsalen oral capsule, liqd-filled, rapid rel 10 mg</i> | 4 | NDS |
| PANRETIN TOPICAL GEL 0.1 % | 4 | NDS; QL (180 per 30 days) |
| <i>penciclovir topical cream 1 %</i> | 1 | QL (5 per 30 days) |
| <i>podofilox topical solution 0.5 %</i> | 1 | |
| REGRANEX TOPICAL GEL 0.01 % | 4 | PA; NDS; QL (30 per 30 days) |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM | 3 | NDS; QL (180 per 30 days) |
| VALCHLOR TOPICAL GEL 0.016 % | 4 | NDS; QL (60 per 30 days) |
| <i>zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 | |
| Dermatological Antibacterials | | |
| <i>clindamycin phosphate topical foam 1 %</i> | 1 | QL (100 per 30 days) |
| <i>clindamycin phosphate topical solution 1 %</i> | 1 | QL (180 per 30 days) |
| <i>clindamycin phosphate topical swab 1 %</i> | 1 | |
| <i>clindamycin-benzoyl peroxide topical gel 1-5 %, 1.2 %(1 % base) -5 %</i> | 1 | |
| <i>ery pads topical swab 2 %</i> | 1 | |
| <i>erythromycin with ethanol topical gel 2 %</i> | 1 | QL (180 per 30 days) |
| <i>erythromycin with ethanol topical solution 2 %</i> | 1 | QL (180 per 30 days) |
| <i>erythromycin-benzoyl peroxide topical gel 3-5 %</i> | 1 | |
| <i>gentamicin topical cream 0.1 %</i> | 1 | QL (120 per 30 days) |
| <i>gentamicin topical ointment 0.1 %</i> | 1 | QL (120 per 30 days) |
| <i>metronidazole topical cream 0.75 %</i> | 1 | |
| <i>metronidazole topical gel 0.75 %, 1 %</i> | 1 | |
| <i>metronidazole topical lotion 0.75 %</i> | 1 | |
| <i>mupirocin topical ointment 2 %</i> | 1 | QL (220 per 30 days) |
| <i>selenium sulfide topical lotion 2.5 %</i> | 1 | |
| <i>silver sulfadiazine topical cream 1 %</i> | 1 | QL (100 per 30 days) |
| <i>ssd topical cream 1 %</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------|
| <i>sulfacetamide sodium (acne) topical suspension 10 %</i> | 1 | |
| Dermatological Anti-Inflammatory Agents | | |
| <i>ala-cort topical cream 1 %</i> | 1 | |
| <i>alclometasone topical cream 0.05 %</i> | 1 | |
| <i>alclometasone topical ointment 0.05 %</i> | 1 | |
| <i>betamethasone dipropionate topical cream 0.05 %</i> | 1 | QL (90 per 30 days) |
| <i>betamethasone dipropionate topical lotion 0.05 %</i> | 1 | |
| <i>betamethasone dipropionate topical ointment 0.05 %</i> | 1 | QL (90 per 30 days) |
| <i>betamethasone valerate topical cream 0.1 %</i> | 1 | QL (180 per 30 days) |
| <i>betamethasone valerate topical foam 0.12 %</i> | 1 | QL (120 per 30 days) |
| <i>betamethasone valerate topical lotion 0.1 %</i> | 1 | |
| <i>betamethasone valerate topical ointment 0.1 %</i> | 1 | QL (180 per 30 days) |
| <i>betamethasone, augmented topical cream 0.05 %</i> | 1 | QL (100 per 30 days) |
| <i>betamethasone, augmented topical gel 0.05 %</i> | 1 | QL (100 per 30 days) |
| <i>betamethasone, augmented topical lotion 0.05 %</i> | 1 | |
| <i>betamethasone, augmented topical ointment 0.05 %</i> | 1 | QL (100 per 30 days) |
| <i>clobetasol scalp solution 0.05 %</i> | 1 | |
| <i>clobetasol topical cream 0.05 %</i> | 1 | QL (120 per 30 days) |
| <i>clobetasol topical foam 0.05 %</i> | 1 | QL (100 per 30 days) |
| <i>clobetasol topical gel 0.05 %</i> | 1 | QL (120 per 28 days) |
| <i>clobetasol topical lotion 0.05 %</i> | 1 | |
| <i>clobetasol topical ointment 0.05 %</i> | 1 | QL (120 per 28 days) |
| <i>clobetasol topical shampoo 0.05 %</i> | 1 | |
| <i>clobetasol-emollient topical cream 0.05 %</i> | 1 | QL (120 per 30 days) |
| <i>clobetasol-emollient topical foam 0.05 %</i> | 1 | QL (100 per 30 days) |
| <i>desonide topical cream 0.05 %</i> | 1 | QL (60 per 30 days) |
| <i>desonide topical lotion 0.05 %</i> | 1 | |
| <i>desonide topical ointment 0.05 %</i> | 1 | QL (60 per 30 days) |
| <i>desoximetasone topical cream 0.05 %, 0.25 %</i> | 1 | QL (120 per 30 days) |
| <i>desoximetasone topical gel 0.05 %</i> | 1 | QL (120 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------|
| <i>desoximetasone topical ointment 0.05 %, 0.25 %</i> | 1 | QL (120 per 30 days) |
| <i>diflorasone topical ointment 0.05 %</i> | 1 | QL (180 per 30 days) |
| EUCRISA TOPICAL OINTMENT 2 % | 2 | |
| <i>fluocinolone topical cream 0.01 %, 0.025 %</i> | 1 | QL (120 per 30 days) |
| <i>fluocinolone topical ointment 0.025 %</i> | 1 | QL (120 per 30 days) |
| <i>fluocinonide topical cream 0.05 %</i> | 1 | QL (120 per 30 days) |
| <i>fluocinonide topical gel 0.05 %</i> | 1 | QL (120 per 30 days) |
| <i>fluocinonide topical ointment 0.05 %</i> | 1 | QL (240 per 30 days) |
| <i>fluocinonide topical solution 0.05 %</i> | 1 | |
| <i>fluocinonide-emollient topical cream 0.05 %</i> | 1 | QL (120 per 30 days) |
| <i>fluticasone propionate topical cream 0.05 %</i> | 1 | QL (240 per 30 days) |
| <i>fluticasone propionate topical ointment 0.005 %</i> | 1 | QL (240 per 30 days) |
| <i>halobetasol propionate topical cream 0.05 %</i> | 1 | QL (50 per 30 days) |
| <i>halobetasol propionate topical ointment 0.05 %</i> | 1 | QL (50 per 30 days) |
| <i>hydrocortisone 2.5% cream</i> | 1 | QL (60 per 30 days) |
| <i>hydrocortisone butyrate topical lotion 0.1 %</i> | 1 | QL (236 per 30 days) |
| <i>hydrocortisone butyrate topical ointment 0.1 %</i> | 1 | QL (120 per 30 days) |
| <i>hydrocortisone butyrate topical solution 0.1 %</i> | 1 | QL (120 per 30 days) |
| <i>hydrocortisone topical cream 1 %</i> | 1 | QL (60 per 30 days) |
| <i>hydrocortisone topical cream with perineal applicator 2.5 %</i> | 1 | QL (60 per 30 days) |
| <i>hydrocortisone topical lotion 2.5 %</i> | 1 | |
| <i>hydrocortisone topical ointment 1 %, 2.5 %</i> | 1 | QL (240 per 30 days) |
| <i>hydrocortisone valerate topical cream 0.2 %</i> | 1 | |
| <i>hydrocortisone valerate topical ointment 0.2 %</i> | 1 | QL (60 per 30 days) |
| <i>mometasone topical cream 0.1 %</i> | 1 | QL (180 per 30 days) |
| <i>mometasone topical ointment 0.1 %</i> | 1 | QL (180 per 30 days) |
| <i>mometasone topical solution 0.1 %</i> | 1 | |
| <i>pimecrolimus topical cream 1 %</i> | 1 | QL (100 per 30 days) |
| <i>proctosol hc topical cream with perineal applicator 2.5 %</i> | 1 | QL (60 per 30 days) |
| <i>proctozone-hc topical cream with perineal applicator 2.5 %</i> | 1 | QL (60 per 30 days) |
| <i>tacrolimus topical ointment 0.03 %, 0.1 %</i> | 1 | QL (100 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------|
| <i>triamcinolone acetonide topical cream 0.025 % , 0.1 % , 0.5 %</i> | 1 | QL (454 per 30 days) |
| <i>triamcinolone acetonide topical lotion 0.025 % , 0.1 %</i> | 1 | |
| <i>triamcinolone acetonide topical ointment 0.025 % , 0.1 % , 0.5 %</i> | 1 | |
| Dermatological Retinoids | | |
| <i>adapalene topical cream 0.1 %</i> | 1 | |
| <i>tazarotene topical cream 0.1 %</i> | 1 | QL (120 per 30 days) |
| TAZORAC TOPICAL CREAM 0.05 % | 3 | NDS; QL (60 per 30 days) |
| <i>tretinoin topical cream 0.025 % , 0.1 %</i> | 1 | PA; QL (45 per 30 days) |
| <i>tretinoin topical cream 0.05 %</i> | 1 | PA; QL (60 per 30 days) |
| <i>tretinoin topical gel 0.01 % , 0.025 % , 0.05 %</i> | 1 | PA; QL (45 per 30 days) |
| Scabicides And Pediculicides | | |
| <i>malathion topical lotion 0.5 %</i> | 1 | |
| <i>permethrin topical cream 5 %</i> | 1 | QL (120 per 30 days) |
| Devices | | |
| Devices | | |
| 1ST TIER UNIFINE PENTP 5MM 31G 31 GAUGE X 3/16" | 1 | PA; ST |
| 1ST TIER UNIFINE PNTIP 4MM 32G 32 GAUGE X 5/32" | 1 | PA; ST |
| 1ST TIER UNIFINE PNTIP 6MM 31G 31 GAUGE X 1/4" | 1 | PA; ST |
| 1ST TIER UNIFINE PNTIP 8MM 31G STRL,SINGLE-USE,SHRT 31 GAUGE X 5/16" | 1 | PA; ST |
| 1ST TIER UNIFINE PNTP 29GX1/2" 29 GAUGE X 1/2" | 1 | PA; ST |
| 1ST TIER UNIFINE PNTP 31GX3/16 31 GAUGE X 3/16" | 1 | PA; ST |
| 1ST TIER UNIFINE PNTP 32GX5/32 32 GAUGE X 5/32" | 1 | PA; ST |
| ABOUTTIME PEN NEEDLE 30G X 8MM 30 GAUGE X 5/16" | 1 | PA; ST |
| ABOUTTIME PEN NEEDLE 31G X 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| ABOUTTIME PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| ABOUTTIME PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| ADVOCATE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ADVOCATE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ADVOCATE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ADVOCATE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ADVOCATE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ADVOCATE INS SYR 0.3 ML 29GX1/2 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| ADVOCATE INS SYR 0.5 ML 29GX1/2 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| ADVOCATE INS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| ADVOCATE INS SYR 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ADVOCATE PEN NDL 12.7MM 29G 29 GAUGE X 1/2" | 1 | PA; ST |
| ADVOCATE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| ADVOCATE PEN NEEDLE 4MM 33G 33 GAUGE X 5/32" | 1 | PA; ST |
| ADVOCATE PEN NEEDLES 5MM 31G 31 GAUGE X 3/16" | 1 | PA; ST |
| ADVOCATE PEN NEEDLES 8MM 31G 31 GAUGE X 5/16" | 1 | PA; ST |
| ALCOHOL 70% SWABS | 1 | PA; ST |
| ALCOHOL PADS TOPICAL PADS, MEDICATED | 1 | PA; ST |
| ALCOHOL PREP SWABS TOPICAL PADS, MEDICATED | 1 | PA; ST |
| AQINJECT PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| AQINJECT PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| ASSURE ID DUO PRO NDL 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| ASSURE ID DUO-SHIELD 30GX3/16" 30 GAUGE X 3/16" | 1 | PA; ST |
| ASSURE ID DUO-SHIELD 30GX5/16" 30 GAUGE X 5/16" | 1 | PA; ST |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| ASSURE ID PEN NEEDLE 30GX3/16" 30 GAUGE X 3/16" | 1 | PA; ST |
| ASSURE ID PEN NEEDLE 30GX5/16" 30 GAUGE X 5/16" | 1 | PA; ST |
| ASSURE ID PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | PA; ST |
| ASSURE ID PRO PEN NDL 30G 5MM 30 GAUGE X 3/16" | 1 | PA; ST |
| ASSURE ID SYR 0.5 ML 29GX1/2" (RX) 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| ASSURE ID SYR 0.5 ML 31GX15/64" 0.5 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| ASSURE ID SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| BD AUTOSHIELD DUO NDL 5MMX30G 30 GAUGE X 3/16" | 1 | PA; ST |
| BD ECLIPSE 30GX1/2" SYRINGE 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| BD ECLIPSE NEEDLE 30GX1/2" (OTC) 30 X 1/2 " | 1 | PA; ST |
| BD INS SYR 0.3 ML 8MMX31G(1/2) 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| BD INS SYRINGE 1/2 ML 6MMX31G (ONLY FOR 500 UNIT/ML INSULIN) 1/2 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| BD INS SYRN UF 1 ML 12.7MMX30G NOT FOR RETAIL SALE 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| BD INSULIN SYR 1 ML 25GX1" 1 ML 25 X 1" | 1 | PA; ST |
| BD INSULIN SYR 1 ML 25GX5/8" 1 ML 25 GAUGE X 5/8" | 1 | PA; ST |
| BD INSULIN SYR 1 ML 26GX1/2" 1 ML 26 X 1/2" | 1 | PA; ST |
| BD INSULIN SYR 1 ML 27GX12.7MM 1 ML 27 GAUGE X 1/2" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| BD INSULIN SYR 1 ML 27GX5/8" MICRO-FINE 1 ML 27 GAUGE X 5/8" | 1 | PA; ST |
| BD INSULIN SYRINGE SLIP TIP SYRINGE 1 ML | 1 | PA; ST |
| BD LUER-LOK SYRINGE 1 ML | 1 | PA; ST |
| BD NANO 2 GEN PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| BD SAFETGLD INS 0.3 ML 29G 13MM 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| BD SAFETGLD INS 0.5 ML 13MMX29G 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| BD SAFETYGLD INS 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| BD SAFETYGLD INS 0.5 ML 30G 8MM 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| BD SAFETYGLD INS 1 ML 29G 13MM 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| BD SAFETYGLID INS 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| BD SAFETYGLIDE SYRINGE 27GX5/8 1 ML 27 GAUGE X 5/8" | 1 | PA; ST |
| BD SAFTYGLD INS 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| BD SAFTYGLD INS 0.5 ML 29G 13MM 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| BD SAFTYGLD INS 0.5 ML 6MMX31G 0.5 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| BD SINGLE USE SWAB | 1 | PA; ST |
| BD UF MICRO PEN NEEDLE 6MMX32G 32 GAUGE X 1/4" | 1 | PA; ST |
| BD UF MINI PEN NEEDLE 5MMX31G 31 GAUGE X 3/16" | 1 | PA; ST |
| BD UF NANO PEN NEEDLE 4MMX32G 32 GAUGE X 5/32" | 1 | PA; ST |
| BD UF ORIG PEN NDL 12.7MMX29G 29 GAUGE X 1/2" | 1 | PA; ST |
| BD UF SHORT PEN NEEDLE 8MMX31G 31 GAUGE X 5/16" | 1 | PA; ST |
| BD VEO INS 0.3 ML 6MMX31G (1/2) 0.3 ML 31 GAUGE X 15/64" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| BD VEO INS SYRING 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| BD VEO INS SYRN 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| BD VEO INS SYRN 0.5 ML 6MMX31G 1/2 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| BORDERED GAUZE 2"X2" 2 X 2 " | 1 | PA; ST |
| CAREFINE PEN NEEDLE 12.7MM 29G 29 GAUGE X 1/2" | 1 | PA; ST |
| CAREFINE PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | 1 | PA; ST |
| CAREFINE PEN NEEDLE 5MM 32G 32 GAUGE X 3/16" | 1 | PA; ST |
| CAREFINE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | 1 | PA; ST |
| CAREFINE PEN NEEDLE 8MM 30G 30 GAUGE X 5/16" | 1 | PA; ST |
| CAREFINE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | 1 | PA; ST |
| CAREFINE PEN NEEDLES 8MM 31G 31 GAUGE X 5/16" | 1 | PA; ST |
| CARETOUCH ALCOHOL 70% PREP PAD | 1 | PA; ST |
| CARETOUCH PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | 1 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | PA; ST |
| CARETOUCH PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | 1 | PA; ST |
| CARETOUCH PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | 1 | PA; ST |
| CARETOUCH SYR 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| CARETOUCH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| CARETOUCH SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| CARETOUCH SYR 1 ML 28GX5/16" 1 ML 28 X 5/16" | 1 | PA; ST |
| CARETOUCH SYR 1 ML 29GX5/16" 1 ML 29 GAUGE X 5/16 | 1 | PA; ST |
| CARETOUCH SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | 1 | PA; ST |
| CARETOUCH SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | 1 | PA; ST |
| CLICKFINE 31G X 5/16" NEEDLES 8MM, UNIVERSAL 31 GAUGE X 5/16" | 1 | PA; ST |
| CLICKFINE PEN NEEDLE 32GX5/32" 32GX4MM, STERILE 32 GAUGE X 5/32" | 1 | PA; ST |
| CLICKFINE UNIVERSAL 31G X 1/4" 6MM, STORE BRAND 31 GAUGE X 1/4" | 1 | PA; ST |
| COMFORT EZ 0.3 ML 31G 15/64" 0.3 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| COMFORT EZ 0.5 ML 31G 15/64" 1/2 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| COMFORT EZ INS 0.3 ML 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| COMFORT EZ INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| COMFORT EZ INS 1 ML 31G 15/64" 1 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| COMFORT EZ INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | 1 | PA; ST |
| COMFORT EZ INSULIN SYR 0.3 ML 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| COMFORT EZ INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLE 12MM 29G 29 GAUGE X 1/2" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLES 4MM 32G SINGLE USE, MICRO 32 GAUGE X 5/32" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLES 4MM 33G 33 GAUGE X 5/32" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLES 5MM 31G MINI 31 GAUGE X 3/16" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI 32 GAUGE X 3/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| COMFORT EZ PEN NEEDLES 5MM 33G 33 GAUGE X 3/16" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLES 6MM 31G 31 GAUGE X 1/4" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLES 6MM 33G 33 GAUGE X 1/4" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLES 8MM 31G SHORT 31 GAUGE X 5/16" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLES 8MM 32G 32 GAUGE X 5/16" | 1 | PA; ST |
| COMFORT EZ PEN NEEDLES 8MM 33G 33 GAUGE X 5/16" | 1 | PA; ST |
| COMFORT EZ PRO PEN NDL 30G 8MM 30 GAUGE X 5/16" | 1 | PA; ST |
| COMFORT EZ PRO PEN NDL 31G 4MM 31 GAUGE X 5/32" | 1 | PA; ST |
| COMFORT EZ PRO PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| COMFORT EZ SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| COMFORT EZ SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| COMFORT EZ SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| COMFORT EZ SYR 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| COMFORT EZ SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| COMFORT EZ SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| COMFORT EZ SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| COMFORT EZ SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| COMFORT POINT PEN NDL 31GX1/3" 31 GAUGE X 1/3" | 1 | PA; ST |
| COMFORT POINT PEN NDL 31GX1/6" 31 GAUGE X 1/6" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| COMFORT TOUCH PEN NDL 31G 4MM 31 GAUGE X 5/32" | 1 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 5MM 32 GAUGE X 3/16" | 1 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 6MM 32 GAUGE X 1/4" | 1 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 8MM 32 GAUGE X 5/16" | 1 | PA; ST |
| COMFORT TOUCH PEN NDL 33G 4MM 33 GAUGE X 5/32" | 1 | PA; ST |
| COMFORT TOUCH PEN NDL 33G 6MM 33 GAUGE X 1/4" | 1 | PA; ST |
| COMFORT TOUCH PEN NDL 33GX5MM 33 GAUGE X 3/16" | 1 | PA; ST |
| CURAD GAUZE PADS 2" X 2" 2 X 2 " | 1 | PA; ST |
| CURITY ALCOHOL PREPS 2 PLY,MEDIUM | 1 | PA; ST |
| CURITY GAUZE SPONGES (12 PLY)-200/BAG 2 X 2 " | 1 | PA; ST |
| CURITY GAUZE PADS 1'S(12 PLY) 2 X 2 " | 1 | PA; ST |
| DERMACEA 2"X2" GAUZE 12 PLY, USP TYPE VII 2 X 2 " | 1 | PA; ST |
| DERMACEA GAUZE 2"X2" SPONGE 8 PLY 2 X 2 " | 1 | PA; ST |
| DERMACEA NON-WOVEN 2"X2" SPNGE 2 X 2 " | 1 | PA; ST |
| DROPLET 0.5 ML 29GX12.5MM(1/2) 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| DROPLET 0.5 ML 30GX12.5MM(1/2) 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| DROPLET INS 0.3 ML 29GX12.5MM 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| DROPLET INS 0.3 ML 30GX12.5MM 0.3 ML 30 GAUGE X 1/2" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| DROPLET INS 0.5 ML 30GX6MM(1/2) 0.5ML 30 GAUGE X 15/64" | 1 | PA; ST |
| DROPLET INS 0.5 ML 30GX8MM(1/2) 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| DROPLET INS 0.5 ML 31GX6MM(1/2) 0.5 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| DROPLET INS 0.5 ML 31GX8MM(1/2) 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| DROPLET INS SYR 0.3 ML 30GX6MM 0.3 ML 30 GAUGE X 15/64" | 1 | PA; ST |
| DROPLET INS SYR 0.3 ML 30GX8MM 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| DROPLET INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| DROPLET INS SYR 0.3 ML 31GX8MM 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| DROPLET INS SYR 1 ML 29GX12.5MM 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| DROPLET INS SYR 1 ML 30GX12.5MM 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| DROPLET INS SYR 1 ML 30GX6MM 1 ML 30 GAUGE X 15/64" | 1 | PA; ST |
| DROPLET INS SYR 1 ML 30GX8MM 1 ML 30 GAUGE X 5/16 | 1 | PA; ST |
| DROPLET INS SYR 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| DROPLET INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 | 1 | PA; ST |
| DROPLET MICRON 34G X 9/64" 34 GAUGE X 9/64" | 1 | PA; ST |
| DROPLET PEN NEEDLE 29G 10MM 29 GAUGE X 3/8" | 1 | PA; ST |
| DROPLET PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | 1 | PA; ST |
| DROPLET PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | 1 | PA; ST |
| DROPLET PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| DROPLET PEN NEEDLE 31G 6MM 31 GAUGE X 1/4" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| DROPLET PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| DROPLET PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| DROPLET PEN NEEDLE 32G 5MM 32 GAUGE X 3/16" | 1 | PA; ST |
| DROPLET PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" | 1 | PA; ST |
| DROPLET PEN NEEDLE 32G 8MM 32 GAUGE X 5/16" | 1 | PA; ST |
| DROPSAFE ALCOHOL 70% PREP PADS | 1 | PA; ST |
| DROPSAFE INS SYR 0.3 ML 31G 6MM 0.3 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| DROPSAFE INS SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| DROPSAFE INS SYR 0.5 ML 31G 6MM 0.5 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| DROPSAFE INS SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| DROPSAFE INSUL SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| DROPSAFE INSUL SYR 1 ML 31G 8MM 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| DROPSAFE INSULN 1 ML 29G 12.5MM 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| DROPSAFE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | PA; ST |
| DROPSAFE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | PA; ST |
| DROPSAFE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | PA; ST |
| DRUG MART ULTRA COMFORT SYR 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16 | 1 | PA; ST |
| EASY CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| EASY CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| EASY CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| EASY COMFORT 0.3 ML 31G 1/2" 0.3 ML 31 X 1/2" | 1 | PA; ST |
| EASY COMFORT 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| EASY COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| EASY COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| EASY COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| EASY COMFORT 0.5 ML 32GX5/16" 1/2 ML 32 GAUGE X 5/16" | 1 | PA; ST |
| EASY COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| EASY COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| EASY COMFORT 1 ML 32GX5/16" 1 ML 32 GAUGE X 5/16" | 1 | PA; ST |
| EASY COMFORT ALCOHOL 70% PAD | 1 | PA; ST |
| EASY COMFORT INSULIN 1 ML SYR 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| EASY COMFORT PEN NDL 31GX1/4" 31 GAUGE X 1/4" | 1 | PA; ST |
| EASY COMFORT PEN NDL 31GX3/16" 31 GAUGE X 3/16" | 1 | PA; ST |
| EASY COMFORT PEN NDL 31GX5/16" 31 GAUGE X 5/16" | 1 | PA; ST |
| EASY COMFORT PEN NDL 32GX5/32" 32 GAUGE X 5/32" | 1 | PA; ST |
| EASY COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" | 1 | PA; ST |
| EASY COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" | 1 | PA; ST |
| EASY COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" | 1 | PA; ST |
| EASY COMFORT SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| EASY GLIDE INS 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| EASY GLIDE INS 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| EASY GLIDE INS 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| EASY GLIDE PEN NEEDLE 4MM 33G 33 GAUGE X 5/32" | 1 | PA; ST |
| EASY TOUCH 0.3 ML SYR 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH 0.5 ML SYR 27GX1/2" 1/2 ML 27 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH 0.5 ML SYR 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH 0.5 ML SYR 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH 0.5 ML SYR 30GX5/16 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH 1 ML SYR 27GX1/2" 1 ML 27 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH 1 ML SYR 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH 1 ML SYR 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH ALCOHOL 70% PADS GAMMA-STERILIZED | 1 | PA; ST |
| EASY TOUCH FLIPLOK 1 ML 27GX0.5 1 ML 27 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH INSULIN 1 ML 29GX1/2 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH INSULIN 1 ML 30GX1/2 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH INSULIN SYR 0.3 ML 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH INSULIN SYR 1 ML 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 1 | PA; ST |
| EASY TOUCH INSULIN SYR 1 ML RETRACTABLE 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| EASY TOUCH INSULN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH INSULN 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH LUER LOK INSUL 1 ML | 1 | PA; ST |
| EASY TOUCH PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH PEN NEEDLE 30GX5/16 30 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX3/16 31 GAUGE X 3/16" | 1 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX5/16 31 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | 1 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX3/16 32 GAUGE X 3/16" | 1 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX5/32 32 GAUGE X 5/32" | 1 | PA; ST |
| EASY TOUCH SAF PEN NDL 29G 5MM 29 GAUGE X 3/16" | 1 | PA; ST |
| EASY TOUCH SAF PEN NDL 29G 8MM 29 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH SAF PEN NDL 30G 5MM 30 GAUGE X 3/16" | 1 | PA; ST |
| EASY TOUCH SAF PEN NDL 30G 8MM 30 GAUGE X 5/16" | 1 | PA; ST |
| EASY TOUCH SYR 0.5 ML 28G 12.7MM 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH SYR 0.5 ML 29G 12.7MM 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| EASY TOUCH SYR 1 ML 27G 16MM 1 ML 27 GAUGE X 5/8" | 1 | PA; ST |
| EASY TOUCH SYR 1 ML 28G 12.7MM 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH SYR 1 ML 29G 12.7MM 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| EASY TOUCH UNI-SLIP SYR 1 ML | 1 | PA; ST |
| EASYTOUCH SAF PEN NDL 30G 6MM 30 GAUGE X 1/4" | 1 | PA; ST |
| EMBRACE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | 1 | PA; ST |
| EMBRACE PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | 1 | PA; ST |
| EMBRACE PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | 1 | PA; ST |
| EMBRACE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| EMBRACE PEN NEEDLE 31G 6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| EMBRACE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| EMBRACE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| EQL INSULIN 0.3 ML SYRINGE SHORT NEEDLE 0.3 ML 30 | 1 | PA; ST |
| EQL INSULIN 0.5 ML SYRINGE SHORT NEEDLE 1/2 ML 30 GAUGE | 1 | PA; ST |
| EQL INSULIN 1 ML SYRINGE SHORT NEEDLE 1 ML 30 GAUGE X 7/16" | 1 | PA; ST |
| FIFTY50 INS 0.5 ML 31GX5/16" SHORT NEEDLE (OTC) 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| FIFTY50 INS SYR 1 ML 31GX5/16" SHORT NEEDLE (OTC) 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| FIFTY50 PEN 31G X 3/16" NEEDLE (OTC) 31 GAUGE X 3/16" | 1 | PA; ST |
| FP INSULIN 1 ML SYRINGE 1 ML 28 GAUGE | 1 | PA; ST |
| FREESTYLE PREC 0.5 ML 30GX5/16 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| FREESTYLE PREC 0.5 ML 31GX5/16 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| FREESTYLE PREC 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | 1 | PA; ST |
| FREESTYLE PREC 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | 1 | PA; ST |
| GAUZE PAD TOPICAL BANDAGE 2 X 2 " | 1 | PA; ST |
| GNP ULT C 0.3 ML 29GX1/2" (1/2) 1/2 UNIT 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| GNP ULTRA COMFORT 0.5 ML SYR 1/2 ML 29 , 1/2 ML 30 GAUGE | 1 | PA; ST |
| GNP ULTRA COMFORT 1 ML SYRINGE 1 ML 28 GAUGE, 1 ML 29 GAUGE, 1 ML 30 GAUGE X 7/16" | 1 | PA; ST |
| GNP ULTRA COMFORT 3/10 ML SYR 0.3 ML 30 | 1 | PA; ST |
| HEALTHWISE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| HEALTHWISE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| HEALTHWISE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| HEALTHWISE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| HEALTHWISE INS 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | 1 | PA; ST |
| HEALTHWISE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | 1 | PA; ST |
| HEALTHWISE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| HEALTHWISE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| HEALTHWISE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| HEALTHY ACCENTS PENTIP 4MM 32G 32 GAUGE X 5/32" | 1 | PA; ST |
| HEALTHY ACCENTS PENTIP 5MM 31G 31 GAUGE X 3/16" | 1 | PA; ST |
| HEALTHY ACCENTS PENTIP 6MM 31G 31 GAUGE X 1/4" | 1 | PA; ST |
| HEALTHY ACCENTS PENTIP 8MM 31G 31 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| HEALTHY ACCENTS PENTP 12MM 29G 29 GAUGE X 1/2" | 1 | PA; ST |
| HEB INCONTROL ALCOHOL 70% PADS | 1 | PA; ST |
| INCONTROL PEN NEEDLE 12MM 29G 29 GAUGE X 1/2" | 1 | PA; ST |
| INCONTROL PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | 1 | PA; ST |
| INCONTROL PEN NEEDLE 5MM 31G 31 GAUGE X 3/16" | 1 | PA; ST |
| INCONTROL PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | 1 | PA; ST |
| INCONTROL PEN NEEDLE 8MM 31G 31 GAUGE X 5/16" | 1 | PA; ST |
| INSULIN SYR 0.3 ML 31GX1/4(1/2) 0.3 ML 31 GAUGE X 1/4" | 1 | PA; ST |
| INSULIN SYRIN 0.3 ML 30GX1/2" SHORT NEEDLE 0.3 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| INSULIN SYRIN 0.5 ML 28GX1/2" (OTC) 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| INSULIN SYRIN 0.5 ML 29GX1/2" (OTC) 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| INSULIN SYRIN 0.5 ML 30GX1/2" SHORT NEEDLE (OTC) 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| INSULIN SYRIN 0.5 ML 30GX5/16" SHORT NEEDLE (OTC) 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| INSULIN SYRING 0.5 ML 27G 1/2" OUTER 1/2 ML 27 GAUGE X 1/2" | 1 | PA; ST |
| INSULIN SYRINGE 0.3 ML 0.3 ML 29 GAUGE | 1 | PA; ST |
| INSULIN SYRINGE 0.3 ML 31GX1/4 0.3 ML 31 GAUGE X 1/4" | 1 | PA; ST |
| INSULIN SYRINGE 0.5 ML 1/2 ML 29 | 1 | PA; ST |
| INSULIN SYRINGE 0.5 ML 31GX1/4 1/2 ML 31 GAUGE X 1/4" | 1 | PA; ST |
| INSULIN SYRINGE 1 ML 1 ML 29 GAUGE | 1 | PA; ST |
| INSULIN SYRINGE 1 ML 27G 1/2" INNER 1 ML 27 GAUGE X 1/2" | 1 | PA; ST |
| INSULIN SYRINGE 1 ML 28GX1/2" (OTC) 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| INSULIN SYRINGE 1 ML 30GX1/2" (RX) 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| INSULIN SYRINGE 1 ML 30GX5/16" SHORT NEEDLE (OTC) 1 ML 30 GAUGE X 5/16 | 1 | PA; ST |
| INSULIN SYRINGE 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | 1 | PA; ST |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE | 1 | PA; ST |
| INSUPEN 30G ULTRAFIN NEEDLE 30 GAUGE X 5/16" | 1 | PA; ST |
| INSUPEN 31G ULTRAFIN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16" | 1 | PA; ST |
| INSUPEN 32G 6MM PEN NEEDLE 32 GAUGE X 1/4" | 1 | PA; ST |
| INSUPEN 32G 8MM PEN NEEDLE 32 GAUGE X 5/16" | 1 | PA; ST |
| INSUPEN PEN NEEDLE 29GX12MM 29 GAUGE X 1/2" | 1 | PA; ST |
| INSUPEN PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | PA; ST |
| INSUPEN PEN NEEDLE 32GX4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| INSUPEN PEN NEEDLE 33GX4MM 33 GAUGE X 5/32" | 1 | PA; ST |
| IV ANTISEPTIC WIPES | 1 | PA; ST |
| KENDALL ALCOHOL 70% PREP PAD | 1 | PA; ST |
| LISCO SPONGES 100/BAG 2 X 2 " | 1 | PA; ST |
| LITE TOUCH 31GX1/4" PEN NEEDLE 31 GAUGE X 1/4" | 1 | PA; ST |
| LITE TOUCH INSULIN 0.5 ML SYR 1/2 ML 28 GAUGE, 1/2 ML 29 , 1/2 ML 30 GAUGE | 1 | PA; ST |
| LITE TOUCH INSULIN 1 ML SYR 1 ML 28 GAUGE, 1 ML 29 GAUGE, 1 ML 30 GAUGE X 7/16" | 1 | PA; ST |
| LITE TOUCH INSULIN SYR 1 ML 1 ML 31 GAUGE X 5/16 | 1 | PA; ST |
| LITE TOUCH PEN NEEDLE 29G 29 GAUGE X 1/2" | 1 | PA; ST |
| LITE TOUCH PEN NEEDLE 31G 31 GAUGE X 3/16", 31 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| LITETOUCH INS 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| LITETOUCH INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| LITETOUCH INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| LITETOUCH INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| LITETOUCH SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| LITETOUCH SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| LITETOUCH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| LITETOUCH SYRIN 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| LITETOUCH SYRIN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| LITETOUCH SYRIN 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | 1 | PA; ST |
| MAGELLAN INSUL SYRINGE 0.3 ML 0.3 ML 30 X 5/16" | 1 | PA; ST |
| MAGELLAN INSUL SYRINGE 0.5 ML 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| MAGELLAN INSULIN SYR 0.3 ML 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| MAGELLAN INSULIN SYR 0.5 ML 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| MAGELLAN INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| MAXICOMFORT II PEN NDL 31GX6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| MAXICOMFORT INS 0.5 ML 27GX1/2" 1/2 ML 27 GAUGE X 1/2" | 1 | PA; ST |
| MAXI-COMFORT INS 0.5 ML 28G 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| MAXICOMFORT INS 1 ML 27GX1/2" 1 ML 27 GAUGE X 1/2" | 1 | PA; ST |
| MAXI-COMFORT INS 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| MAXICOMFORT PEN NDL 29G X 5MM 29 GAUGE X 3/16" | 1 | PA; ST |
| MAXICOMFORT PEN NDL 29G X 8MM 29 GAUGE X 5/16" | 1 | PA; ST |
| MICRODOT PEN NEEDLE 31GX6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| MICRODOT PEN NEEDLE 32GX4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| MICRODOT PEN NEEDLE 33GX4MM 33 GAUGE X 5/32" | 1 | PA; ST |
| MICRODOT READYGARD NDL 31G 5MM OUTER 31 GAUGE X 3/16" | 1 | PA; ST |
| MINI PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| MINI PEN NEEDLE 32G 5MM 32 GAUGE X 3/16" | 1 | PA; ST |
| MINI PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" | 1 | PA; ST |
| MINI PEN NEEDLE 32G 8MM 32 GAUGE X 5/16" | 1 | PA; ST |
| MINI PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" | 1 | PA; ST |
| MINI PEN NEEDLE 33G 5MM 33 GAUGE X 3/16" | 1 | PA; ST |
| MINI PEN NEEDLE 33G 6MM 33 GAUGE X 1/4" | 1 | PA; ST |
| MINI ULTRA-THIN II PEN NDL 31G STERILE 31 GAUGE X 3/16" | 1 | PA; ST |
| MONOJECT 0.5 ML SYRN 28GX1/2" 1/2 ML 28 GAUGE | 1 | PA; ST |
| MONOJECT 1 ML SYRN 27X1/2" 1 ML 27 GAUGE X 1/2" | 1 | PA; ST |
| MONOJECT 1 ML SYRN 28GX1/2" (OTC) 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| MONOJECT INSUL SYR U100 (OTC) 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| MONOJECT INSUL SYR U100 .5ML,29GX1/2" (OTC) 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| MONOJECT INSUL SYR U100 0.5 ML CONVERTS TO 29G (OTC) 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML 1 ML 25 GAUGE X 5/8" | 1 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML 3'S, 29GX1/2" (OTC) 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML W/O NEEDLE (OTC) | 1 | PA; ST |
| MONOJECT INSULIN SYR 0.3 ML (OTC) 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| MONOJECT INSULIN SYR 0.3 ML 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| MONOJECT INSULIN SYR 0.5 ML (OTC) 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| MONOJECT INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| MONOJECT INSULIN SYR 1 ML 3'S (OTC) 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| MONOJECT INSULIN SYR U-100 0.5 ML 29 GAUGE X 1/2", 29 GAUGE X 1/2" | 1 | PA; ST |
| MONOJECT SYRINGE 0.3 ML 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| MONOJECT SYRINGE 0.5 ML 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| MONOJECT SYRINGE 1 ML 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| NOVOFINE 30 NEEDLE | 1 | PA; ST |
| NOVOFINE 32G NEEDLES 32 GAUGE X 1/4" | 1 | PA; ST |
| NOVOFINE PLUS PEN NDL 32GX1/6" 32 GAUGE X 1/6" | 1 | PA; ST |
| NOVOTWIST NEEDLE 32G 5MM 32 GAUGE X 1/5" | 1 | PA; ST |
| OMNIPOD 5 G6-G7 INTRO KT(GEN5) SUBCUTANEOUS CARTRIDGE | 2 | |
| OMNIPOD 5 G6-G7 PODS (GEN 5) SUBCUTANEOUS CARTRIDGE | 2 | |
| OMNIPOD CLASSIC PODS (GEN 3) SUBCUTANEOUS CARTRIDGE | 2 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| OMNIPOD DASH INTRO KIT (GEN 4) SUBCUTANEOUS CARTRIDGE | 2 | |
| OMNIPOD DASH PDM KIT (GEN 4) | 2 | |
| OMNIPOD DASH PODS (GEN 4) SUBCUTANEOUS CARTRIDGE | 2 | |
| PC UNIFINE PENTIPS 8MM NEEDLE SHORT 31 GAUGE X 5/16" | 1 | PA; ST |
| PEN NEEDLE 30G 5MM OUTER 30 GAUGE X 3/16" | 1 | PA; ST |
| PEN NEEDLE 30G 8MM INNER 30 GAUGE X 5/16" | 1 | PA; ST |
| PEN NEEDLE 30G X 5/16" 30 GAUGE X 5/16" | 1 | PA; ST |
| PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2" | 1 | PA; ST |
| PEN NEEDLES 12MM 29G 29GX12MM,STRL 29 GAUGE X 1/2" | 1 | PA; ST |
| PEN NEEDLES 4MM 32G 32 GAUGE X 5/32" | 1 | PA; ST |
| PEN NEEDLES 6MM 31G 31GX6MM, STRL 31 GAUGE X 1/4" | 1 | PA; ST |
| PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT (OTC) 31 GAUGE X 5/16" | 1 | PA; ST |
| PENTIPS PEN NEEDLE 29G 1/2" 29 GAUGE X 1/2" | 1 | PA; ST |
| PENTIPS PEN NEEDLE 31G 1/4" 31 GAUGE X 1/4" | 1 | PA; ST |
| PENTIPS PEN NEEDLE 31GX3/16" MINI, 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| PENTIPS PEN NEEDLE 31GX5/16" SHORT, 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| PENTIPS PEN NEEDLE 32G 1/4" 32 GAUGE X 1/4" | 1 | PA; ST |
| PENTIPS PEN NEEDLE 32GX5/32" 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| PIP PEN NEEDLE 31G X 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| PIP PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| PREVENT PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | PA; ST |
| PREVENT PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | PA; ST |
| PRO COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| PRO COMFORT 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| PRO COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| PRO COMFORT 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| PRO COMFORT 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| PRO COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| PRO COMFORT ALCOHOL 70% PADS | 1 | PA; ST |
| PRO COMFORT PEN NDL 31GX5/16" 31 GAUGE X 5/16" | 1 | PA; ST |
| PRO COMFORT PEN NDL 32G X 1/4" 32 GAUGE X 1/4" | 1 | PA; ST |
| PRO COMFORT PEN NDL 4MM 32G 32 GAUGE X 5/32" | 1 | PA; ST |
| PRO COMFORT PEN NDL 5MM 32G 32 GAUGE X 3/16" | 1 | PA; ST |
| PRODIGY INS SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| PRODIGY SYRNG 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| PRODIGY SYRNGE 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| PURE CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| PURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| PURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| PURE COMFORT ALCOHOL 70% PADS | 1 | PA; ST |
| PURE COMFORT PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| PURE COMFORT PEN NDL 32G 5MM 32 GAUGE X 3/16" | 1 | PA; ST |
| PURE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | 1 | PA; ST |
| PURE COMFORT PEN NDL 32G 8MM 32 GAUGE X 5/16" | 1 | PA; ST |
| RAYA SURE PEN NEEDLE 29G 12MM 29 GAUGE X 15/32" | 1 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" | 1 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 5MM 31 GAUGE X 13/64" | 1 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 6MM 31 GAUGE X 15/64" | 1 | PA; ST |
| RELION INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| RELION INS SYR 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| RELION INS SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| RELI-ON INSULIN 0.5 ML SYR 1/2 ML 29 | 1 | PA; ST |
| RELI-ON INSULIN 1 ML SYR 1 ML 29 GAUGE X 7/16" | 1 | PA; ST |
| RELION MINI PEN 31G X 1/4" NDL 31 GAUGE X 1/4" | 1 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.3 ML 30GX5/16",10X10 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.5 ML 29GX1/2",10X10 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.5 ML 30GX5/16",10X10 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| SAFESNAP INS SYR UNITS-100 1 ML 28GX1/2",10X10 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| SAFESNAP INS SYR UNITS-100 1 ML 29GX1/2",10X10 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| SAFETY PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" | 1 | PA; ST |
| SAFETY PEN NEEDLE 5MM X 31G 31 GAUGE X 3/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| SAFETY SYRINGE 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| SECURESAFE PEN NDL 30GX5/16" OUTER 30 GAUGE X 5/16" | 1 | PA; ST |
| SECURESAFE SYR 0.5 ML 29G 1/2" OUTER 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| SECURESAFE SYRNG 1 ML 29G 1/2" OUTER 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| SKY SAFETY PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | 1 | PA; ST |
| SKY SAFETY PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | 1 | PA; ST |
| SM ULT CFT 0.3 ML 31GX5/16(1/2) 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| STERILE PADS 2" X 2" 2 X 2 " | 1 | PA; ST |
| SURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| SURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| NEEDLES, INSULIN DISP., SAFETY | 1 | PA; ST |
| SURE COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| SURE COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 1 | PA; ST |
| SURE COMFORT 3/10 ML SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| SURE COMFORT 3/10 ML SYRINGE INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| SURE COMFORT 30G PEN NEEDLE 30 GAUGE X 5/16" | 1 | PA; ST |
| SURE COMFORT ALCOHOL PREP PADS | 1 | PA; ST |
| SURE COMFORT INS 0.3 ML 31GX1/4 0.3 ML 31 GAUGE X 1/4" | 1 | PA; ST |
| SURE COMFORT INS 0.5 ML 31GX1/4 1/2 ML 31 GAUGE X 1/4" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| SURE COMFORT INS 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | 1 | PA; ST |
| SURE COMFORT PEN NDL 29GX1/2" 12.7MM 29 GAUGE X 1/2" | 1 | PA; ST |
| SURE COMFORT PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| SURE COMFORT PEN NDL 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| SURE COMFORT PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| SURE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | 1 | PA; ST |
| SURE-FINE PEN NEEDLES 12.7MM 29 GAUGE X 1/2" | 1 | PA; ST |
| SURE-FINE PEN NEEDLES 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| SURE-FINE PEN NEEDLES 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| SURE-JECT INSU SYR U100 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| SURE-JECT INSU SYR U100 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| SURE-JECT INSU SYR U100 1 ML 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| SURE-JECT INSUL SYR U100 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| SURE-JECT INSULIN SYRINGE 1 ML 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| SURE-PREP ALCOHOL PREP PADS | 1 | PA; ST |
| TECHLITE 0.3 ML 29GX12MM (1/2) 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| TECHLITE 0.3 ML 30GX12MM (1/2) 0.3 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| TECHLITE 0.3 ML 30GX8MM (1/2) 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| TECHLITE 0.3 ML 31GX6MM (1/2) 0.3 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| TECHLITE 0.3 ML 31GX8MM (1/2) 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| TECHLITE 0.5 ML 29GX12MM (1/2) 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| TECHLITE 0.5 ML 30GX12MM (1/2) 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| TECHLITE 0.5 ML 30GX8MM (1/2) 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| TECHLITE 0.5 ML 31GX6MM (1/2) 0.5 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| TECHLITE 0.5 ML 31GX8MM (1/2) 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| TECHLITE INS SYR 1 ML 29GX12MM 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| TECHLITE INS SYR 1 ML 30GX12MM 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| TECHLITE INS SYR 1 ML 30GX8MM 1 ML 30 GAUGE X 5/16 | 1 | PA; ST |
| TECHLITE INS SYR 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | 1 | PA; ST |
| TECHLITE INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 | 1 | PA; ST |
| TECHLITE PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | 1 | PA; ST |
| TECHLITE PEN NEEDLE 29GX3/8" 29 GAUGE X 3/8" | 1 | PA; ST |
| TECHLITE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | PA; ST |
| TECHLITE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | PA; ST |
| TECHLITE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | PA; ST |
| TECHLITE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | 1 | PA; ST |
| TECHLITE PEN NEEDLE 32GX5/16" 32 GAUGE X 5/16" | 1 | PA; ST |
| TECHLITE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | 1 | PA; ST |
| TECHLITE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| TERUMO INS SYRINGE U100-1 ML 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| TERUMO INS SYRINGE U100-1 ML 1 ML 30 GAUGE X 3/8" | 1 | PA; ST |
| TERUMO INS SYRINGE U100-1/2 ML 1/2 ML 30 X 3/8" | 1 | PA; ST |
| TERUMO INS SYRINGE U100-1/3 ML 0.3 ML 30 X 3/8" | 1 | PA; ST |
| TERUMO INS SYRNG U100-1/2 ML 0.5 ML 29 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| THINPRO INS SYRIN U100-0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 X 3/8", 0.3 ML 31 X 3/8" | 1 | PA; ST |
| THINPRO INS SYRIN U100-0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 31 X 3/8", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" | 1 | PA; ST |
| THINPRO INS SYRIN U100-1 ML 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 3/8", 1 ML 31 X 3/8" | 1 | PA; ST |
| TOPCARE CLICKFINE 31G X 1/4" 31 GAUGE X 1/4" | 1 | PA; ST |
| TOPCARE CLICKFINE 31G X 5/16" 31 GAUGE X 5/16" | 1 | PA; ST |
| TOPCARE ULTRA COMFORT SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 1 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 30G 5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 32G 5/16" 1/2 ML 32 GAUGE X 5/16" | 1 | PA; ST |
| TRUE CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| TRUE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| TRUE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| TRUE COMFORT 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| TRUE COMFORT 0.5 ML 30G 5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| TRUE COMFORT 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| TRUE COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| TRUE COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| TRUE COMFORT ALCOHOL 70% PADS | 1 | PA; ST |
| TRUE COMFORT PEN NDL 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| TRUE COMFORT PEN NDL 31GX5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| TRUE COMFORT PEN NDL 31GX6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| TRUE COMFORT PEN NDL 32G 5MM 32 GAUGE X 3/16" | 1 | PA; ST |
| TRUE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | 1 | PA; ST |
| TRUE COMFORT PEN NDL 32GX4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| TRUE COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" | 1 | PA; ST |
| TRUE COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" | 1 | PA; ST |
| TRUE COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" | 1 | PA; ST |
| TRUE COMFORT PRO 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| TRUE COMFORT PRO 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| TRUE COMFORT PRO 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| TRUE COMFORT PRO 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | 1 | PA; ST |
| TRUE COMFORT PRO ALCOHOL PADS | 1 | PA; ST |
| TRUE COMFORT SFTY 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| TRUE COMFRT PRO 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| TRUE COMFRT SFTY 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| TRUE COMFRT SFTY 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| TRUE COMFRT SFTY 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | 1 | PA; ST |
| TRUEPLUS PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | 1 | PA; ST |
| TRUEPLUS PEN NEEDLE 31G X 1/4" 31 GAUGE X 1/4" | 1 | PA; ST |
| TRUEPLUS PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | PA; ST |
| TRUEPLUS PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | PA; ST |
| TRUEPLUS PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | 1 | PA; ST |
| TRUEPLUS SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| TRUEPLUS SYR 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| TRUEPLUS SYR 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| TRUEPLUS SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| TRUEPLUS SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| TRUEPLUS SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| TRUEPLUS SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| TRUEPLUS SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| TRUEPLUS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| TRUEPLUS SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| TRUEPLUS SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| ULTICAR INS 0.3 ML 31GX1/4(1/2) 0.3 ML 31 GAUGE X 1/4" | 1 | PA; ST |
| ULTICARE INS 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | 1 | PA; ST |
| ULTICARE INS SYR 0.3 ML 30G 8MM 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ULTICARE INS SYR 0.3 ML 31G 6MM 0.3 ML 31 GAUGE X 1/4" | 1 | PA; ST |
| ULTICARE INS SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTICARE INS SYR 0.5 ML 31G 6MM 1/2 ML 31 GAUGE X 1/4" | 1 | PA; ST |
| ULTICARE INS SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| ULTICARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | PA; ST |
| ULTICARE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | 1 | PA; ST |
| ULTICARE PEN NEEDLE 8MM 31G 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTICARE PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" | 1 | PA; ST |
| ULTICARE PEN NEEDLES 4MM 32G MICRO, 32GX4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| ULTICARE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | 1 | PA; ST |
| ULTICARE SAFE PEN NDL 30G 8MM 30 GAUGE X 5/16" | 1 | PA; ST |
| ULTICARE SAFE PEN NDL 5MM 30G 30 GAUGE X 3/16" | 1 | PA; ST |
| ULTICARE SYR 0.3 ML 29G 12.7MM 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| ULTICARE SYR 0.3 ML 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| ULTICARE SYR 0.3 ML 31GX5/16" SHORT NDL 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTICARE SYR 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| ULTICARE SYR 0.5 ML 31GX5/16" SHORT NDL 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| ULTICARE SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTIGUARD SAFE 1 ML 30G 12.7MM 1 ML 30 X 1/2" | 1 | PA; ST |
| ULTIGUARD SAFE0.3 ML 30G 12.7MM 0.3 ML 30 X 1/2" | 1 | PA; ST |
| ULTIGUARD SAFE0.5 ML 30G 12.7MM 1/2 ML 30 X 1/2" | 1 | PA; ST |
| ULTIGUARD SAFEPACK 1 ML 31G 8MM 1 ML 31 X 5/16" | 1 | PA; ST |
| ULTIGUARD SAFEPACK 29G 12.7MM 29 GAUGE X 1/2" | 1 | PA; ST |
| ULTIGUARD SAFEPACK 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| ULTIGUARD SAFEPACK 31G 6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| ULTIGUARD SAFEPACK 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTIGUARD SAFEPACK 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| ULTIGUARD SAFEPACK 32G 6MM 32 GAUGE X 1/4" | 1 | PA; ST |
| ULTIGUARD SAFEPK 0.3 ML 31G 8MM 0.3 ML 31 X 5/16" | 1 | PA; ST |
| ULTIGUARD SAFEPK 0.5 ML 31G 8MM 1/2 ML 31 X 5/16" | 1 | PA; ST |
| ULTILET ALCOHOL STERL SWAB | 1 | PA; ST |
| ULTILET INSULIN SYRINGE 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTILET INSULIN SYRINGE 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTILET INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTILET PEN NEEDLE 29 GAUGE | 1 | PA; ST |
| ULTILET PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | 1 | PA; ST |
| ULTRA COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| ULTRA COMFORT 0.5 ML 28GX1/2" CONVERTS TO 29G 1/2 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| ULTRA COMFORT 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| ULTRA COMFORT 0.5 ML SYRINGE 1/2 ML 28 GAUGE | 1 | PA; ST |
| ULTRA COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2" | 1 | PA; ST |
| ULTRA FLO 0.3 ML 30G 1/2" (1/2) 0.3 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| ULTRA FLO 0.3 ML 30G 5/16"(1/2) 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA FLO 0.3 ML 31G 5/16"(1/2) 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA FLO PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| ULTRA FLO PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA FLO PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| ULTRA FLO PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" | 1 | PA; ST |
| ULTRA FLO PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" | 1 | PA; ST |
| ULTRA FLO SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| ULTRA FLO SYR 0.3 ML 30G 5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA FLO SYR 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA FLO SYR 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| ULTRA THIN PEN NDL 32G X 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| ULTRACARE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ULTRACARE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| ULTRACARE INS 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| ULTRACARE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ULTRACARE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTRACARE INS 1 ML 30G X 5/16" 1 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ULTRACARE INS 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| ULTRACARE INS 1 ML 31G X 5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | 1 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | 1 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | 1 | PA; ST |
| ULTRACARE PEN NEEDLE 33GX5/32" 33 GAUGE X 5/32" | 1 | PA; ST |
| ULTRA-THIN II 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA-THIN II INS 0.3 ML 30G 0.3 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA-THIN II INS 0.3 ML 31G 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 29G 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 30G 0.5 ML 30 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 31G 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| ULTRA-THIN II INS SYR 1 ML 29G 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| ULTRA-THIN II INS SYR 1 ML 30G 1 ML 30 GAUGE X 5/16 | 1 | PA; ST |
| ULTRA-THIN II PEN NDL 29GX1/2" 29 GAUGE X 1/2" | 1 | PA; ST |
| ULTRA-THIN II PEN NDL 31GX5/16 31 GAUGE X 5/16" | 1 | PA; ST |
| UNIFINE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| UNIFINE PENTIPS 12MM 29G 29GX12MM, STRL 29 GAUGE X 1/2" | 1 | PA; ST |
| UNIFINE PENTIPS 31GX3/16" 31GX5MM,STRL,MINI 31 GAUGE X 3/16" | 1 | PA; ST |
| UNIFINE PENTIPS 32GX1/4" 32 GAUGE X 1/4" | 1 | PA; ST |
| UNIFINE PENTIPS 32GX5/32" 32GX4MM, STRL, NANO 32 GAUGE X 5/32" | 1 | PA; ST |
| UNIFINE PENTIPS 33GX5/32" 33 GAUGE X 5/32" | 1 | PA; ST |
| UNIFINE PENTIPS 6MM 31G 31 GAUGE X 1/4" | 1 | PA; ST |
| UNIFINE PENTIPS MAX 30GX3/16" 30 GAUGE X 3/16" | 1 | PA; ST |
| UNIFINE PENTIPS NEEDLES 29G 29 GAUGE | 1 | PA; ST |
| UNIFINE PENTIPS PLUS 29GX1/2" 12MM 29 GAUGE X 1/2" | 1 | PA; ST |
| UNIFINE PENTIPS PLUS 30GX3/16" 30 GAUGE X 3/16" | 1 | PA; ST |
| UNIFINE PENTIPS PLUS 31GX1/4" ULTRA SHORT, 6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| UNIFINE PENTIPS PLUS 31GX3/16" MINI 31 GAUGE X 3/16" | 1 | PA; ST |
| UNIFINE PENTIPS PLUS 31GX5/16" SHORT 31 GAUGE X 5/16" | 1 | PA; ST |
| UNIFINE PENTIPS PLUS 32GX5/32" 32 GAUGE X 5/32" | 1 | PA; ST |
| UNIFINE PENTIPS PLUS 33GX5/32" 33 GAUGE X 5/32" | 1 | PA; ST |
| UNIFINE PROTECT 30G 5MM 30 GAUGE X 3/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| UNIFINE PROTECT 30G 8MM 30 GAUGE X 5/16" | 1 | PA; ST |
| UNIFINE PROTECT 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| UNIFINE SAFECONTROL 30G 5MM 30 GAUGE X 3/16" | 1 | PA; ST |
| UNIFINE SAFECONTROL 30G 8MM 30 GAUGE X 5/16" | 1 | PA; ST |
| UNIFINE SAFECONTROL 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| UNIFINE SAFECONTROL 31G 6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| UNIFINE SAFECONTROL 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| UNIFINE SAFECONTROL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| UNIFINE ULTRA PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| VANISHPOINT 0.5 ML 30GX1/2" SY OUTER 0.5 ML 30 GAUGE X 1/2" | 1 | PA; ST |
| VANISHPOINT INS 1 ML 30GX3/16" 1 ML 30 GAUGE X 3/16" | 1 | PA; ST |
| VANISHPOINT U-100 29X1/2 SYR 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| VERIFINE INS SYR 1 ML 29G 1/2" 1 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| VERIFINE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | 1 | PA; ST |
| VERIFINE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| VERIFINE PEN NEEDLE 31G X 6MM 31 GAUGE X 1/4" | 1 | PA; ST |
| VERIFINE PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" | 1 | PA; ST |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| VERIFINE PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" | 1 | PA; ST |
| VERIFINE PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| VERIFINE PEN NEEDLE 32G X 5MM 32 GAUGE X 3/16" | 1 | PA; ST |
| VERIFINE PLUS PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | PA; ST |
| VERIFINE PLUS PEN NDL 31G 8MM 31 GAUGE X 5/16" | 1 | PA; ST |
| VERIFINE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | PA; ST |
| VERIFINE PLUS PEN NDL 32G 4MM-SHARPS CONTAINER 32 GAUGE X 5/32" | 1 | PA; ST |
| VERIFINE SYRING 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | PA; ST |
| VERIFINE SYRING 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| VERIFINE SYRNG 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| VERIFINE SYRNG 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | PA; ST |
| VERSALON ALL PURPOSE SPONGE 25'S,N-STERILE,3PLY 2 X 2 " | 1 | PA; ST |
| WEBCOL ALCOHOL PREPS 20'S,LARGE | 1 | PA; ST |
| Enzyme Replacement/Modifiers | | |
| Enzyme Replacement/Modifiers | | |
| CERDELGA ORAL CAPSULE 84 MG | 4 | PA; NDS |
| CREON ORAL CAPSULE,DELAYED RELEASE(DR/EC) 12,000-38,000 -60,000 UNIT, 24,000-76,000 -120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000-180,000 UNIT, 6,000-19,000 -30,000 UNIT | 2 | |
| GALAFOLD ORAL CAPSULE 123 MG | 4 | PA; NDS; QL (14 per 28 days) |
| <i>javygtor oral tablet,soluble 100 mg</i> | 4 | PA; NDS |
| <i>miglustat oral capsule 100 mg</i> | 4 | PA; NDS; QL (90 per 30 days) |
| <i>nitisinone oral capsule 10 mg, 2 mg, 5 mg</i> | 4 | PA; NDS |
| <i>nitisinone oral capsule 20 mg</i> | 4 | NDS |
| PULMOZYME INHALATION SOLUTION 1 MG/ML | 4 | PA BvD; NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| REVCovi INTRAMUSCULAR SOLUTION 2.4 MG/1.5 ML (1.6 MG/ML) | 4 | PA; NDS |
| <i>sapropterin oral tablet, soluble 100 mg</i> | 4 | PA; NDS |
| ZENPEP ORAL CAPSULE, DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000- 63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000- 17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT | 2 | |
| Eye, Ear, Nose, Throat Agents | | |
| Eye, Ear, Nose, Throat Agents, Miscellaneous | | |
| <i>apraclonidine ophthalmic (eye) drops 0.5 %</i> | 1 | |
| <i>atropine ophthalmic (eye) drops 1 %</i> | 3 | NDS |
| <i>azelastine nasal spray, non-aerosol 137 mcg (0.1 %)</i> | 1 | QL (30 per 25 days) |
| <i>azelastine ophthalmic (eye) drops 0.05 %</i> | 1 | |
| <i>bepotastine besilate ophthalmic (eye) drops 1.5 %</i> | 1 | ST |
| <i>cromolyn ophthalmic (eye) drops 4 %</i> | 1 | |
| CYSTARAN OPHTHALMIC (EYE) DROPS 0.44 % | 4 | PA; NDS; QL (60 per 28 days) |
| <i>epinastine ophthalmic (eye) drops 0.05 %</i> | 1 | |
| <i>ipratropium bromide nasal spray, non-aerosol 21 mcg (0.03 %)</i> | 1 | QL (30 per 28 days) |
| <i>ipratropium bromide nasal spray, non-aerosol 42 mcg (0.06 %)</i> | 1 | QL (15 per 10 days) |
| <i>olopatadine nasal spray, non-aerosol 0.6 %</i> | 1 | QL (30.5 per 30 days) |
| Eye, Ear, Nose, Throat Anti-Infectives Agents | | |
| <i>acetic acid otic (ear) solution 2 %</i> | 1 | |
| <i>bacitracin ophthalmic (eye) ointment 500 unit/gram</i> | 1 | |
| <i>bacitracin-polymyxin b ophthalmic (eye) ointment 500-10,000 unit/gram</i> | 1 | |
| <i>ciprofloxacin hcl ophthalmic (eye) drops 0.3 %</i> | 1 | |
| <i>ciprofloxacin-dexamethasone otic (ear) drops, suspension 0.3-0.1 %</i> | 1 | QL (7.5 per 7 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %)</i> | 1 | QL (3.5 per 4 days) |
| <i>gatifloxacin ophthalmic (eye) drops 0.5 %</i> | 1 | |
| <i>gentamicin ophthalmic (eye) drops 0.3 %</i> | 1 | |
| <i>hydrocortisone-acetic acid otic (ear) drops 1-2 %</i> | 1 | |
| <i>levofloxacin ophthalmic (eye) drops 0.5 %</i> | 1 | |
| <i>moxifloxacin ophthalmic (eye) drops 0.5 %</i> | 1 | |
| NATACYN OPHTHALMIC (EYE) DROPS,SUSPENSION 5 % | 3 | NDS |
| <i>neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> | 1 | |
| <i>neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | 1 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %</i> | 1 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %</i> | 1 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml</i> | 1 | |
| <i>neomycin-polymyxin-hc ophthalmic (eye) drops,suspension 3.5-10,000-10 mg-unit-mg/ml</i> | 1 | |
| <i>neomycin-polymyxin-hc otic (ear) drops,suspension 3.5-10,000-1 mg/ml-unit/ml-%</i> | 1 | |
| <i>neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-%</i> | 1 | |
| <i>neo-polycin hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> | 1 | |
| <i>neo-polycin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | 1 | |
| <i>ofloxacin ophthalmic (eye) drops 0.3 %</i> | 1 | |
| <i>ofloxacin otic (ear) drops 0.3 %</i> | 1 | |
| <i>polycin ophthalmic (eye) ointment 500-10,000 unit/gram</i> | 1 | |
| <i>polymyxin b sulf-trimethoprim ophthalmic (eye) drops 10,000 unit- 1 mg/ml</i> | 1 | |
| <i>sulfacetamide sodium ophthalmic (eye) drops 10 %</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------|
| <i>sulfacetamide sodium ophthalmic (eye) ointment 10 %</i> | 1 | |
| <i>sulfacetamide-prednisolone ophthalmic (eye) drops 10 %-0.23 % (0.25 %)</i> | 1 | |
| <i>tobramycin ophthalmic (eye) drops 0.3 %</i> | 1 | |
| <i>tobramycin-dexamethasone ophthalmic (eye) drops,suspension 0.3-0.1 %</i> | 1 | |
| <i>trifluridine ophthalmic (eye) drops 1 %</i> | 1 | |
| XDEMVI OPTHALMIC (EYE) DROPS 0.25 % | 4 | PA; NDS |
| ZIRGAN OPTHALMIC (EYE) GEL 0.15 % | 3 | NDS; QL (5 per 30 days) |
| ZYLET OPTHALMIC (EYE) DROPS,SUSPENSION 0.3-0.5 % | 2 | |
| Eye, Ear, Nose, Throat Anti-Inflammatory Agents | | |
| <i>bromfenac ophthalmic (eye) drops 0.07 %, 0.075 %, 0.09 %</i> | 1 | |
| CEQUA OPTHALMIC (EYE) DROPPERETTE 0.09 % | 2 | |
| <i>cyclosporine ophthalmic (eye) dropperette 0.05 %</i> | 1 | QL (60 per 30 days) |
| <i>dexamethasone sodium phosphate ophthalmic (eye) drops 0.1 %</i> | 1 | |
| <i>diclofenac sodium ophthalmic (eye) drops 0.1 %</i> | 1 | |
| <i>difluprednate ophthalmic (eye) drops 0.05 %</i> | 1 | |
| EYSUVIS OPTHALMIC (EYE) DROPS,SUSPENSION 0.25 % | 2 | QL (8.3 per 14 days) |
| <i>flunisolide nasal spray,non-aerosol 25 mcg (0.025 %)</i> | 1 | QL (50 per 25 days) |
| <i>fluocinolone acetonide oil otic (ear) drops 0.01 %</i> | 1 | |
| <i>fluorometholone ophthalmic (eye) drops,suspension 0.1 %</i> | 3 | NDS |
| <i>flurbiprofen sodium ophthalmic (eye) drops 0.03 %</i> | 1 | |
| <i>fluticasone propionate nasal spray,suspension 50 mcg/actuation</i> | 1 | QL (16 per 30 days) |
| ILEVRO OPTHALMIC (EYE) DROPS,SUSPENSION 0.3 % | 2 | |
| <i>ketorolac ophthalmic (eye) drops 0.4 %</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------|
| <i>ketorolac ophthalmic (eye) drops 0.5 %</i> | 1 | QL (10 per 25 days) |
| LOTEMAX OPHTHALMIC (EYE) OINTMENT 0.5 % | 2 | QL (3.5 per 14 days) |
| LOTEMAX SM OPHTHALMIC (EYE) DROPS,GEL 0.38 % | 2 | QL (5 per 16 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,gel 0.5 %</i> | 1 | QL (10 per 13 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension 0.2 %</i> | 1 | |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension 0.5 %</i> | 1 | QL (15 per 19 days) |
| <i>mometasone nasal spray,non-aerosol 50 mcg/actuation</i> | 1 | QL (34 per 30 days) |
| PRED FORTE OPHTHALMIC (EYE) DROPS,SUSPENSION 1 % | 2 | |
| <i>prednisolone acetate ophthalmic (eye) drops,suspension 1 %</i> | 2 | |
| <i>prednisolone sodium phosphate ophthalmic (eye) drops 1 %</i> | 1 | |
| XHANCE NASAL AEROSOL BREATH ACTIVATED 93 MCG/ACTUATION | 2 | QL (32 per 30 days) |
| XIIDRA OPHTHALMIC (EYE) DROPPERETTE 5 % | 3 | NDS; QL (60 per 30 days) |
| Gastrointestinal Agents | | |
| Antiulcer Agents And Acid Suppressants | | |
| <i>amoxicil-clarithromy-lansopraz oral combo pack 500-500-30 mg</i> | 1 | |
| <i>cimetidine oral tablet 200 mg, 300 mg, 400 mg, 800 mg</i> | 1 | |
| <i>esomeprazole magnesium oral capsule,delayed release(dr/ec) 20 mg</i> | 1 | QL (30 per 30 days) |
| <i>esomeprazole magnesium oral capsule,delayed release(dr/ec) 40 mg</i> | 1 | QL (60 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 10 mg, 20 mg</i> | 1 | ST; QL (30 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 40 mg</i> | 1 | ST; QL (60 per 30 days) |
| <i>famotidine oral suspension for reconstitution 40 mg/5 ml (8 mg/ml)</i> | 1 | |
| <i>famotidine oral tablet 20 mg, 40 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| <i>lansoprazole oral capsule, delayed release(dr/ec) 15 mg</i> | 1 | QL (30 per 30 days) |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> | 1 | |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | 1 | |
| <i>omeprazole oral capsule, delayed release(dr/ec) 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>omeprazole-sodium bicarbonate oral capsule 20-1.1 mg-gram</i> | 4 | ST; NDS; QL (30 per 30 days) |
| <i>omeprazole-sodium bicarbonate oral capsule 40-1.1 mg-gram</i> | 1 | ST; QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 20 mg</i> | 1 | QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 40 mg</i> | 1 | QL (60 per 30 days) |
| <i>rabeprazole oral tablet, delayed release (dr/ec) 20 mg</i> | 1 | QL (30 per 30 days) |
| <i>sucralfate oral tablet 1 gram</i> | 1 | |
| Gastrointestinal Agents, Other | | |
| BYLVAY ORAL CAPSULE 400 MCG | 4 | NDS |
| <i>carglumic acid oral tablet, dispersible 200 mg</i> | 4 | PA; NDS |
| <i>constulose oral solution 10 gram/15 ml</i> | 1 | |
| <i>cromolyn oral concentrate 100 mg/5 ml</i> | 1 | |
| <i>dicyclomine oral capsule 10 mg</i> | 1 | |
| <i>dicyclomine oral solution 10 mg/5 ml</i> | 1 | |
| <i>dicyclomine oral tablet 20 mg</i> | 1 | |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5 ml</i> | 1 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | 1 | |
| <i>enulose oral solution 10 gram/15 ml</i> | 1 | |
| GATTEX 30-VIAL SUBCUTANEOUS KIT 5 MG | 4 | PA; NDS |
| <i>generlac oral solution 10 gram/15 ml</i> | 1 | |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | 1 | |
| <i>kionex (with sorbitol) oral suspension 15-19.3 gram/60 ml, 15-20 gram/60 ml</i> | 1 | |
| <i>lactulose oral solution 10 gram/15 ml</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------|
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 2 | QL (30 per 30 days) |
| LOKELMA ORAL POWDER IN PACKET 10 GRAM | 2 | QL (34 per 30 days) |
| LOKELMA ORAL POWDER IN PACKET 5 GRAM | 2 | QL (30 per 30 days) |
| <i>loperamide oral capsule 2 mg</i> | 1 | |
| <i>lubiprostone oral capsule 24 mcg, 8 mcg</i> | 2 | QL (60 per 30 days) |
| <i>methscopolamine oral tablet 2.5 mg, 5 mg</i> | 1 | |
| <i>metoclopramide hcl oral solution 5 mg/5 ml</i> | 1 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | 1 | |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 2 | QL (30 per 30 days) |
| RELISTOR ORAL TABLET 150 MG | 4 | PA; NDS; QL (90 per 30 days) |
| RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6 ML | 4 | PA; NDS; QL (16.8 per 28 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML | 4 | PA; NDS; QL (16.8 per 28 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 8 MG/0.4 ML | 4 | PA; NDS; QL (11.2 per 28 days) |
| <i>sodium phenylbutyrate oral tablet 500 mg</i> | 4 | NDS |
| <i>sodium polystyrene sulfonate oral powder</i> | 1 | |
| <i>sps (with sorbitol) oral suspension 15-20 gram/60 ml</i> | 1 | |
| TRULANCE ORAL TABLET 3 MG | 2 | |
| <i>ursodiol oral capsule 300 mg</i> | 1 | |
| <i>ursodiol oral tablet 250 mg, 500 mg</i> | 1 | |
| VELTASSA ORAL POWDER IN PACKET 16.8 GRAM, 25.2 GRAM, 8.4 GRAM | 2 | QL (30 per 30 days) |
| XERMELO ORAL TABLET 250 MG | 4 | PA; NDS; QL (84 per 28 days) |
| Laxatives | | |
| CLENPIQ ORAL SOLUTION 10 MG-3.5 GRAM- 12 GRAM/160 ML | 2 | |
| CLENPIQ ORAL SOLUTION 10 MG-3.5 GRAM- 12 GRAM/175 ML | 3 | NDS |
| <i>gavilyte-c oral recon soln 240-22.72-6.72 - 5.84 gram</i> | 1 | |
| <i>gavilyte-g oral recon soln 236-22.74-6.74 - 5.86 gram</i> | 1 | |
| <i>gavilyte-n oral recon soln 420 gram</i> | 1 | |
| <i>peg-electrolyte soln oral recon soln 420 gram</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------|
| <i>sod sul-potass sul-mag sul sol inner 17.5-3.13-1.6 gram</i> | 2 | |
| <i>sodium,potassium,mag sulfates oral recon soln 17.5-3.13-1.6 gram 2 pack (480ml)</i> | 2 | |
| SUTAB ORAL TABLET 1.479-0.188- 0.225 GRAM | 2 | |
| Genitourinary Agents | | |
| Antispasmodics, Urinary | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 1 | |
| <i>fesoterodine oral tablet extended release 24 hr 4 mg, 8 mg</i> | 1 | |
| <i>flavoxate oral tablet 100 mg</i> | 1 | |
| MYRBETRIQ ORAL SUSPENSION,EXTENDED REL RECON 8 MG/ML | 2 | QL (300 per 30 days) |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR 25 MG, 50 MG | 2 | QL (30 per 30 days) |
| <i>oxybutynin chloride oral syrup 5 mg/5 ml</i> | 1 | |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 1 | |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 15 mg, 5 mg</i> | 1 | |
| <i>solifenacin oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>tolterodine oral capsule,extended release 24hr 2 mg, 4 mg</i> | 1 | |
| <i>tolterodine oral tablet 1 mg, 2 mg</i> | 1 | |
| <i>trospium oral capsule,extended release 24hr 60 mg</i> | 1 | |
| <i>trospium oral tablet 20 mg</i> | 1 | |
| Genitourinary Agents, Miscellaneous | | |
| <i>alfuzosin oral tablet extended release 24 hr 10 mg</i> | 1 | QL (30 per 30 days) |
| <i>dutasteride oral capsule 0.5 mg</i> | 1 | |
| <i>dutasteride-tamsulosin oral capsule, er multiphase 24 hr 0.5-0.4 mg</i> | 1 | |
| <i>finasteride oral tablet 5 mg</i> | 1 | |
| <i>silodosin oral capsule 4 mg, 8 mg</i> | 1 | |
| <i>tamsulosin oral capsule 0.4 mg</i> | 1 | |
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| <i>tiopronin oral tablet 100 mg</i> | 4 | NDS |
| <i>tiopronin oral tablet, delayed release (dr/ec) 100 mg, 300 mg</i> | 4 | NDS |
| Heavy Metal Antagonists | | |
| Heavy Metal Antagonists | | |
| <i>deferasirox oral granules in packet 180 mg, 360 mg, 90 mg</i> | 4 | PA; NDS |
| <i>deferasirox oral tablet 180 mg, 360 mg</i> | 3 | PA; NDS |
| <i>deferasirox oral tablet 90 mg</i> | 1 | PA |
| <i>deferasirox oral tablet, dispersible 125 mg</i> | 3 | PA; NDS |
| <i>deferasirox oral tablet, dispersible 250 mg, 500 mg</i> | 4 | PA; NDS |
| <i>deferiprone oral tablet 1,000 mg, 500 mg</i> | 4 | PA; NDS |
| FERRIPROX (2 TIMES A DAY) ORAL TABLET, MODIFIED RELEASE 1,000 MG | 4 | PA; NDS |
| FERRIPROX ORAL SOLUTION 100 MG/ML | 4 | PA; NDS |
| <i>penicillamine oral tablet 250 mg</i> | 4 | PA; NDS |
| <i>trientine oral capsule 250 mg</i> | 4 | PA; NDS; QL (240 per 30 days) |
| <i>trientine oral capsule 500 mg</i> | 4 | PA; NDS; QL (120 per 30 days) |
| Hormonal Agents, Stimulant/Replacement/Modifying | | |
| Androgens | | |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 1 | |
| <i>testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> | 1 | |
| <i>testosterone enanthate intramuscular oil 200 mg/ml</i> | 1 | QL (5 per 28 days) |
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)</i> | 1 | QL (300 per 30 days) |
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i> | 1 | QL (150 per 30 days) |
| <i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram)</i> | 1 | QL (300 per 30 days) |
| <i>testosterone transdermal solution in metered pump w/app 30 mg/actuation (1.5 ml)</i> | 1 | QL (180 per 30 days) |
| Estrogens And Antiestrogens | | |
| <i>dotti transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 1 | QL (8 per 28 days) |
| DUAVEE ORAL TABLET 0.45-20 MG | 2 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------|
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | |
| <i>estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 1 | QL (8 per 28 days) |
| <i>estradiol transdermal patch weekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 1 | QL (4 per 28 days) |
| <i>estradiol vaginal cream 0.01 % (0.1 mg/gram)</i> | 1 | |
| <i>estradiol vaginal tablet 10 mcg</i> | 1 | QL (18 per 28 days) |
| <i>estradiol valerate intramuscular oil 10 mg/ml, 20 mg/ml, 40 mg/ml</i> | 1 | |
| <i>estradiol-norethindrone acet oral tablet 0.5-0.1 mg</i> | 1 | |
| FEMRING VAGINAL RING 0.05 MG/24 HR, 0.1 MG/24 HR | 3 | NDS; QL (1 per 84 days) |
| <i>fyavolv oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | 1 | |
| <i>jinteli oral tablet 1-5 mg-mcg</i> | 1 | |
| <i>lyllana transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 1 | QL (8 per 28 days) |
| <i>mimvey oral tablet 1-0.5 mg</i> | 1 | |
| <i>norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | 1 | |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG | 2 | |
| PREMARIN VAGINAL CREAM 0.625 MG/GRAM | 2 | |
| PREMPHASE ORAL TABLET 0.625 MG (14)/ 0.625MG-5MG(14) | 2 | |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 2 | |
| <i>raloxifene oral tablet 60 mg</i> | 1 | |
| <i>yuvaferm vaginal tablet 10 mcg</i> | 1 | QL (18 per 28 days) |
| Glucocorticoids/Mineralocorticoids | | |
| <i>dexamethasone oral solution 0.5 mg/5 ml</i> | 1 | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | 1 | |
| <i>fludrocortisone oral tablet 0.1 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 1 | |
| <i>methylprednisolone oral tablets,dose pack 4 mg</i> | 1 | |
| <i>prednisolone 15 mg/5 ml soln d/f 15 mg/5 ml (3 mg/ml)</i> | 1 | PA BvD |
| <i>prednisolone oral solution 15 mg/5 ml</i> | 1 | PA BvD |
| <i>prednisolone sodium phosphate oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)</i> | 1 | |
| <i>prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i> | 1 | PA BvD |
| PREDNISONE INTENSOL ORAL CONCENTRATE 5 MG/ML | 1 | |
| <i>prednisone oral solution 5 mg/5 ml</i> | 1 | PA BvD |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | PA BvD |
| <i>prednisone oral tablets,dose pack 10 mg, 10 mg (48 pack), 5 mg, 5 mg (48 pack)</i> | 1 | |
| Pituitary | | |
| ACTHAR INJECTION GEL 80 UNIT/ML | 4 | PA; NDS; QL (35 per 28 days) |
| ACTHAR SELFJECT SUBCUTANEOUS PEN INJECTOR 40 UNIT/0.5 ML, 80 UNIT/ML | 4 | PA; NDS; QL (35 per 28 days) |
| <i>desmopressin 10 mcg/0.1 ml spr 10 mcg/spray (0.1 ml)</i> | 1 | |
| <i>desmopressin nasal spray,non-aerosol 10 mcg/spray (0.1 ml)</i> | 1 | |
| <i>desmopressin oral tablet 0.1 mg, 0.2 mg</i> | 1 | |
| EGRIFTA SV SUBCUTANEOUS RECON SOLN 2 MG | 4 | PA; NDS; QL (30 per 30 days) |
| INCRELEX SUBCUTANEOUS SOLUTION 10 MG/ML | 4 | NDS |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | 4 | PA NSO; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG | 4 | PA NSO; NDS |
| LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | 4 | NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED) | 4 | NDS |
| LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT 45 MG | 4 | NDS |
| NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) | 4 | PA; NDS |
| <i>octreotide acetate injection solution 1,000 mcg/ml, 500 mcg/ml</i> | 4 | NDS |
| <i>octreotide acetate injection solution 100 mcg/ml, 200 mcg/ml, 50 mcg/ml</i> | 1 | |
| ORGOVYX ORAL TABLET 120 MG | 4 | PA NSO; NDS |
| ORILISSA ORAL TABLET 150 MG | 4 | PA; NDS; QL (28 per 28 days) |
| ORILISSA ORAL TABLET 200 MG | 4 | PA; NDS; QL (56 per 28 days) |
| SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG | 4 | PA; NDS |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) | 4 | PA; NDS; QL (60 per 30 days) |
| SOMAVERT SUBCUTANEOUS RECON SOLN 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 4 | PA; NDS |
| SYNAREL NASAL SPRAY, NON-AEROSOL 2 MG/ML | 4 | PA; NDS |
| Progestins | | |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SYRINGE 104 MG/0.65 ML | 2 | QL (0.65 per 90 days) |
| <i>medroxyprogesterone intramuscular suspension 150 mg/ml</i> | 1 | QL (1 per 84 days) |
| <i>medroxyprogesterone intramuscular syringe 150 mg/ml</i> | 1 | QL (1 per 84 days) |
| <i>medroxyprogesterone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml)</i> | 1 | |
| <i>norethindrone acetate oral tablet 5 mg</i> | 1 | |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| Thyroid And Antithyroid Agents | | |
| <i>levothyroxine oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | |
| LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 2 | |
| <i>liothyronine oral tablet 25 mcg, 5 mcg, 50 mcg</i> | 1 | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>propylthiouracil oral tablet 50 mg</i> | 1 | |
| SYNTHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 2 | |
| TIROSINT ORAL CAPSULE 100 MCG, 112 MCG, 125 MCG, 13 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 37.5 MCG, 44 MCG, 50 MCG, 62.5 MCG, 75 MCG, 88 MCG | 2 | QL (30 per 30 days) |
| TIROSINT-SOL ORAL SOLUTION 100 MCG/ML, 112 MCG/ML, 125 MCG/ML, 13 MCG/ML, 137 MCG/ML, 150 MCG/ML, 175 MCG/ML, 200 MCG/ML, 25 MCG/ML, 37.5 MCG/ML, 44 MCG/ML, 50 MCG/ML, 62.5 MCG/ML, 75 MCG/ML, 88 MCG/ML | 2 | QL (30 per 30 days) |
| Immunological Agents | | |
| Immunological Agents | | |
| ARCALYST SUBCUTANEOUS RECON SOLN 220 MG | 4 | NDS |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 0.5 MG, 1 MG | 3 | PA BvD; NDS |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 5 MG | 4 | PA BvD; NDS |
| <i>azathioprine oral tablet 100 mg, 50 mg, 75 mg</i> | 1 | PA BvD |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------|
| BENLYSTA SUBCUTANEOUS AUTO-INJECTOR 200 MG/ML | 4 | PA; NDS; QL (8 per 28 days) |
| BENLYSTA SUBCUTANEOUS SYRINGE 200 MG/ML | 4 | PA; NDS; QL (8 per 28 days) |
| BESREMI SUBCUTANEOUS SYRINGE 500 MCG/ML | 4 | PA NSO; NDS; QL (2 per 28 days) |
| CIMZIA POWDER FOR RECONST SUBCUTANEOUS KIT 400 MG (200 MG X 2 VIALS) | 4 | PA; NDS |
| CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) | 4 | PA; NDS |
| COSENTYX (2 SYRINGES) SUBCUTANEOUS SYRINGE 150 MG/ML | 4 | PA; NDS |
| COSENTYX PEN (2 PENS) SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 4 | PA; NDS |
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML | 4 | PA; NDS |
| COSENTYX UNOREADY PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML | 4 | PA; NDS |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | PA BvD |
| <i>cyclosporine modified oral solution 100 mg/ml</i> | 1 | PA BvD |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | 1 | PA BvD |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML | 4 | PA; NDS; QL (4.56 per 28 days) |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML | 4 | PA; NDS |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML | 4 | PA; NDS; QL (1.34 per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML | 4 | PA; NDS; QL (4.56 per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML | 4 | PA; NDS |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) | 4 | PA; NDS |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML | 4 | PA; NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) | 4 | PA; NDS |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) | 4 | PA; NDS |
| <i>everolimus (immunosuppressive) oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg</i> | 4 | PA BvD; NDS |
| GAMMAGARD LIQUID INJECTION SOLUTION 10 % | 4 | PA BvD; NDS |
| GAMMAGARD S-D (IGA < 1 MCG/ML) INTRAVENOUS RECON SOLN 10 GRAM, 5 GRAM | 4 | PA BvD; NDS |
| GAMMAPLEX (WITH SORBITOL) INTRAVENOUS SOLUTION 5 % | 4 | PA BvD; NDS |
| GAMMAPLEX INTRAVENOUS SOLUTION 10 %, 10 % (100 ML), 10 % (200 ML) | 4 | PA BvD; NDS |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %) | 4 | PA BvD; NDS |
| <i>gengraf oral capsule 100 mg, 25 mg</i> | 1 | PA BvD |
| <i>gengraf oral solution 100 mg/ml</i> | 1 | PA BvD |
| HADLIMA PUSHTOUCH SUBCUTANEOUS AUTO-INJECTOR 40 MG/0.8 ML | 4 | PA; NDS |
| HADLIMA SUBCUTANEOUS SYRINGE 40 MG/0.8 ML | 4 | PA; NDS |
| HADLIMA(CF) PUSHTOUCH SUBCUTANEOUS AUTO-INJECTOR 40 MG/0.4 ML | 4 | PA; NDS |
| HADLIMA(CF) SUBCUTANEOUS SYRINGE 40 MG/0.4 ML | 4 | PA; NDS |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA PEN PSOR-UVEITS-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML | 4 | PA; NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------------|
| HUMIRA(CF) PEN CROHNS-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA(CF) PEN PEDIATRIC UC SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML | 4 | PA; NDS |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML | 4 | PA; NDS |
| KEVZARA SUBCUTANEOUS PEN INJECTOR 150 MG/1.14 ML, 200 MG/1.14 ML | 4 | PA; NDS |
| KEVZARA SUBCUTANEOUS SYRINGE 150 MG/1.14 ML, 200 MG/1.14 ML | 4 | PA; NDS |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> | 1 | |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | 1 | PA BvD |
| <i>mycophenolate mofetil oral suspension for reconstitution 200 mg/ml</i> | 4 | PA BvD; NDS |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | 1 | PA BvD |
| <i>mycophenolate sodium oral tablet, delayed release (dr/ec) 180 mg, 360 mg</i> | 3 | PA BvD; NDS |
| OCTAGAM INTRAVENOUS SOLUTION 10 %, 5 % | 4 | PA BvD; NDS |
| ORENCIA CLICKJECT SUBCUTANEOUS AUTO-INJECTOR 125 MG/ML | 4 | PA; NDS |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML | 4 | PA; NDS |
| OTEZLA ORAL TABLET 20 MG | 4 | PA; LA; NDS; QL (90 per 30 days) |
| OTEZLA ORAL TABLET 30 MG | 4 | PA; NDS; QL (60 per 30 days) |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51) | 4 | PA; LA; NDS; QL (110 per 365 days) |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47), 10 MG (4)-20 MG (4)-30 MG(19) | 4 | PA; NDS; QL (110 per 365 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| PRIVIGEN INTRAVENOUS SOLUTION 10 % | 4 | PA BvD; NDS |
| PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG | 3 | PA BvD; NDS |
| REZUROCK ORAL TABLET 200 MG | 4 | PA NSO; NDS |
| RIDAURA ORAL CAPSULE 3 MG | 4 | NDS |
| RINVOQ LQ ORAL SOLUTION 1 MG/ML | 4 | PA; NDS; QL (360 per 30 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG | 4 | PA; NDS; QL (30 per 30 days) |
| SIMLANDI(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML | 4 | PA; NDS |
| SIMLANDI(CF) SUBCUTANEOUS SYRINGE KIT 40 MG/0.4 ML | 4 | PA; NDS |
| <i>sirolimus oral solution 1 mg/ml</i> | 4 | PA BvD; NDS |
| <i>sirolimus oral tablet 0.5 mg, 1 mg</i> | 1 | PA BvD |
| <i>sirolimus oral tablet 2 mg</i> | 3 | PA BvD; NDS |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 4 | PA; NDS |
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML | 4 | PA; NDS |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML) | 4 | PA; NDS; QL (1.2 per 56 days) |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 360 MG/2.4 ML (150 MG/ML) | 4 | PA; NDS; QL (2.4 per 56 days) |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | 4 | PA; NDS |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML | 4 | PA; NDS |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> | 1 | PA BvD |
| TAVNEOS ORAL CAPSULE 10 MG | 4 | PA; NDS; QL (180 per 30 days) |
| TREMFYA INTRAVENOUS SOLUTION 200 MG/20 ML (10 MG/ML) | 4 | PA; NDS |
| TREMFYA PEN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML | 4 | PA; NDS |
| TREMFYA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 4 | PA; NDS |
| TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML, 200 MG/2 ML | 4 | PA; NDS |
| XELJANZ ORAL SOLUTION 1 MG/ML | 4 | PA; NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| XELJANZ ORAL TABLET 10 MG, 5 MG | 4 | PA; NDS |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG | 4 | PA; NDS |
| Vaccines | | |
| ABRYSVO (PF) INTRAMUSCULAR RECON SOLN 120 MCG/0.5 ML | 2 | \$0 copay |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 2 | |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 2 | \$0 copay |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SYRINGE 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 2 | \$0 copay |
| AREXVY (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 120 MCG/0.5 ML | 2 | \$0 copay |
| AREXVY ANTIGEN COMPONENT 120 MCG | 2 | \$0 copay |
| BCG VACCINE, LIVE (PF) PERCUTANEOUS SUSPENSION FOR RECONSTITUTION 50 MG | 2 | \$0 copay |
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML | 2 | \$0 copay |
| BOOSTRIX TDAP INTRAMUSCULAR SUSPENSION 2.5-8-5 LF-MCG-LF/0.5ML | 2 | \$0 copay |
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5-8-5 LF-MCG-LF/0.5ML | 2 | \$0 copay |
| DAPTACEL (DTAP PEDIATRIC) (PF) INTRAMUSCULAR SUSPENSION 15-10-5 LF-MCG-LF/0.5ML | 2 | |
| ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML | 2 | PA BvD; \$0 copay |
| ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML | 2 | PA BvD; \$0 copay |
| ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML | 2 | PA BvD; \$0 copay |
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML | 2 | \$0 copay; QL (1.5 per 365 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML | 2 | \$0 copay; QL (1.5 per 365 days) |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 1,440 ELISA UNIT/ML | 2 | \$0 copay |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT/0.5 ML | 2 | |
| HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/0.5 ML | 2 | PA BvD; \$0 copay |
| HIBERIX (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 2 | |
| IMOVAX RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT | 2 | PA BvD; \$0 copay |
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE 25-58-10 LF-MCG-LF/0.5ML | 2 | |
| IPOL INJECTION SUSPENSION 40-8-32 UNIT/0.5 ML | 2 | \$0 copay |
| IXCHIQ (PF) INTRAMUSCULAR RECON SOLN 1,000 TCID50/0.5 ML | 2 | \$0 copay |
| IXIARO (PF) INTRAMUSCULAR SYRINGE 6 MCG/0.5 ML | 2 | \$0 copay |
| JYNNEOS (PF) SUBCUTANEOUS SUSPENSION 0.5X TO 3.95X 10EXP8 UNIT/0.5 | 2 | \$0 copay |
| KINRIX (PF) INTRAMUSCULAR SYRINGE 25 LF-58 MCG-10 LF/0.5 ML | 2 | |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION 4 MCG/0.5 ML | 2 | \$0 copay |
| MENQUADFI (PF) INTRAMUSCULAR SOLUTION 10 MCG/0.5 ML | 2 | \$0 copay |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT 10-5 MCG/0.5 ML | 2 | \$0 copay |
| M-M-R II (PF) SUBCUTANEOUS RECON SOLN 1,000-12,500 TCID50/0.5 ML | 2 | \$0 copay |
| MRESVIA (PF) INTRAMUSCULAR SYRINGE 50 MCG/0.5 ML | 2 | |
| PEDIARIX (PF) INTRAMUSCULAR SYRINGE 10 MCG-25LF-25 MCG-10LF/0.5 ML | 2 | |
| PEDVAX HIB (PF) INTRAMUSCULAR SOLUTION 7.5 MCG/0.5 ML | 2 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------------|
| PENBRAYA (PF) INTRAMUSCULAR KIT 5-120 MCG/0.5 ML | 3 | NDS; \$0 copay |
| PENTACEL (PF) INTRAMUSCULAR KIT 15LF-48MCG-62DU -10 MCG/0.5ML | 2 | |
| PREHEVBRIO (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML | 2 | PA BvD; \$0 copay |
| PRIORIX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3.4-4.2- 3.3CCID50/0.5ML | 2 | \$0 copay |
| PROQUAD (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3-4.3-3- 3.99 TCID50/0.5 | 2 | |
| QUADRACEL (PF) INTRAMUSCULAR SUSPENSION 15 LF-48 MCG- 5 LF UNIT/0.5ML | 2 | |
| QUADRACEL (PF) INTRAMUSCULAR SYRINGE 15 LF-48 MCG- 5 LF UNIT/0.5ML | 2 | |
| RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT | 2 | PA BvD; \$0 copay |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML | 2 | PA BvD; \$0 copay |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML | 2 | PA BvD; \$0 copay |
| ROTARIX ORAL SUSPENSION 10EXP6 CCID50 /1.5 ML | 2 | |
| ROTARIX ORAL SUSPENSION FOR RECONSTITUTION 10EXP6 CCID50/ML | 2 | |
| ROTATEQ VACCINE ORAL SOLUTION 2 ML | 2 | |
| SHINGRIX (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 50 MCG/0.5 ML | 2 | \$0 copay; QL (2 per 365 days) |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF UNIT/0.5 ML | 2 | \$0 copay |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT- 2 LF UNIT/0.5ML | 2 | \$0 copay |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML | 2 | \$0 copay |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| TETANUS,DIPHThERIA TOX PED(PF) INTRAMUSCULAR SUSPENSION 5-25 LF UNIT/0.5 ML | 2 | |
| TICOVAC INTRAMUSCULAR SYRINGE 1.2 MCG/0.25 ML | 2 | QL (1.5 per 365 days) |
| TICOVAC INTRAMUSCULAR SYRINGE 2.4 MCG/0.5 ML | 2 | \$0 copay; QL (1.5 per 365 days) |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 2 | \$0 copay |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML | 2 | \$0 copay |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5 ML | 2 | \$0 copay |
| TYPHIM VI INTRAMUSCULAR SYRINGE 25 MCG/0.5 ML | 2 | \$0 copay |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML | 2 | |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 50 UNIT/ML | 2 | \$0 copay |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML | 2 | |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 50 UNIT/ML | 2 | \$0 copay |
| VARIVAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 1,350 UNIT/0.5 ML | 2 | \$0 copay; QL (2 per 365 days) |
| VAXCHORA VACCINE ORAL SUSPENSION FOR RECONSTITUTION 4X10EXP8 TO 2X 10EXP9 CF UNIT | 2 | |
| YF-VAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10 EXP4.74 UNIT/0.5 ML, 10 EXP4.74 UNIT/0.5 ML(2.5 ML IN 1 VIAL) | 2 | \$0 copay |
| Inflammatory Bowel Disease Agents | | |
| Inflammatory Bowel Disease Agents | | |
| <i>alose tron oral tablet 0.5 mg</i> | 1 | |
| <i>alose tron oral tablet 1 mg</i> | 4 | NDS |
| <i>balsalazide oral capsule 750 mg</i> | 1 | |
| <i>budesonide oral capsule, delayed, extend. release 3 mg</i> | 3 | NDS |
| <i>budesonide rectal foam 2 mg/actuation</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------|
| DIPENTUM ORAL CAPSULE 250 MG | 4 | ST; NDS |
| <i>hydrocortisone rectal enema 100 mg/60 ml</i> | 1 | |
| <i>mesalamine oral capsule (with del rel tablets) 400 mg</i> | 1 | |
| <i>mesalamine oral capsule, extended release 500 mg</i> | 1 | |
| <i>mesalamine oral capsule, extended release 24hr 0.375 gram</i> | 1 | |
| <i>mesalamine oral tablet, delayed release (dr/ec) 1.2 gram</i> | 1 | QL (120 per 30 days) |
| <i>mesalamine oral tablet, delayed release (dr/ec) 800 mg</i> | 1 | |
| <i>mesalamine rectal enema 4 gram/60 ml</i> | 1 | |
| <i>mesalamine rectal suppository 1,000 mg</i> | 1 | |
| <i>sulfasalazine oral tablet 500 mg</i> | 1 | |
| <i>sulfasalazine oral tablet, delayed release (dr/ec) 500 mg</i> | 3 | NDS |
| Metabolic Bone Disease Agents | | |
| Metabolic Bone Disease Agents | | |
| <i>alendronate oral solution 70 mg/75 ml</i> | 1 | QL (300 per 28 days) |
| <i>alendronate oral tablet 10 mg</i> | 1 | QL (30 per 30 days) |
| <i>alendronate oral tablet 35 mg, 70 mg</i> | 1 | QL (4 per 28 days) |
| <i>calcitonin (salmon) nasal spray, non-aerosol 200 unit/actuation</i> | 1 | QL (3.7 per 28 days) |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | 1 | |
| <i>calcitriol oral solution 1 mcg/ml</i> | 1 | |
| <i>cinacalcet oral tablet 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>cinacalcet oral tablet 60 mg</i> | 2 | QL (60 per 30 days) |
| <i>cinacalcet oral tablet 90 mg</i> | 4 | NDS; QL (120 per 30 days) |
| <i>doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg</i> | 1 | |
| <i>ibandronate oral tablet 150 mg</i> | 1 | QL (1 per 28 days) |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg</i> | 1 | |
| PROLIA SUBCUTANEOUS SYRINGE 60 MG/ML | 2 | QL (1 per 180 days) |
| RAYALDEE ORAL CAPSULE, EXTENDED RELEASE 24 HR 30 MCG | 4 | NDS; QL (60 per 30 days) |
| <i>risedronate oral tablet 150 mg</i> | 1 | QL (1 per 28 days) |
| <i>risedronate oral tablet 30 mg, 5 mg</i> | 1 | QL (30 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| <i>risedronate oral tablet 35 mg, 35 mg (12 pack), 35 mg (4 pack)</i> | 1 | QL (4 per 28 days) |
| <i>risedronate oral tablet, delayed release (dr/ec) 35 mg</i> | 1 | QL (4 per 28 days) |
| <i>teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml)</i> | 2 | QL (2.48 per 28 days) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) | 4 | NDS; QL (1.56 per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) | 4 | PA; NDS |
| Miscellaneous Therapeutic Agents | | |
| Miscellaneous Therapeutic Agents | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5 ML | 4 | PA; NDS |
| <i>betaine oral powder 1 gram/scoop</i> | 4 | PA; NDS |
| <i>bupirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 1 | |
| <i>diazoxide oral suspension 50 mg/ml</i> | 4 | NDS |
| ELMIRON ORAL CAPSULE 100 MG | 3 | NDS; QL (90 per 30 days) |
| ENDARI ORAL POWDER IN PACKET 5 GRAM | 4 | PA; NDS; QL (180 per 30 days) |
| FIRDAPSE ORAL TABLET 10 MG | 4 | PA; NDS; QL (240 per 30 days) |
| <i>glutamine (sickle cell) oral powder in packet 5 gram</i> | 3 | PA; NDS; QL (180 per 30 days) |
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS AUTO-INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML | 2 | |
| GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML | 2 | |
| GVOKE SUBCUTANEOUS SOLUTION 1 MG/0.2 ML | 2 | |
| <i>hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 1 | |
| <i>levocarnitine (with sugar) oral solution 100 mg/ml</i> | 1 | |
| <i>levocarnitine oral tablet 330 mg</i> | 3 | NDS |
| <i>levocarnitine sf 1 g/10 ml sol 100 mg/ml</i> | 1 | |
| MESNEX ORAL TABLET 400 MG | 4 | NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| <i>nitroglycerin rectal ointment 0.4 % (w/w)</i> | 3 | NDS; QL (30 per 30 days) |
| <i>pyridostigmine bromide oral syrup 60 mg/5 ml</i> | 1 | |
| <i>pyridostigmine bromide oral tablet 30 mg, 60 mg</i> | 1 | |
| <i>pyridostigmine bromide oral tablet extended release 180 mg</i> | 1 | |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2 ML (150 MG/ML) | 4 | PA; NDS; QL (4 per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML | 4 | PA; NDS; QL (2 per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 300 MG/2 ML (150 MG/ML) | 4 | PA; NDS; QL (4 per 28 days) |
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG | 4 | PA NSO; NDS; QL (56 per 28 days) |
| TYBOST ORAL TABLET 150 MG | 2 | QL (30 per 30 days) |
| VEOZAH ORAL TABLET 45 MG | 3 | PA; NDS; QL (30 per 30 days) |
| VOWST ORAL CAPSULE | 4 | NDS; QL (12 per 30 days) |
| ZEGALOGUE AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 0.6 MG/0.6 ML | 2 | |
| ZEGALOGUE SYRINGE SUBCUTANEOUS SYRINGE 0.6 MG/0.6 ML | 2 | |
| Ophthalmic Agents | | |
| Antiglaucoma Agents | | |
| <i>acetazolamide oral capsule, extended release 500 mg</i> | 1 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 1 | |
| <i>betaxolol ophthalmic (eye) drops 0.5 %</i> | 1 | |
| <i>bimatoprost ophthalmic (eye) drops 0.03 %</i> | 1 | QL (2.5 per 25 days) |
| <i>brimonidine ophthalmic (eye) drops 0.1 %, 0.15 %, 0.2 %</i> | 1 | |
| <i>brimonidine-timolol ophthalmic (eye) drops 0.2-0.5 %</i> | 1 | |
| <i>brinzolamide ophthalmic (eye) drops,suspension 1 %</i> | 1 | |
| <i>carteolol ophthalmic (eye) drops 1 %</i> | 1 | |
| <i>dorzolamide ophthalmic (eye) drops 2 %</i> | 1 | |
| <i>dorzolamide-timolol (pf) ophthalmic (eye) dropperette 2-0.5 %</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------|
| <i>dorzolamide-timolol ophthalmic (eye) drops 22.3-6.8 mg/ml</i> | 1 | |
| <i>latanoprost ophthalmic (eye) drops 0.005 %</i> | 1 | QL (2.5 per 25 days) |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i> | 1 | |
| LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 % | 2 | QL (2.5 per 25 days) |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 1 | |
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i> | 1 | |
| RHOPRESSA OPHTHALMIC (EYE) DROPS 0.02 % | 2 | QL (2.5 per 25 days) |
| ROCKLATAN OPHTHALMIC (EYE) DROPS 0.02-0.005 % | 2 | QL (2.5 per 25 days) |
| SIMBRINZA OPHTHALMIC (EYE) DROPS,SUSPENSION 1-0.2 % | 2 | |
| <i>tafluprost (pf) ophthalmic (eye) dropperette 0.0015 %</i> | 1 | QL (30 per 30 days) |
| <i>timolol maleate ophthalmic (eye) drops 0.25 %, 0.5 %</i> | 1 | |
| <i>timolol maleate ophthalmic (eye) gel forming solution 0.25 %, 0.5 %</i> | 1 | |
| <i>travoprost ophthalmic (eye) drops 0.004 %</i> | 1 | QL (2.5 per 25 days) |
| VYZULTA OPHTHALMIC (EYE) DROPS 0.024 % | 3 | NDS; QL (5 per 30 days) |
| Replacement Preparations | | |
| Replacement Preparations | | |
| <i>d5 % and 0.9 % sodium chloride intravenous parenteral solution</i> | 1 | PA BvD; HI |
| <i>d5 %-0.45 % sodium chloride intravenous parenteral solution</i> | 1 | PA BvD; HI |
| <i>electrolyte-148 intravenous parenteral solution</i> | 1 | |
| ISOLYTE S IV SOLUTION-EXCEL SINGLE USE | 3 | PA BvD; HI; NDS |
| ISOLYTE S PH 7.4 INTRAVENOUS PARENTERAL SOLUTION | 3 | PA BvD; HI; NDS |
| ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS PARENTERAL SOLUTION 5 % | 3 | PA BvD; HI; NDS |
| <i>klor-con m10 oral tablet,er particles/crystals 10 meq</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>klor-con m15 oral tablet,er particles/crystals 15 meq</i> | 1 | |
| <i>klor-con m20 oral tablet,er particles/crystals 20 meq</i> | 1 | |
| <i>magnesium sulfate injection solution 500 mg/ml (50 %)</i> | 3 | NDS |
| <i>magnesium sulfate injection syringe 500 mg/ml (50 %)</i> | 1 | |
| <i>potassium chloride intravenous solution 2 meq/ml, 2 meq/ml (20 ml)</i> | 1 | PA BvD; HI |
| <i>potassium chloride oral capsule, extended release 10 meq, 8 meq</i> | 1 | |
| <i>potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml</i> | 1 | |
| <i>potassium chloride oral tablet extended release 10 meq, 20 meq, 8 meq</i> | 1 | |
| <i>potassium chloride oral tablet,er particles/crystals 10 meq, 15 meq, 20 meq</i> | 1 | |
| <i>potassium chloride-0.45 % nacl intravenous parenteral solution 20 meq/l</i> | 1 | PA BvD; HI |
| <i>potassium citrate oral tablet extended release 10 meq (1,080 mg), 15 meq, 5 meq (540 mg)</i> | 1 | |
| <i>sodium chloride 0.45 % intravenous parenteral solution 0.45 %</i> | 1 | |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i> | 1 | PA BvD; HI |
| <i>sodium chloride 0.9% solution mini-bag, single use</i> | 1 | PA BvD; HI |
| TPN ELECTROLYTES INTRAVENOUS SOLUTION 35-20-5 MEQ/20 ML | 3 | PA BvD; NDS |
| Respiratory Tract Agents | | |
| Anti-Inflammatories, Inhaled Corticosteroids | | |
| ARNUIITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION | 2 | QL (30 per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE, 50-25 MCG/DOSE | 3 | NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>breyna inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | 1 | QL (30.9 per 30 days) |
| <i>budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml</i> | 1 | PA BvD; QL (120 per 30 days) |
| <i>budesonide inhalation suspension for nebulization 1 mg/2 ml</i> | 1 | PA BvD; QL (60 per 30 days) |
| <i>budesonide-formoterol inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | 1 | QL (30.6 per 30 days) |
| <i>fluticasone furoate-vilanterol inhalation blister with device 100-25 mcg/dose, 200-25 mcg/dose</i> | 1 | QL (60 per 30 days) |
| <i>fluticasone propionate inhalation blister with device 100 mcg/actuation, 250 mcg/actuation</i> | 1 | |
| <i>fluticasone propionate inhalation blister with device 50 mcg/actuation</i> | 1 | QL (120 per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation, 220 mcg/actuation, 44 mcg/actuation</i> | 1 | |
| <i>fluticasone propion-salmeterol inhalation aerosol powdr breath activated 113-14 mcg/actuation, 232-14 mcg/actuation, 55-14 mcg/actuation</i> | 1 | QL (1 per 30 days) |
| <i>fluticasone propion-salmeterol inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 1 | QL (60 per 30 days) |
| <i>fluticasone propion-salmeterol inhalation hfa aerosol inhaler 115-21 mcg/actuation, 230-21 mcg/actuation, 45-21 mcg/actuation</i> | 1 | QL (12 per 30 days) |
| <i>wixela inhub inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 1 | QL (60 per 30 days) |
| Antileukotrienes | | |
| <i>montelukast oral tablet 10 mg</i> | 1 | |
| <i>montelukast oral tablet, chewable 4 mg, 5 mg</i> | 1 | |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> | 1 | |
| Bronchodilators | | |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation</i> | 1 | QL (17 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)</i> | 1 | QL (13.4 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------------|
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)</i> | 1 | QL (36 per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %)</i> | 1 | PA BvD; QL (360 per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 2.5 mg/0.5 ml</i> | 1 | PA BvD; QL (120 per 30 days) |
| <i>albuterol sulfate oral syrup 2 mg/5 ml</i> | 1 | |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | 1 | |
| ANORO ELLIPTA INHALATION BLISTER WITH DEVICE 62.5-25 MCG/ACTUATION | 2 | QL (60 per 30 days) |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION | 3 | NDS; QL (25.8 per 28 days) |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION | 2 | QL (10.7 per 30 days) |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION | 2 | QL (8 per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 1 | PA BvD; QL (312.5 per 30 days) |
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | 1 | PA BvD; QL (540 per 30 days) |
| <i>levalbuterol tartrate inhalation hfa aerosol inhaler 45 mcg/actuation</i> | 1 | |
| PROAIR RESPICLICK INHALATION AEROSOL POWDR BREATH ACTIVATED 90 MCG/ACTUATION | 3 | NDS; QL (2 per 30 days) |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE | 2 | QL (60 per 30 days) |
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION | 2 | QL (4 per 30 days) |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION | 2 | QL (4 per 30 days) |
| STRIVERDI RESPIMAT INHALATION MIST 2.5 MCG/ACTUATION | 2 | QL (4 per 28 days) |
| <i>terbutaline oral tablet 2.5 mg, 5 mg</i> | 1 | |
| <i>theophylline oral solution 80 mg/15 ml</i> | 1 | |
| <i>theophylline oral tablet extended release 12 hr 100 mg, 200 mg, 300 mg, 450 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | 1 | |
| <i>tiotropium bromide inhalation capsule, w/inhalation device 18 mcg</i> | 1 | QL (30 per 30 days) |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200-62.5-25 MCG | 2 | QL (60 per 30 days) |
| Respiratory Tract Agents, Other | | |
| <i>acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)</i> | 1 | PA BvD |
| BRONCHITOL INHALATION CAPSULE, W/INHALATION DEVICE 40 MG | 4 | PA; NDS |
| <i>cromolyn inhalation solution for nebulization 20 mg/2 ml</i> | 1 | PA BvD |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML | 4 | PA; NDS; QL (1 per 28 days) |
| FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML | 4 | PA; NDS; QL (1 per 28 days) |
| KALYDECO ORAL GRANULES IN PACKET 13.4 MG | 4 | NDS |
| KALYDECO ORAL GRANULES IN PACKET 25 MG, 5.8 MG, 50 MG, 75 MG | 4 | PA; NDS; QL (56 per 28 days) |
| KALYDECO ORAL TABLET 150 MG | 4 | PA; NDS; QL (56 per 28 days) |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 4 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS RECON SOLN 100 MG | 4 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML | 4 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML | 4 | PA; LA; NDS; QL (0.4 per 28 days) |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 4 | PA; NDS; QL (60 per 30 days) |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG, 75-94 MG | 4 | PA; NDS; QL (56 per 28 days) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 4 | PA; NDS; QL (112 per 28 days) |
| <i>pirfenidone oral capsule 267 mg</i> | 4 | PA; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 267 mg</i> | 4 | PA; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 534 mg, 801 mg</i> | 4 | PA; NDS; QL (90 per 30 days) |
| PROLASTIN-C INTRAVENOUS SOLUTION 1,000 MG (+/-)/20 ML | 4 | PA BvD; NDS |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| <i>roflumilast oral tablet 250 mcg, 500 mcg</i> | 1 | QL (30 per 30 days) |
| SYMDEKO ORAL TABLETS, SEQUENTIAL 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) | 4 | PA; NDS; QL (56 per 28 days) |
| TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 100-50-75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) | 4 | NDS; QL (56 per 28 days) |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) | 4 | PA; NDS; QL (84 per 28 days) |
| XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML | 4 | PA; NDS |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG | 4 | PA; NDS |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML | 4 | PA; NDS |
| Skeletal Muscle Relaxants | | |
| Skeletal Muscle Relaxants | | |
| <i>baclofen oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | |
| <i>chlorzoxazone oral tablet 250 mg</i> | 4 | NDS |
| <i>chlorzoxazone oral tablet 500 mg</i> | 1 | |
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>dantrolene oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 1 | |
| <i>tizanidine oral tablet 2 mg, 4 mg</i> | 1 | |
| Sleep Disorder Agents | | |
| Sleep Disorder Agents | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> | 1 | PA; QL (30 per 30 days) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 2 | QL (30 per 30 days) |
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> | 1 | QL (30 per 30 days) |
| HETLIOZ LQ ORAL SUSPENSION 4 MG/ML | 4 | PA; NDS; QL (150 per 30 days) |
| <i>modafinil oral tablet 100 mg</i> | 1 | PA; QL (30 per 30 days) |
| <i>modafinil oral tablet 200 mg</i> | 1 | PA; QL (60 per 30 days) |
| <i>sodium oxybate oral solution 500 mg/ml</i> | 4 | PA; LA; NDS; QL (540 per 30 days) |
| <i>tasimelteon oral capsule 20 mg</i> | 4 | PA; NDS; QL (30 per 30 days) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| <i>zolpidem oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>zolpidem oral tablet,ext release multiphase 12.5 mg, 6.25 mg</i> | 1 | QL (30 per 30 days) |
| Vasodilating Agents | | |
| Vasodilating Agents | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 4 | PA; NDS; QL (90 per 30 days) |
| <i>alyq oral tablet 20 mg</i> | 4 | PA; NDS; QL (60 per 30 days) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | 4 | PA; NDS; QL (30 per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | 4 | PA; LA; NDS; QL (60 per 30 days) |
| OPSUMIT ORAL TABLET 10 MG | 4 | PA; NDS; QL (30 per 30 days) |
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i> | 1 | PA; QL (360 per 30 days) |
| <i>sildenafil oral tablet 100 mg, 25 mg, 50 mg</i> | 5 | NDS; EX; CB (8 EA per 30 days) |
| <i>tadalafil (pulm. hypertension) oral tablet 20 mg</i> | 4 | PA; NDS; QL (60 per 30 days) |
| <i>tadalafil oral tablet 2.5 mg, 5 mg</i> | 1 | PA; QL (30 per 30 days) |
| UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG | 4 | PA; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 200 MCG | 4 | PA; NDS; QL (240 per 30 days) |
| UPTRAVI ORAL TABLETS,DOSE PACK 200 MCG (140)- 800 MCG (60) | 4 | PA; NDS |
| Vitamins And Minerals | | |
| Vitamins And Minerals | | |
| <i>bal-care dha combo pack 27-1-430 mg</i> | 1 | |
| <i>bal-care dha essential pack 27 mg iron-1 mg -374 mg</i> | 1 | |
| <i>c-nate dha softgel 28 mg iron-1 mg -200 mg</i> | 1 | |
| <i>completenate tablet chew 29 mg iron- 1 mg</i> | 1 | |
| <i>cyanocobalamin (vitamin b-12) injection solution</i> | 5 | NDS; EX |
| <i>ergocalciferol (vitamin d2) oral capsule 1,250 mcg (50,000 unit)</i> | 5 | NDS; EX |
| <i>folic acid oral tablet 1 mg</i> | 5 | NDS; EX |
| <i>folivane-ob capsule 85-1 mg</i> | 1 | |
| <i>kosher prenatal plus iron tab 30 mg iron- 1 mg</i> | 1 | |
| <i>marnatal-f capsule 60 mg iron-1 mg</i> | 1 | |
| <i>m-natal plus tablet 27 mg iron- 1 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>mynatal advance oral tablet 90-1-50 mg</i> | 1 | |
| <i>mynatal capsule 65 mg iron- 1 mg</i> | 1 | |
| <i>mynatal oral tablet 90-1-50 mg</i> | 1 | |
| <i>mynatal plus captab 65 mg iron- 1 mg</i> | 1 | |
| <i>mynatal-z captab 65 mg iron- 1 mg</i> | 1 | |
| <i>mynate 90 plus oral tablet extended release 90 mg iron-1 mg</i> | 1 | |
| <i>newgen tablet 32-1,000 mg-mcg</i> | 1 | |
| <i>niva-plus tablet 27 mg iron- 1 mg</i> | 1 | |
| <i>obstetrix dha combo pack 29 mg iron- 1,700 mcg dfe</i> | 1 | |
| <i>obstetrix dha oral combo pack,tablet and cap,dr 29 mg iron-1 mg -50 mg</i> | 1 | |
| <i>o-cal prenatal oral tablet 15 mg iron- 1,000 mcg</i> | 1 | |
| <i>pnv 29-1 tablet (rx) 29 mg iron- 1 mg</i> | 1 | |
| <i>pnv prenatal plus multivit tab gluten-free (rx) 27 mg iron- 1 mg</i> | 1 | |
| <i>pnv-dha + docusate oral capsule 27-1.25-55-300 mg</i> | 1 | |
| <i>pnv-omega softgel 28-1-300 mg</i> | 1 | |
| <i>pr natal 400 combo pack 29-1-400 mg</i> | 1 | |
| <i>pr natal 400 ec combo pack 29-1-400 mg</i> | 1 | |
| <i>pr natal 430 combo pack 29 mg iron-1 mg - 430 mg</i> | 1 | |
| <i>pr natal 430 ec combo pack 29-1-430 mg</i> | 1 | |
| <i>prena1 true combo pack 30 mg iron- 1.4 mg-300 mg</i> | 1 | |
| <i>prenaissance oral capsule 29-1.25-55-325 mg</i> | 1 | |
| <i>prenaissance plus oral capsule 28-1-50-250 mg</i> | 1 | |
| <i>prenatabs fa tablet 29-1 mg</i> | 1 | |
| <i>prenatal 19 (with docusate) oral tablet 29 mg iron- 1 mg-25 mg</i> | 1 | |
| <i>prenatal 19 chewable tablet 29 mg iron- 1 mg</i> | 1 | |
| <i>prenatal low iron oral tablet 27 mg iron- 1 mg</i> | 1 | |
| <i>prenatal plus iron tablet (rx) 29 mg iron- 1 mg</i> | 1 | |
| <i>prenatal vitamin plus low iron oral tablet 27 mg iron- 1 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>prenatal-u capsule 106.5-1 mg</i> | 1 | |
| <i>preplus ca-fe 27 mg-fa 1 mg tb (rx) 27 mg iron- 1 mg</i> | 1 | |
| <i>pretab 29 mg-1 mg tablet (rx) 29-1 mg</i> | 1 | |
| <i>r-natal ob softgel 20 mg iron- 1 mg-320 mg</i> | 1 | |
| <i>select-ob chewable caplet 29 mg iron- 1 mg</i> | 1 | |
| <i>select-ob chewable caplet 29 mg iron- 1 mg</i> | 1 | |
| <i>se-natal 19 chewable tablet 29 mg iron- 1 mg</i> | 1 | |
| <i>taron-c dha capsule 35-1-200 mg</i> | 1 | |
| <i>taron-prex prenatal-dha oral capsule 30 mg iron-1.2 mg-55 mg-265 mg</i> | 1 | |
| <i>triveen-duo dha oral combo pack 29-1-400 mg</i> | 1 | |
| <i>virt-c dha softgel (rx) 35-1-200 mg</i> | 1 | |
| <i>virt-nate dha softgel 28 mg iron-1 mg -200 mg</i> | 1 | |
| <i>virt-pn dha softgel (rx) 27 mg iron-1 mg -300 mg</i> | 1 | |
| <i>virt-pn plus softgel (rx) 28-1-300 mg</i> | 1 | |
| <i>vitafol gummies 3.33 mg iron- 0.33 mg</i> | 1 | |
| <i>vitafol nano tablet 18 mg iron- 1 mg</i> | 1 | |
| <i>vitafol-ob+dha combo pack 65-1-250 mg</i> | 1 | |
| <i>vp-ch-pnv oral capsule 30 mg iron-1 mg -50 mg-260 mg</i> | 1 | |
| <i>vp-pnv-dha softgel (rx) 28 mg iron- 1 mg-200 mg</i> | 1 | |
| <i>zatean-pn dha capsule 27 mg iron-1 mg -300 mg</i> | 1 | |
| <i>zatean-pn plus softgel 28-1-300 mg</i> | 1 | |
| <i>zingiber tablet 1.2 mg-40 mg- 124.1 mg-100 mg</i> | 1 | |

2025 LEON HEALTH FORMULARY UPDATED 02/19/2025

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 9)

INDEX

| | | |
|--------------------------------------|----------|--|
| 1 | | |
| 1ST TIER UNIFINE | | |
| PENTIPS | 77 | |
| 1ST TIER UNIFINE | | |
| PENTIPS PLUS | 77 | |
| A | | |
| <i>abacavir</i> | 50 | |
| <i>abacavir-lamivudine</i> | 50 | |
| ABELCET | 40 | |
| ABILIFY ASIMTUFII | 46 | |
| ABILIFY MAINTENA | 46 | |
| <i>abiraterone</i> | 22 | |
| ABOUTTIME PEN NEEDLE | | |
| | 77, 78 | |
| ABRYSVO (PF)..... | 129 | |
| <i>acamprosate</i> | 15 | |
| <i>acarbose</i> | 36 | |
| <i>accutane</i> | 73 | |
| <i>acebutolol</i> | 61 | |
| <i>acetaminophen-codeine</i> ... | 12 | |
| <i>acetazolamide</i> | 135 | |
| <i>acetic acid</i> | 113 | |
| <i>acetylcysteine</i> | 140 | |
| <i>acitretin</i> | 73 | |
| ACTHAR | 122 | |
| ACTHAR SELFJECT | 122 | |
| ACTHIB (PF)..... | 129 | |
| ACTIMMUNE | 134 | |
| <i>acyclovir</i> | 54, 73 | |
| <i>acyclovir sodium</i> | 54 | |
| ADACEL(TDAP | | |
| ADOLESN/ADULT)(PF) | | |
| | 129 | |
| <i>adapalene</i> | 77 | |
| <i>adefovir</i> | 54 | |
| ADEMPAS..... | 142 | |
| ADVOCATE PEN NEEDLE | | |
| | 78 | |
| ADVOCATE SYRINGES ... | 78 | |
| AJOVY AUTOINJECTOR.. | 42 | |
| AJOVY SYRINGE | 42 | |
| AKEEGA | 22 | |
| <i>ala-cort</i> | 75 | |
| <i>albendazole</i> | 44 | |
| <i>albuterol sulfate</i> | 138, 139 | |
| <i>alclometasone</i> | 75 | |
| ALCOHOL PADS | 78 | |
| ALCOHOL PREP PADS.... | 93 | |
| ALCOHOL PREP SWABS | 78 | |
| ALCOHOL SWABS | 78 | |
| ALECENSA | 22 | |
| <i>alendronate</i> | 133 | |
| <i>alfuzosin</i> | 119 | |
| <i>aliskiren</i> | 65 | |
| <i>allopurinol</i> | 42 | |
| <i>alogliptin</i> | 36 | |
| <i>alogliptin-metformin</i> | 36 | |
| <i>alogliptin-pioglitazone</i> | 36 | |
| <i>alose tron</i> | 132 | |
| <i>alprazolam</i> | 16 | |
| <i>altavera (28)</i> | 69 | |
| ALUNBRIG..... | 22 | |
| <i>alyacen 1/35 (28)</i> | 69 | |
| <i>alyq</i> | 142 | |
| <i>amantadine hcl</i> | 45 | |
| <i>ambrisentan</i> | 142 | |
| <i>amethia</i> | 69 | |
| <i>amikacin</i> | 17 | |
| <i>amiloride</i> | 63 | |
| <i>amiloride-hydrochlorothiazide</i> | | |
| | 63 | |
| <i>amiodarone</i> | 60 | |
| <i>amitriptyline</i> | 34 | |
| <i>amlodipine</i> | 63 | |
| <i>amlodipine-atorvastatin</i> | 64 | |
| <i>amlodipine-benazepril</i> | 63 | |
| <i>amlodipine-olmesartan</i> | 63 | |
| <i>amlodipine-valsartan</i> | 63 | |
| <i>amlodipine-valsartan-</i> | | |
| <i>hcthiazid</i> | 63 | |
| <i>ammonium lactate</i> | 73, 74 | |
| <i>amoxapine</i> | 34 | |
| <i>amoxicil-clarithromy-</i> | | |
| <i>lansopraz</i> | 116 | |
| <i>amoxicillin</i> | 20 | |
| <i>amoxicillin-pot clavulanate</i> | 20 | |
| <i>amphotericin b</i> | 40 | |
| <i>amphotericin b liposome</i> ... | 40 | |
| <i>ampicillin</i> | 20 | |
| <i>ampicillin sodium</i> | 20 | |
| <i>ampicillin-sulbactam</i> | 20 | |
| <i>anagrelide</i> | 57 | |
| <i>anastrozole</i> | 22 | |
| ANORO ELLIPTA..... | 139 | |
| <i>apomorphine</i> | 45 | |
| <i>apraclonidine</i> | 113 | |
| <i>aprepitant</i> | 44 | |
| <i>apri</i> | 69 | |
| APTIOM | 30 | |
| APTIVUS | 51 | |
| AQINJECT PEN NEEDLE . | 78 | |
| <i>aranelle (28)</i> | 69 | |
| ARCALYST | 124 | |
| AREXVY (PF)..... | 129 | |
| AREXVY ANTIGEN | | |
| COMPONENT | 129 | |
| ARIKAYCE | 17 | |
| <i>aripiprazole</i> | 46, 47 | |
| ARISTADA | 47 | |
| ARISTADA INITIO | 47 | |

| | | | | | |
|--------------------------------------|-----|-------------------------------------|-----|-------------------------------------|---------|
| <i>armodafinil</i> | 141 | <i>bal-care dha</i> | 142 | <i>benazepril-</i> | |
| ARNUITY ELLIPTA | 137 | <i>bal-care dha essential</i> | 142 | <i>hydrochlorothiazide</i> | 59 |
| <i>ascomp with codeine</i> | 12 | <i>balsalazide</i> | 132 | BENLYSTA | 125 |
| <i>asenapine maleate</i> | 47 | BALVERSA | 22 | <i>benzonatate</i> | 73 |
| <i>ashlyna</i> | 69 | <i>balziva (28)</i> | 69 | <i>benztropine</i> | 45 |
| <i>aspirin-dipyridamole</i> | 57 | BCG VACCINE, LIVE (PF) | | <i>bepotastine besilate</i> | 113 |
| ASSURE ID DUO PRO SFTY | | | 129 | BESREMI | 125 |
| PEN NDL | 78 | BD ALCOHOL SWABS | 80 | <i>betaine</i> | 134 |
| ASSURE ID DUO-SHIELD | 79 | BD AUTOSHIELD DUO PEN | | <i>betamethasone dipropionate</i> | |
| ASSURE ID INSULIN | | NEEDLE | 79 | | 75 |
| SAFETY..... | 79 | BD ECLIPSE LUER-LOK .. | 79 | <i>betamethasone valerate</i> ... | 75 |
| ASSURE ID PEN NEEDLE | 79 | BD INSULIN SYRINGE | 79 | <i>betamethasone, augmented</i> | |
| ASSURE ID PRO PEN | | BD INSULIN SYRINGE | | | 75 |
| NEEDLE | 79 | (HALF UNIT)..... | 79 | BETASERON | 66 |
| ASTAGRAF XL | 124 | BD INSULIN SYRINGE SLIP | | <i>betaxolol</i> | 61, 135 |
| <i>atazanavir</i> | 51 | TIP | 80 | <i>bethanechol chloride</i> | 119 |
| <i>atenolol</i> | 61 | BD INSULIN SYRINGE U- | | <i>bexarotene</i> | 22 |
| <i>atenolol-chlorthalidone</i> | 61 | 500..... | 79 | BEXSERO | 129 |
| <i>atomoxetine</i> | 66 | BD INSULIN SYRINGE | | <i>bicalutamide</i> | 22 |
| <i>atorvastatin</i> | 64 | ULTRA-FINE | 79 | BICILLIN L-A | 20 |
| <i>atovaquone</i> | 45 | BD NANO 2ND GEN PEN | | BIKTARVY | 51 |
| <i>atovaquone-proguanil</i> | 45 | NEEDLE | 80 | <i>bimatoprost</i> | 135 |
| <i>atropine</i> | 113 | BD SAFETYGLIDE INSULIN | | <i>bisoprolol fumarate</i> | 61 |
| ATROVENT HFA | 139 | SYRINGE | 80 | <i>bisoprolol-</i> | |
| <i>abra eq</i> | 69 | BD SAFETYGLIDE | | <i>hydrochlorothiazide</i> | 61 |
| AUGTYRO | 22 | SYRINGE | 80 | <i>blisovi 24 fe</i> | 69 |
| AUSTEDO..... | 66 | BD ULTRA-FINE MICRO | | <i>blisovi fe 1.5/30 (28)</i> | 69 |
| AUSTEDO XR..... | 66 | PEN NEEDLE | 80 | BOOSTRIX TDAP | 129 |
| AUSTEDO XR TITRATION | | BD ULTRA-FINE MINI PEN | | BORDERED GAUZE..... | 81 |
| KT(WK1-4)..... | 66 | NEEDLE | 80 | <i>bosentan</i> | 142 |
| AUVELITY..... | 34 | BD ULTRA-FINE NANO PEN | | BOSULIF | 22 |
| <i>aviane</i> | 69 | NEEDLE | 80 | BRAFTOVI | 22 |
| AVONEX..... | 66 | BD ULTRA-FINE ORIG PEN | | BREO ELLIPTA..... | 137 |
| AYVAKIT | 22 | NEEDLE | 80 | <i>breyna</i> | 138 |
| <i>azathioprine</i> | 124 | BD ULTRA-FINE SHORT | | BREZTRI AEROSPHERE | 139 |
| <i>azelastine</i> | 113 | PEN NEEDLE..... | 80 | <i>briellyn</i> | 69 |
| <i>azithromycin</i> | 19 | BD VEO INSULIN SYR | | BRILINTA | 57 |
| <i>aztreonam</i> | 20 | (HALF UNIT)..... | 80 | <i>brimonidine</i> | 135 |
| B | | BD VEO INSULIN SYRINGE | | <i>brimonidine-timolol</i> | 135 |
| <i>bacitracin</i> | 113 | UF..... | 81 | <i>brinzolamide</i> | 135 |
| <i>bacitracin-polymyxin b</i> | 113 | BELSOMRA | 141 | BRIVIACT | 30 |
| <i>baclofen</i> | 141 | <i>benazepril</i> | 59 | <i>bromfenac</i> | 115 |

| | | | | | |
|---------------------------------------|----------|--------------------------------------|--------|--------------------------------------|---------|
| <i>bromocriptine</i> | 45 | <i>carbidopa-levodopa-</i> | | <i>cholestyramine light</i> | 64 |
| BRONCHITOL..... | 140 | <i>entacapone</i> | 46 | <i>ciclopirox</i> | 40 |
| BRUKINSA..... | 22 | <i>carbinoxamine maleate</i> | 42 | <i>cilostazol</i> | 57 |
| <i>budesonide</i> | 132, 138 | CAREFINE PEN NEEDLE | 81 | CIMDUO..... | 51 |
| <i>budesonide-formoterol</i> | 138 | CARETOUCH ALCOHOL | | <i>cimetidine</i> | 116 |
| <i>bumetanide</i> | 63 | PREP PAD | 81 | CIMZIA | 125 |
| <i>buprenorphine</i> | 12 | CARETOUCH INSULIN | | CIMZIA POWDER FOR | |
| <i>buprenorphine hcl</i> | 15 | SYRINGE | 81, 82 | RECONST | 125 |
| <i>buprenorphine-naloxone</i> ... | 15 | CARETOUCH PEN NEEDLE | | <i>cinacalcet</i> | 133 |
| <i>bupropion hcl</i> | 34 | | 81 | CINRYZE | 55 |
| <i>bupropion hcl (smoking</i> | | <i>carglumic acid</i> | 117 | <i>ciprofloxacin hcl</i> | 21, 113 |
| <i>deter</i>) | 16 | <i>carteolol</i> | 135 | <i>ciprofloxacin in 5 % dextrose</i> | |
| <i>buspirone</i> | 134 | <i>cartia xt</i> | 61 | | 21 |
| <i>butalbital-acetaminop-caf-cod</i> | | <i>carvedilol</i> | 61 | <i>ciprofloxacin-dexamethasone</i> | |
| | 12 | <i>caspofungin</i> | 40 | | 113 |
| <i>butalbital-acetaminophen</i> .. | 12 | CAYSTON..... | 20 | <i>citalopram</i> | 34 |
| <i>butalbital-acetaminophen-caff</i> | | <i>cefaclor</i> | 18 | <i>clarithromycin</i> | 19 |
| | 12 | <i>cefadroxil</i> | 18 | <i>clemastine</i> | 42 |
| <i>butalbital-aspirin-caffeine</i> .. | 12 | <i>cefazolin</i> | 18 | CLENPIQ | 118 |
| <i>butorphanol</i> | 12 | <i>cefdinir</i> | 18 | CLICKFINE PEN NEEDLE | 82 |
| BYLVAY | 117 | <i>cefepime</i> | 18 | <i>clindamycin hcl</i> | 17 |
| C | | <i>cefixime</i> | 18 | <i>clindamycin in 5 % dextrose</i> | |
| <i>cabergoline</i> | 45 | <i>cefoxitin</i> | 18 | | 17 |
| CABLIVI | 57 | <i>cefopodoxime</i> | 19 | <i>clindamycin pediatric</i> | 17 |
| CABOMETYX..... | 22 | <i>cefprozil</i> | 19 | <i>clindamycin phosphate</i> | 17, |
| <i>calcipotriene</i> | 74 | <i>ceftazidime</i> | 19 | 42, 74 | |
| <i>calcitonin (salmon)</i> | 133 | <i>ceftriaxone</i> | 19 | <i>clindamycin-benzoyl peroxide</i> | |
| <i>calcitriol</i> | 133 | <i>cefuroxime axetil</i> | 19 | | 74 |
| CALQUENCE..... | 22 | <i>cefuroxime sodium</i> | 19 | CLINIMIX 5%/D15W | |
| CALQUENCE | | <i>celecoxib</i> | 14 | SULFITE FREE | 57 |
| (ACALABRUTINIB MAL)22 | | <i>cephalexin</i> | 19 | CLINIMIX 4.25%/D10W | |
| <i>camila</i> | 69 | CEQUA | 115 | SULF FREE | 57 |
| <i>candesartan</i> | 58 | CERDELGA | 112 | CLINIMIX 4.25%/D5W | |
| <i>candesartan-</i> | | <i>cevimeline</i> | 73 | SULFIT FREE..... | 57 |
| <i>hydrochlorothiazid</i> | 58 | <i>chlordiazepoxide hcl</i> | 16 | CLINIMIX 5%- | |
| CAPLYTA..... | 47 | <i>chlorhexidine gluconate</i> | 73 | D20W(SULFITE-FREE) . | 57 |
| CAPRELSA..... | 22, 23 | <i>chloroquine phosphate</i> | 45 | CLINIMIX E 2.75%/D5W | |
| <i>captopril</i> | 59 | <i>chlorpromazine</i> | 47 | SULF FREE | 57 |
| <i>carbamazepine</i> | 30 | <i>chlorthalidone</i> | 63 | CLINIMIX E 4.25%/D10W | |
| <i>carbidopa</i> | 45 | <i>chlorzoxazone</i> | 141 | SUL FREE | 57 |
| <i>carbidopa-levodopa</i> | 45 | <i>cholestyramine (with sugar)</i> | | CLINIMIX E 4.25%/D5W | |
| | | | 64 | SULF FREE | 57 |

| | | |
|---------------------------------------|--------------------------------------|--------------------------------------|
| CLINIMIX E 5%/D15W | COPIKTRA..... | <i>daptomycin</i> |
| SULFIT FREE..... | CORLANOR..... | <i>darunavir</i> |
| CLINIMIX E 5%/D20W | COSENTYX..... | <i>dasatinib</i> |
| SULFIT FREE..... | COSENTYX (2 SYRINGES) | DAURISMO..... |
| <i>clobazam</i> | | <i>deblitane</i> |
| <i>clobetasol</i> | COSENTYX PEN (2 PENS) | <i>deferasirox</i> |
| <i>clobetasol-emollient</i> | | <i>deferiprone</i> |
| <i>clomipramine</i> | COSENTYX UNOREADY | DELSTRIGO..... |
| <i>clonazepam</i> | PEN..... | <i>demeclocycline</i> |
| <i>clonidine</i> | COTELLIC..... | DEPO-SUBQ PROVERA |
| <i>clonidine hcl</i> | CREON..... | |
| <i>clopidogrel</i> | <i>cromolyn</i> | DERMACEA..... |
| <i>clorazepate dipotassium</i> ... | <i>cryselle (28)</i> | DERMACEA NON-WOVEN |
| <i>clotrimazole</i> | CURAD GAUZE PAD..... | |
| <i>clotrimazole-betamethasone</i> | CURITY ALCOHOL SWABS | DESCOVY..... |
| | | <i>desipramine</i> |
| <i>clozapine</i> | CURITY GAUZE..... | <i>desmopressin</i> |
| <i>c-nate dha</i> | <i>cyanocobalamin (vitamin b-</i> | <i>desog-e.estradiol/e.estradiol</i> |
| COARTEM..... | 12)..... | |
| COBENFY..... | <i>cyclobenzaprine</i> | <i>desogestrel-ethinyl estradiol</i> |
| COBENFY STARTER PACK | <i>cyclophosphamide</i> | |
| | <i>cyclosporine</i> | <i>desonide</i> |
| <i>codeine sulfate</i> | | <i>desoximetasone</i> |
| <i>codeine-butalbital-asa-caff</i> | <i>cyclosporine modified</i> | |
| <i>colchicine</i> | <i>cyproheptadine</i> | <i>desvenlafaxine succinate</i> .. |
| <i>colesevelam</i> | <i>cyred eq</i> | <i>dexamethasone</i> |
| <i>colestipol</i> | CYSTARAN..... | <i>dexamethasone sodium</i> |
| <i>colistin (colistimethate na)</i> . | D | <i>phosphate</i> |
| COMBIVENT RESPIMAT | <i>d5 % and 0.9 % sodium</i> | <i>dexmethylphenidate</i> |
| COMETRIQ..... | <i>chloride</i> | <i>dextroamphetamine sulfate</i> |
| COMFORT EZ INSULIN | <i>d5 %-0.45 % sodium chloride</i> | |
| SYRINGE..... | | <i>dextroamphetamine-</i> |
| COMFORT EZ PEN | <i>dabigatran etexilate</i> | <i>amphetamine</i> |
| NEEDLES..... | <i>dalfampridine</i> | <i>dextrose 10 % in water</i> |
| COMFORT EZ PRO | <i>danazol</i> | (<i>d10w</i>)..... |
| SAFETY PEN NDL..... | <i>dantrolene</i> | <i>dextrose 5 % in water (d5w)</i> |
| COMFORT TOUCH PEN | DANZITEN..... | |
| NEEDLE..... | <i>dapaglifloz propaned-</i> | DIACOMIT..... |
| COMPLERA..... | <i>metformin</i> | <i>diazepam</i> |
| <i>completenate</i> | <i>dapagliflozin propanediol</i> ... | |
| <i>compro</i> | <i>dapsone</i> | <i>diazepam intensol</i> |
| <i>constulose</i> | DAPTACEL (DTAP | <i>diazoxide</i> |
| | PEDIATRIC) (PF)..... | <i>diclofenac potassium</i> |
| | | <i>diclofenac sodium</i> |

| | | | | | |
|-------------------------------------|--------|---------------------------------------|--------|---|------------|
| <i>diclofenac-misoprostol</i> | 14 | DROPLET INSULIN | | EASY TOUCH INSULIN | |
| <i>dicloxacillin</i> | 20 | SYRINGE | 84, 85 | SAFETY SYR | 88 |
| <i>dicyclomine</i> | 117 | DROPLET MICRON PEN | | EASY TOUCH INSULIN | |
| DIFICID | 19 | NEEDLE | 85 | SYRINGE | 88, 89, 90 |
| <i>diflorasone</i> | 76 | DROPLET PEN NEEDLE. | 85, | EASY TOUCH LUER LOCK | |
| <i>diflunisal</i> | 14 | 86 | | INSULIN | 89 |
| <i>difluprednate</i> | 115 | DROPSAFE ALCOHOL | | EASY TOUCH PEN NEEDLE | |
| <i>digoxin</i> | 62 | PREP PADS | 86 | | 89 |
| <i>dihydroergotamine</i> | 42 | DROPSAFE INSULIN | | EASY TOUCH SAFETY PEN | |
| DILANTIN..... | 30 | SYRINGE | 86 | NEEDLE | 89, 90 |
| <i>diltiazem hcl</i> | 61, 62 | DROPSAFE PEN NEEDLE | | EASY TOUCH | |
| <i>dilt-xr</i> | 62 | | 86 | SHEATHLOCK INSULIN | |
| <i>dimethyl fumarate</i> | 67 | <i>drospirenone-ethinyl estradiol</i> | | | 88, 89 |
| DIPENTUM | 133 | | 70 | EASY TOUCH UNI-SLIP ... | 90 |
| <i>diphenoxylate-atropine</i> ... | 117 | DROXIA | 57 | <i>ec-naproxen</i> | 14 |
| <i>dipyridamole</i> | 57 | <i>droxidopa</i> | 58 | <i>econazole nitrate</i> | 40 |
| <i>disopyramide phosphate</i> ... | 60 | DUAVEE | 120 | EDARBI | 58 |
| <i>disulfiram</i> | 16 | <i>duloxetine</i> | 34 | EDARBYCLOR..... | 59 |
| <i>divalproex</i> | 30 | DUPIXENT PEN..... | 125 | EDURANT..... | 51 |
| <i>dofetilide</i> | 60 | DUPIXENT SYRINGE..... | 125 | <i>efavirenz</i> | 51 |
| <i>donepezil</i> | 33 | <i>dutasteride</i> | 119 | <i>efavirenz-emtricitabin-tenofovir</i> | |
| DOPTELET (10 TAB PACK) | | <i>dutasteride-tamsulosin</i> | 119 | | 51 |
| | 56 | E | | <i>efavirenz-lamivu-tenofovir</i> | |
| DOPTELET (15 TAB PACK) | | EASY COMFORT ALCOHOL | | <i>disop</i> | 51 |
| | 56 | PAD | 87 | EGRIFTA SV | 122 |
| DOPTELET (30 TAB PACK) | | EASY COMFORT INSULIN | | <i>electrolyte-148</i> | 136 |
| | 56 | SYRINGE | 87 | ELIGARD | 23 |
| <i>dorzolamide</i> | 135 | EASY COMFORT PEN | | ELIGARD (3 MONTH)..... | 23 |
| <i>dorzolamide-timolol</i> | 136 | NEEDLES..... | 87 | ELIGARD (4 MONTH)..... | 23 |
| <i>dorzolamide-timolol (pf)</i> ... | 135 | EASY COMFORT SAFETY | | ELIGARD (6 MONTH)..... | 23 |
| <i>dotti</i> | 120 | PEN NEEDLE | 86, 87 | ELIQUIS | 55 |
| DOVATO | 51 | EASY GLIDE INSULIN | | ELIQUIS DVT-PE TREAT | |
| <i>doxazosin</i> | 58 | SYRINGE | 87, 88 | 30D START | 55 |
| <i>doxepin</i> | 34 | EASY GLIDE PEN NEEDLE | | ELMIRON | 134 |
| <i>doxercalciferol</i> | 133 | | 88 | <i>eluryng</i> | 70 |
| <i>doxy-100</i> | 21 | EASY TOUCH..... | 89 | EMBRACE PEN NEEDLE. | 90 |
| <i>doxycycline hyclate</i> | 21 | EASY TOUCH ALCOHOL | | EMEND | 44 |
| <i>doxycycline monohydrate</i> .. | 21 | PREP PADS | 88 | EMGALITY PEN..... | 43 |
| DRIZALMA SPRINKLE | 34 | EASY TOUCH FLIPLOCK | | EMGALITY SYRINGE..... | 43 |
| <i>dronabinol</i> | 44 | INSULIN | 89 | EMSAM | 35 |
| DROPLET INSULIN | | EASY TOUCH FLIPLOCK | | <i>emtricitabine</i> | 51 |
| SYR(HALF UNIT) | 84, 85 | SYRINGE | 88 | <i>emtricitabine-tenofovir (tdf)</i> | 51 |

| | | | | | |
|--------------------------------------|----------|--|-----|---------------------------------------|--------------|
| EMTRIVA | 51 | <i>esomeprazole magnesium</i> | 116 | <i>fenoprofen</i> | 14 |
| <i>enalapril maleate</i> | 59 | <i>estarylla</i> | 70 | <i>fentanyl</i> | 12 |
| <i>enalapril-hydrochlorothiazide</i> | 59 | <i>estazolam</i> | 16 | <i>fentanyl citrate</i> | 12 |
| ENBREL | 125, 126 | <i>estradiol</i> | 121 | FERRIPROX | 120 |
| ENBREL MINI | 125 | <i>estradiol valerate</i> | 121 | FERRIPROX (2 TIMES A | |
| ENBREL SURECLICK ... | 126 | <i>estradiol-norethindrone acet</i> | 121 | DAY) | 120 |
| ENDARI | 134 | | 121 | <i>fesoterodine</i> | 119 |
| <i>endocet</i> | 12 | <i>eszopiclone</i> | 141 | FETZIMA | 35 |
| ENGERIX-B (PF) | 129 | <i>ethambutol</i> | 43 | FIASP FLEXTOUCH U-100 | |
| ENGERIX-B PEDIATRIC | | <i>ethosuximide</i> | 30 | INSULIN | 38 |
| (PF) | 129 | <i>ethynodiol diac-eth estradiol</i> | 70 | FIASP PENFILL U-100 | |
| <i>enoxaparin</i> | 55 | | 70 | INSULIN | 38 |
| <i>enpresse</i> | 70 | <i>etodolac</i> | 14 | FIASP U-100 INSULIN | 38 |
| <i>enskyce</i> | 70 | <i>etonogestrel-ethinyl estradiol</i> | 70 | <i>finasteride</i> | 119 |
| <i>entacapone</i> | 46 | | 70 | <i>ingolimod</i> | 67 |
| <i>entecavir</i> | 54 | <i>etravirine</i> | 51 | FINTEPLA | 30 |
| ENTRESTO | 59 | EUCRISA | 76 | FIRDAPSE | 134 |
| ENTRESTO SPRINKLE ... | 59 | <i>everolimus (antineoplastic)</i> | 23 | FIRMAGON KIT W DILUENT | |
| <i>enulose</i> | 117 | <i>everolimus</i> | 126 | SYRINGE | 23, 24 |
| EPCLUSA | 53, 54 | (immunosuppressive) .. | 126 | <i>flavoxate</i> | 119 |
| EPIDIOLEX | 30 | EVOTAZ | 51 | <i>flecainide</i> | 60 |
| <i>epinastine</i> | 113 | <i>exemestane</i> | 23 | <i>fluconazole</i> | 41 |
| <i>epinephrine</i> | 62 | EYSUVIS | 115 | <i>fluconazole in nacl (iso-osm)</i> | 40 |
| <i>epitol</i> | 30 | <i>ezetimibe</i> | 64 | | 40 |
| <i>eplerenone</i> | 65 | <i>ezetimibe-simvastatin</i> | 64 | <i>flucytosine</i> | 41 |
| EPRONTIA | 30 | F | | <i>fludrocortisone</i> | 121 |
| <i>ergocalciferol (vitamin d2)</i> | 142 | <i>falmina (28)</i> | 70 | <i>flunisolide</i> | 115 |
| <i>ergoloid</i> | 33 | <i>famciclovir</i> | 54 | <i>fluocinolone</i> | 76 |
| ERIVEDGE | 23 | <i>famotidine</i> | 116 | <i>fluocinolone acetonide oil</i> | 115 |
| ERLEADA | 23 | FANAPT | 47 | <i>fluocinonide</i> | 76 |
| <i>erlotinib</i> | 23 | FASENRA | 140 | <i>fluocinonide-emollient</i> | 76 |
| <i>errin</i> | 70 | FASENRA PEN | 140 | <i>fluorometholone</i> | 115 |
| <i>ertapenem</i> | 20 | <i>febuxostat</i> | 42 | <i>fluorouracil</i> | 74 |
| <i>ery pads</i> | 74 | <i>felbamate</i> | 30 | <i>fluoxetine</i> | 35 |
| <i>erythromycin</i> | 19, 114 | <i>felodipine</i> | 63 | <i>fluphenazine decanoate</i> ... | 47 |
| <i>erythromycin ethylsuccinate</i> | 19 | FEMRING | 121 | <i>fluphenazine hcl</i> | 48 |
| | 19 | <i>fenofibrate</i> | 64 | <i>flurbiprofen</i> | 14 |
| <i>erythromycin with ethanol</i> | 74 | <i>fenofibrate micronized</i> | 64 | <i>flurbiprofen sodium</i> | 115 |
| <i>erythromycin-benzoyl</i> | | <i>fenofibrate nanocrystallized</i> | 64 | <i>fluticasone furoate-vilanterol</i> | |
| <i>peroxide</i> | 74 | | 64 | | 138 |
| <i>escitalopram oxalate</i> | 35 | <i>fenofibric acid (choline)</i> | 64 | <i>fluticasone propionate</i> | 76, 115, 138 |

| | | | |
|---------------------------------------|--------------------------------------|-------------|--|
| <i>fluticasone propion-</i> | <i>generlac</i> | 117 | HEALTHWISE INSULIN |
| <i>salmeterol</i> | <i>gengraf</i> | 126 | SYRINGE |
| 138 | <i>gentamicin</i> | 17, 74, 114 | HEALTHWISE PEN NEEDLE |
| <i>fluvastatin</i> | GENVOYA | 51 | |
| 64 | GILENYA..... | 67 | HEALTHY ACCENTS |
| <i>fluvoxamine</i> | GILOTRIF..... | 24 | UNIFINE PENTIP |
| 35 | <i>glatiramer</i> | 67 | 91, 92 |
| <i>folic acid</i> | <i>glatopa</i> | 67 | <i>heparin (porcine)</i> |
| 142 | GLEOSTINE..... | 24 | 55 |
| <i>folivane-ob</i> | <i>glimepiride</i> | 40 | HEPLISAV-B (PF) |
| 142 | <i>glipizide</i> | 40 | 130 |
| <i>fondaparinux</i> | <i>glipizide-metformin</i> | 40 | HETLIOZ LQ |
| 55 | <i>glutamine (sickle cell)</i> | 134 | 141 |
| <i>fosamprenavir</i> | <i>glyburide</i> | 40 | HIBERIX (PF) |
| 51 | <i>glyburide micronized</i> | 40 | 130 |
| <i>fosfomycin tromethamine</i> .. | <i>glyburide-metformin</i> | 40 | HUMIRA |
| 17 | <i>glycopyrrolate</i> | 117 | 126 |
| <i>fosinopril</i> | GLYXAMBI | 36 | HUMIRA PEN..... |
| 60 | <i>granisetron hcl</i> | 44 | 126 |
| <i>fosinopril-hydrochlorothiazide</i> | <i>griseofulvin microsize</i> | 41 | HUMIRA PEN CROHNS-UC- |
| | <i>griseofulvin ultramicrosize</i> . | 41 | HS START |
| 60 | <i>guanfacine</i> | 58, 67 | 126 |
| FOTIVDA..... | GVOKE | 134 | HUMIRA PEN PSOR- |
| 24 | GVOKE HYPOPEN 2-PACK | | UVEITS-ADOL HS..... |
| FREESTYLE PRECISION 90, | | 134 | 126 |
| 91 | GVOKE PFS 1-PACK | | HUMIRA(CF) |
| FRUZAQLA | SYRINGE | 134 | 127 |
| 24 | H | | HUMIRA(CF) PEDI CROHNS |
| FULPHILA | HADLIMA | 126 | STARTER..... |
| 56 | HADLIMA PUSHTOUCH. 126 | | 126 |
| <i>furosemide</i> | HADLIMA(CF) | 126 | HUMIRA(CF) PEN..... |
| 63 | HADLIMA(CF) PUSHTOUCH | | 127 |
| FUZEON | | 126 | HUMIRA(CF) PEN |
| 51 | HAEGARDA | 56 | CROHNS-UC-HS..... |
| <i>fyavolv</i> | <i>hailey 24 fe</i> | 70 | 127 |
| 121 | <i>halobetasol propionate</i> | 76 | HUMIRA(CF) PEN |
| FYCOMPA | <i>haloette</i> | 70 | PEDIATRIC UC |
| 30, 31 | <i>haloperidol</i> | 48 | 127 |
| G | <i>haloperidol decanoate</i> | 48 | HUMIRA(CF) PEN PSOR- |
| <i>gabapentin</i> | <i>haloperidol lactate</i> | 48 | UV-ADOL HS..... |
| 31 | HARVONI..... | 54 | 127 |
| GALAFOLD | HAVRIX (PF)..... | 130 | HUMULIN R U-500 (CONC) |
| 112 | | | INSULIN |
| <i>galantamine</i> | | | 38 |
| 33 | | | HUMULIN R U-500 (CONC) |
| GAMMAGARD LIQUID ... | | | KWIKPEN |
| 126 | | | 38 |
| GAMMAGARD S-D (IGA < 1 | | | <i>hydralazine</i> |
| MCG/ML) | | | 62 |
| 126 | | | <i>hydrochlorothiazide</i> |
| GAMMAPLEX | | | 63 |
| 126 | | | <i>hydrocodone-acetaminophen</i> |
| GAMMAPLEX (WITH | | | |
| SORBITOL) | | | 12, 13 |
| 126 | | | <i>hydrocodone-ibuprofen</i> |
| GAMUNEX-C | | | 13 |
| 126 | | | <i>hydrocortisone</i> ... 76, 122, 133 |
| GARDASIL 9 (PF) ... | | | 76 |
| 129, 130 | | | <i>hydrocortisone butyrate</i> |
| <i>gatifloxacin</i> | | | 76 |
| 114 | | | <i>hydrocortisone valerate</i> |
| GATTEX 30-VIAL..... | | | 76 |
| 117 | | | <i>hydrocortisone-acetic acid</i> |
| GAUZE PAD | | | |
| 91 | | | 114 |
| <i>gavilyte-c</i> | | | <i>hydromorphone</i> |
| 118 | | | 13 |
| <i>gavilyte-g</i> | | | <i>hydromorphone (pf)</i> |
| 118 | | | 13 |
| <i>gavilyte-n</i> | | | |
| 118 | | | |
| GAVRETO..... | | | |
| 24 | | | |
| <i>gefitinib</i> | | | |
| 24 | | | |
| <i>gemfibrozil</i> | | | |
| 64 | | | |

| | | | |
|----------------------------------|--------|---------------------------------------|--------------|
| <i>hydroxychloroquine</i> | 45 | <i>insulin asp prt-insulin aspart</i> | 63 |
| <i>hydroxyurea</i> | 24 | | 38 |
| <i>hydroxyzine hcl</i> | 42 | <i>insulin aspart u-100</i> | 38 |
| <i>hydroxyzine pamoate</i> | 134 | <i>insulin degludec</i> | 38 |
| I | | <i>insulin glargine u-300 conc</i> | 38 |
| <i>ibandronate</i> | 133 | <i>insulin glargine-yfgn</i> | 39 |
| IBRANCE | 24 | <i>insulin lispro</i> | 39 |
| <i>ibu</i> | 14 | <i>insulin lispro protamin-lispro</i> | 39 |
| <i>ibuprofen</i> | 14 | | 39 |
| <i>icatibant</i> | 62 | INSULIN SYR/NDL U100 | |
| <i>iclevia</i> | 70 | HALF MARK | 92 |
| ICLUSIG | 24 | INSULIN SYRINGE | 80 |
| <i>icosapent ethyl</i> | 64, 65 | INSULIN SYRINGE | |
| IDHIFA | 24 | MICROFINE | 80 |
| ILEVRO | 115 | INSULIN SYRINGE | |
| <i>imatinib</i> | 24 | NEEDLELESS | 80 |
| IMBRUVICA | 24 | INSULIN SYRINGE-NEEDLE | |
| <i>imipenem-cilastatin</i> | 20 | U-100.. 90, 92, 93, 99, 103, | |
| <i>imipramine hcl</i> | 35 | 106 | |
| <i>imipramine pamoate</i> | 35 | INSUPEN PEN NEEDLE.. | 93 |
| <i>imiquimod</i> | 74 | INTELENCE | 51 |
| IMKELDI | 24 | INTRALIPID | 58 |
| IMOVAX RABIES VACCINE | | INVEGA HAFYERA | 48 |
| (PF) | 130 | INVEGA SUSTENNA | 48 |
| IMPAVIDO | 45 | INVEGA TRINZA | 48 |
| INBRIJA | 46 | IPOL | 130 |
| <i>incassia</i> | 70 | <i>ipratropium bromide</i> | 113, 139 |
| INCONTROL ALCOHOL | | <i>ipratropium-albuterol</i> | 139 |
| PADS | 92 | <i>irbesartan</i> | 59 |
| INCONTROL PEN NEEDLE | | <i>irbesartan-</i> | |
| | 92 | <i>hydrochlorothiazide</i> | 59 |
| INCRELEX | 122 | ISENTRESS | 51, 52 |
| <i>indapamide</i> | 63 | ISENTRESS HD | 51 |
| <i>indomethacin</i> | 14, 15 | <i>isibloom</i> | 70 |
| INFANRIX (DTAP) (PF) .. | 130 | ISOLYTE S PH 7.4 | 136 |
| INGREZZA | 67 | ISOLYTE-P IN 5 % | |
| INGREZZA INITIATION | | DEXTROSE | 136 |
| PK(TARDIV) | 67 | ISOLYTE-S | 136 |
| INLYTA | 24 | <i>isoniazid</i> | 43 |
| INQOVI | 24 | <i>isosorbide dinitrate</i> | 65 |
| INREBIC | 24 | <i>isosorbide mononitrate</i> | 65 |
| | | <i>isosorbide-hydralazine</i> | 65 |
| | | <i>isradipine</i> | 63 |
| | | ITOVEBI | 24 |
| | | <i>itraconazole</i> | 41 |
| | | IV PREP WIPES | 93 |
| | | <i>ivabradine</i> | 62 |
| | | <i>ivermectin</i> | 45 |
| | | IWILFIN | 24 |
| | | IXCHIQ (PF) | 130 |
| | | IXIARO (PF) | 130 |
| | | J | |
| | | JAKAFI | 24 |
| | | <i>jantoven</i> | 55 |
| | | JARDIANCE | 36 |
| | | <i>jasmiel (28)</i> | 70 |
| | | <i>javygtor</i> | 112 |
| | | JAYPIRCA | 24, 25 |
| | | JENTADUETO | 36 |
| | | JENTADUETO XR | 37 |
| | | <i>jinteli</i> | 121 |
| | | <i>juleber</i> | 70 |
| | | JULUCA | 52 |
| | | <i>junel 1.5/30 (21)</i> | 70 |
| | | <i>junel 1/20 (21)</i> | 70 |
| | | <i>junel fe 1.5/30 (28)</i> | 70 |
| | | <i>junel fe 1/20 (28)</i> | 70 |
| | | <i>junel fe 24</i> | 70 |
| | | JYNNEOS (PF) | 130 |
| | | K | |
| | | KALYDECO | 140 |
| | | <i>kariva (28)</i> | 70 |
| | | <i>kelnor 1/35 (28)</i> | 70 |
| | | <i>kelnor 1/50 (28)</i> | 70 |
| | | KERENDIA | 65 |
| | | KESIMPTA PEN | 67 |
| | | <i>ketoconazole</i> | 41 |
| | | <i>ketoprofen</i> | 15 |
| | | <i>ketorolac</i> | 15, 115, 116 |
| | | KEVZARA | 127 |
| | | KINRIX (PF) | 130 |
| | | <i>kionex (with sorbitol)</i> | 117 |
| | | KISQALI | 25 |

| | | |
|--|--|--|
| KISQALI FEMARA CO-PACK | <i>levocarnitine (with sugar)</i> 134 | <i>losartan-hydrochlorothiazide</i> |
| 25 | <i>levocetirizine</i> 42 | 59 |
| <i>klor-con m10</i> 136 | <i>levofloxacin</i> 21, 114 | LOTEMAX 116 |
| <i>klor-con m15</i> 137 | <i>levofloxacin in d5w</i> 21 | LOTEMAX SM 116 |
| <i>klor-con m20</i> 137 | <i>levonest (28)</i> 71 | <i>loteprednol etabonate</i> 116 |
| KOSELUGO 25 | <i>levonorgestrel-ethinyl estrad</i> | <i>lovastatin</i> 65 |
| <i>kosher prenatal plus iron</i> . 142 | 71 | <i>low-ogestrel (28)</i> 71 |
| KRAZATI 25 | <i>levonorg-eth estrad triphasic</i> | <i>loxapine succinate</i> 48 |
| KRINTAFEL 45 | 71 | <i>lubiprostone</i> 118 |
| <i>kurvelo (28)</i> 70 | <i>levora-28</i> 71 | LUMAKRAS 25 |
| L | <i>levothyroxine</i> 124 | LUMIGAN 136 |
| <i>l norgest/e.estradiol-e.estrad</i> | LEVOXYL 124 | LUPRON DEPOT 26, 122 |
| 70 | LIBERVANT 31 | LUPRON DEPOT (3 |
| <i>labetalol</i> 61 | <i>lidocaine</i> 15 | MONTH) 26, 122 |
| <i>lacosamide</i> 31 | <i>lidocaine hcl</i> 15 | LUPRON DEPOT (4 |
| <i>lactulose</i> 117 | <i>lidocaine viscous</i> 15 | MONTH) 26 |
| <i>lamivudine</i> 52 | <i>lidocaine-prilocaine</i> 15 | LUPRON DEPOT (6 |
| <i>lamivudine-zidovudine</i> 52 | <i>linezolid</i> 17 | MONTH) 26 |
| <i>lamotrigine</i> 31 | <i>linezolid in dextrose 5%</i> 17 | LUPRON DEPOT-PED ... 123 |
| <i>lansoprazole</i> 117 | LINZESS 118 | LUPRON DEPOT-PED (3 |
| <i>lapatinib</i> 25 | <i>liothyronine</i> 124 | MONTH) 122 |
| <i>larin 1.5/30 (21)</i> 70 | LISCO 93 | <i>lurasidone</i> 48 |
| <i>larin 1/20 (21)</i> 71 | <i>lisinopril</i> 60 | <i>lutea (28)</i> 71 |
| <i>larin fe 1.5/30 (28)</i> 71 | <i>lisinopril-hydrochlorothiazide</i> | LYBALVI 48 |
| <i>larin fe 1/20 (28)</i> 71 | 60 | <i>lyleq</i> 71 |
| <i>latanoprost</i> 136 | LITE TOUCH INSULIN PEN | <i>lyllana</i> 121 |
| LAZCLUZE 25 | NEEDLES 93 | LYNPARZA 26 |
| <i>ledipasvir-sofosbuvir</i> 54 | LITE TOUCH INSULIN | LYSODREN 26 |
| <i>leflunomide</i> 127 | SYRINGE 93, 94 | LYTGOBI 26 |
| <i>lenalidomide</i> 25 | <i>lithium carbonate</i> 67 | <i>lyza</i> 71 |
| LENVIMA 25 | <i>lithium citrate</i> 67 | M |
| <i>lessina</i> 71 | LIVTENCITY 53 | MAGELLAN INSULIN |
| <i>letrozole</i> 25 | LOKELMA 118 | SAFETY SYRNG 94 |
| <i>leucovorin calcium</i> 134 | LONSURF 25 | MAGELLAN SYRINGE 94 |
| LEUKERAN 25 | <i>loperamide</i> 118 | <i>magnesium sulfate</i> 137 |
| LEUKINE 56 | <i>lopinavir-ritonavir</i> 52 | <i>malathion</i> 77 |
| <i>leuprolide</i> 25 | <i>lorazepam</i> 16, 17 | <i>maraviroc</i> 52 |
| <i>leuprolide (3 month)</i> 25 | <i>lorazepam intensol</i> 16 | <i>marlissa (28)</i> 71 |
| <i>levabuterol tartrate</i> 139 | LORBRENA 25 | <i>marnatal-f</i> 142 |
| <i>levetiracetam</i> 31 | <i>loryna (28)</i> 71 | MARPLAN 35 |
| <i>levobunolol</i> 136 | <i>losartan</i> 59 | MATULANE 26 |
| <i>levocarnitine</i> 134 | | <i>matzim la</i> 62 |

| | | | | | |
|---|---------|--|------------|--|---------|
| MAVENCLAD (10 TABLET PACK)..... | 68 | MENVEO A-C-Y-W-135-DIP (PF)..... | 130 | <i>mimvey</i> | 121 |
| MAVENCLAD (4 TABLET PACK)..... | 68 | <i>mercaptopurine</i> | 26 | MINI ULTRA-THIN II | 95 |
| MAVENCLAD (5 TABLET PACK)..... | 68 | <i>meropenem</i> | 20 | <i>minocycline</i> | 22 |
| MAVENCLAD (6 TABLET PACK)..... | 68 | <i>merzee</i> | 71 | <i>minoxidil</i> | 65 |
| MAVENCLAD (7 TABLET PACK)..... | 68 | <i>mesalamine</i> | 133 | MIRENA | 71 |
| MAVENCLAD (8 TABLET PACK)..... | 68 | MESNEX..... | 134 | <i>mirtazapine</i> | 35 |
| MAVENCLAD (9 TABLET PACK)..... | 68 | <i>metformin</i> | 37 | <i>misoprostol</i> | 117 |
| MAVYRET..... | 54 | <i>methadone</i> | 13 | M-M-R II (PF) | 130 |
| MAXICOMFORT II PEN NEEDLE | 94 | <i>methazolamide</i> | 136 | <i>m-natal plus</i> | 142 |
| MAXICOMFORT INSULIN SYRINGE | 94 | <i>methenamine hippurate</i> | 17 | <i>modafinil</i> | 141 |
| MAXI-COMFORT INSULIN SYRINGE | 94 | <i>methimazole</i> | 124 | <i>moexipril</i> | 60 |
| MAXI-COMFORT INSULIN SYRINGE | 94 | <i>methocarbamol</i> | 141 | <i>molindone</i> | 49 |
| MAXICOMFORT SAFETY PEN NEEDLE..... | 95 | <i>methotrexate sodium</i> | 26 | <i>mometasone</i> | 76, 116 |
| MAYZENT..... | 68 | <i>methotrexate sodium (pf)</i> .. | 26 | MONOJECT INSULIN SAFETY SYRINGE | 96 |
| MAYZENT STARTER(FOR 1MG MAINT) | 68 | <i>methoxsalen</i> | 74 | MONOJECT INSULIN SYRINGE | 95, 96 |
| MAYZENT STARTER(FOR 2MG MAINT) | 68 | <i>methscopolamine</i> | 118 | MONOJECT SYRINGE | 95 |
| <i>meclizine</i> | 44 | <i>methsuximide</i> | 31 | MONOJECT ULTRA COMFORT INSULIN ... | 108 |
| <i>medroxyprogesterone</i> | 123 | <i>methylphenidate hcl</i> | 68, 69 | <i>montelukast</i> | 138 |
| <i>mefenamic acid</i> | 15 | <i>methylprednisolone</i> | 122 | <i>morphine</i> | 13 |
| <i>mefloquine</i> | 45 | <i>metoclopramide hcl</i> | 118 | MORPHINE..... | 13 |
| <i>megestrol</i> | 26, 123 | <i>metolazone</i> | 63 | <i>morphine concentrate</i> | 13 |
| MEKINIST | 26 | <i>metoprolol succinate</i> | 61 | MOUNJARO..... | 37 |
| MEKTOVI..... | 26 | <i>metoprolol ta-</i> <i>hydrochlorothiaz</i> | 61 | MOVANTIK | 118 |
| <i>meloxicam</i> | 15 | <i>metoprolol tartrate</i> | 61 | <i>moxifloxacin</i> | 21, 114 |
| <i>memantine</i> | 33 | <i>metronidazole</i> | 18, 42, 74 | <i>moxifloxacin-sod.ace,sul-</i> <i>water</i> | 21 |
| MENACTRA (PF)..... | 130 | <i>metronidazole in nacl (iso-os)</i> | 18 | <i>moxifloxacin-sod.chloride(iso)</i> | 21 |
| MENQUADFI (PF)..... | 130 | <i>metyrosine</i> | 62 | MRESVIA (PF) | 130 |
| | | <i>mexiletine</i> | 60 | MULTAQ | 60 |
| | | <i>miconazole-3</i> | 41 | <i>mupirocin</i> | 74 |
| | | MICRODOT INSULIN PEN NEEDLE | 95 | <i>mycophenolate mofetil</i> ... | 127 |
| | | MICRODOT READYGARD PEN NEEDLE..... | 95 | <i>mycophenolate sodium</i> ... | 127 |
| | | <i>microgestin fe 1/20 (28)</i> | 71 | <i>mynatal</i> | 143 |
| | | <i>midodrine</i> | 58 | <i>mynatal advance</i> | 143 |
| | | <i>mifepristone</i> | 37 | <i>mynatal plus</i> | 143 |
| | | <i>miglitol</i> | 37 | <i>mynatal-z</i> | 143 |
| | | <i>miglustat</i> | 112 | <i>mynate 90 plus</i> | 143 |
| | | <i>mili</i> | 71 | MYRBETRIQ..... | 119 |

| | | |
|------------------------------------|--------|--|
| N | | |
| <i>nabumetone</i> | 15 | NINLARO |
| <i>nadolol</i> | 61 | <i>nitazoxanide</i> |
| <i>nafcillin</i> | 20 | <i>nitisinone</i> |
| <i>naloxone</i> | 16 | <i>nitrofurantoin macrocrystal</i> |
| <i>naltrexone</i> | 16 | <i>nitrofurantoin monohyd/m-</i> |
| NAMZARIC | 33, 34 | <i>cryst</i> |
| <i>naproxen</i> | 15 | <i>nitroglycerin</i> |
| <i>naratriptan</i> | 43 | <i>niva-plus</i> |
| NATACYN | 114 | NIVESTYM |
| <i>nateglinide</i> | 37 | <i>nizatidine</i> |
| NAYZILAM | 31 | NORDITROPIN FLEXPRO |
| <i>nebivolol</i> | 61 | |
| <i>necon 0.5/35 (28)</i> | 71 | |
| <i>nefazodone</i> | 35 | <i>norethindrone (contraceptive)</i> |
| <i>neomycin</i> | 17 | |
| <i>neomycin-bacitracin-poly-hc</i> | | <i>norethindrone acetate</i> |
| | 114 | |
| <i>neomycin-bacitracin-</i> | | <i>norethindrone ac-eth</i> |
| <i>polymyxin</i> | 114 | <i>estradiol</i> |
| <i>neomycin-polymyxin b-</i> | | <i>norethindrone-e.estradiol-iron</i> |
| <i>dexameth</i> | 114 | |
| <i>neomycin-polymyxin-</i> | | <i>norgestimate-ethinyl estradiol</i> |
| <i>gramicidin</i> | 114 | |
| <i>neomycin-polymyxin-hc</i> | 114 | <i>nortrel 0.5/35 (28)</i> |
| <i>neo-polycin</i> | 114 | <i>nortrel 1/35 (21)</i> |
| <i>neo-polycin hc</i> | 114 | <i>nortrel 1/35 (28)</i> |
| NERLYNX | 26 | <i>nortrel 7/7/7 (28)</i> |
| NEULASTA | 56 | <i>nortriptyline</i> |
| NEUPRO | 46 | NORVIR |
| <i>nevirapine</i> | 52 | NOVOFINE 30 |
| <i>newgen</i> | 143 | NOVOFINE 32 |
| NEXLETOL | 65 | NOVOFINE PLUS |
| NEXLIZET | 65 | NOVOLIN 70/30 U-100 |
| NEXPLANON | 71 | INSULIN |
| <i>niacin</i> | 65 | NOVOLIN 70-30 FLEXPEN |
| <i>niacor</i> | 65 | U-100 |
| <i>nicardipine</i> | 63 | NOVOLIN N FLEXPEN |
| NICOTROL | 16 | NOVOLIN N NPH U-100 |
| <i>nifedipine</i> | 63 | INSULIN |
| <i>nikki (28)</i> | 71 | NOVOLIN R FLEXPEN |
| <i>nilutamide</i> | 26 | NOVOLIN R REGULAR |
| | | U100 INSULIN |
| | | NOVOTWIST |
| | | NOXAFIL |
| | | |
| | | NUBEQA |
| | | NUCALA |
| | | NUPLAZID |
| | | NURTEC ODT |
| | | NUTRILIPID |
| | | <i>nyamyc</i> |
| | | <i>nylia 1/35 (28)</i> |
| | | <i>nylia 7/7/7 (28)</i> |
| | | <i>nymyo</i> |
| | | <i>nystatin</i> |
| | | <i>nystatin-triamcinolone</i> |
| | | <i>nystop</i> |
| | | NYVEPRIA |
| | | O |
| | | <i>obstetrix dha</i> |
| | | <i>obstetrix dha prenatal duo</i> |
| | | |
| | | <i>o-cal prenatal</i> |
| | | OCTAGAM |
| | | <i>octreotide acetate</i> |
| | | ODEFSEY |
| | | ODOMZO |
| | | OFEV |
| | | <i>ofloxacin</i> |
| | | OGSIVEO |
| | | OJEMDA |
| | | OJJAARA |
| | | <i>olanzapine</i> |
| | | <i>olmesartan</i> |
| | | <i>olmesartan-amlodipin-</i> |
| | | <i>hcthiazid</i> |
| | | <i>olmesartan-</i> |
| | | <i>hydrochlorothiazide</i> |
| | | <i>olopatadine</i> |
| | | <i>omega-3 acid ethyl esters</i> |
| | | <i>omeprazole</i> |
| | | <i>omeprazole-sodium</i> |
| | | <i>bicarbonate</i> |
| | | OMNIPOD 5 G6-G7 INTRO |
| | | KT(GEN5) |
| | | OMNIPOD 5 G6-G7 PODS |
| | | (GEN 5) |

| | | | | | |
|---|-----|---|------------|---|----------|
| OMNIPOD CLASSIC PODS (GEN 3) | 96 | PEN NEEDLE | 90, 97, 99 | <i>pnv-omega</i> | 143 |
| OMNIPOD DASH INTRO KIT (GEN 4) | 97 | PEN NEEDLE, DIABETIC 83, 95, 97, 99 | | <i>podofilox</i> | 74 |
| OMNIPOD DASH PDM KIT (GEN 4) | 97 | PEN NEEDLE, DIABETIC, SAFETY | 99 | <i>polycin</i> | 114 |
| OMNIPOD DASH PODS (GEN 4) | 97 | PENBRAYA (PF) | 131 | <i>polymyxin b sulfate</i> | 18 |
| <i>ondansetron</i> | 44 | <i>perciclovir</i> | 74 | <i>polymyxin b sulf-trimethoprim</i> | 114 |
| <i>ondansetron hcl</i> | 44 | <i>penicillamine</i> | 120 | POMALYST | 27 |
| ONUREG | 27 | <i>penicillin g potassium</i> | 20 | <i>portia 28</i> | 72 |
| OPSUMIT | 142 | <i>penicillin v potassium</i> | 21 | <i>posaconazole</i> | 41 |
| ORENCIA | 127 | PENTACEL (PF) | 131 | <i>potassium chloride</i> | 137 |
| ORENCIA CLICKJECT ... | 127 | <i>pentamidine</i> | 45 | <i>potassium chloride-0.45 %</i> <i>nacl</i> | 137 |
| ORGOVYX | 123 | PENTIPS PEN NEEDLE ... | 97 | <i>potassium citrate</i> | 137 |
| ORLISSA | 123 | <i>pentoxifylline</i> | 57 | <i>pr natal 400</i> | 143 |
| ORKAMBI | 140 | <i>perindopril erbumine</i> | 60 | <i>pr natal 400 ec</i> | 143 |
| ORSERDU | 27 | <i>perio gard</i> | 73 | <i>pr natal 430</i> | 143 |
| <i>oseltamivir</i> | 53 | <i>permethrin</i> | 77 | <i>pr natal 430 ec</i> | 143 |
| OTEZLA | 127 | <i>perphenazine</i> | 49 | <i>pramipexole</i> | 46 |
| OTEZLA STARTER | 127 | <i>perphenazine-amitriptyline</i> | 35 | <i>prasugrel hcl</i> | 57 |
| <i>oxazepam</i> | 17 | PERSERIS | 49 | <i>pravastatin</i> | 65 |
| <i>oxcarbazepine</i> | 31 | <i>phenelzine</i> | 35 | <i>praziquantel</i> | 45 |
| <i>oxybutynin chloride</i> | 119 | <i>phenobarbital</i> | 32 | <i>prazosin</i> | 58 |
| <i>oxycodone</i> | 13 | PHENYTEK | 32 | PRED FORTE | 116 |
| <i>oxycodone-acetaminophen</i> | 13 | <i>phenytoin</i> | 32 | <i>prednisolone</i> | 122 |
| <i>oxymorphone</i> | 13 | <i>phenytoin sodium extended</i> | 32 | <i>prednisolone acetate</i> | 116 |
| OZEMPIC | 37 | PIFELTRO | 52 | <i>prednisolone sodium</i> <i>phosphate</i> | 116, 122 |
| P | | <i>pilocarpine hcl</i> | 73, 136 | <i>prednisone</i> | 122 |
| <i>pacerone</i> | 60 | <i>pimecrolimus</i> | 76 | PREDNISONE INTENSOL | 122 |
| <i>paliperidone</i> | 49 | <i>pimozide</i> | 49 | <i>pregabalin</i> | 32 |
| PANRETIN | 74 | <i>pimtrea (28)</i> | 72 | PREHEVBRIO (PF) | 131 |
| <i>pantoprazole</i> | 117 | <i>pindolol</i> | 61 | PREMARIN | 121 |
| <i>paricalcitol</i> | 133 | <i>pioglitazone</i> | 37 | PREMPHASE | 121 |
| <i>paroxetine hcl</i> | 35 | <i>pioglitazone-metformin</i> | 37 | PREMPRO | 121 |
| PAXLOVID | 53 | PIP PEN NEEDLE | 97 | <i>prena1 true</i> | 143 |
| <i>pazopanib</i> | 27 | <i>piperacillin-tazobactam</i> | 21 | <i>prenaissance</i> | 143 |
| PEDIARIX (PF) | 130 | PIQRAY | 27 | <i>prenaissance plus</i> | 143 |
| PEDVAX HIB (PF) | 130 | <i>pirfenidone</i> | 140 | <i>prenatabs fa</i> | 143 |
| PEGASYS | 54 | <i>piroxicam</i> | 15 | <i>prenatal 19</i> | 143 |
| <i>peg-electrolyte soln</i> | 118 | <i>pitavastatin calcium</i> | 65 | <i>prenatal 19 (with docusate)</i> | 143 |
| PEMAZYRE | 27 | <i>pnv 29-1</i> | 143 | <i>pnv-dha + docusate</i> | 143 |

| | | | | | |
|--|--------|---|--------|------------------------------------|----------|
| <i>prenatal low iron</i> | 143 | <i>promethegan</i> | 44 | RELENZA DISKHALER | 53 |
| <i>prenatal plus</i> | 143 | <i>propafenone</i> | 60 | RELISTOR | 118 |
| <i>prenatal plus (calcium carb)</i> | 143 | <i>propranolol</i> | 61 | <i>repaglinide</i> | 37 |
| <i>prenatal vitamin plus low iron</i> | 143 | <i>propylthiouracil</i> | 124 | REPATHA PUSHTRONEX | 65 |
| <i>prenatal-u</i> | 144 | PROQUAD (PF)..... | 131 | REPATHA SURECLICK.... | 65 |
| <i>preplus</i> | 144 | PROSOL 20 % | 58 | REPATHA SYRINGE | 65 |
| <i>pretab</i> | 144 | <i>protriptyline</i> | 35 | RETACRIT | 56 |
| PRETOMANID | 44 | PULMOZYME | 112 | RETEVMO | 27 |
| <i>prevalite</i> | 65 | PURE COMFORT ALCOHOL PADS..... | 98 | REVCОВI | 113 |
| PREVENT DROPSAFE PEN NEEDLE | 98 | PURE COMFORT PEN NEEDLE | 98, 99 | REVUFORJ..... | 27 |
| PREVYMIS..... | 53 | PURE COMFORT SAFETY PEN NEEDLE..... | 98 | REXULTI..... | 49 |
| PREZCOBIX | 52 | PURIXAN | 27 | REYATAZ..... | 52 |
| PREZISTA..... | 52 | <i>pyrazinamide</i> | 44 | REZLIDHIA | 27 |
| PRIFTIN | 44 | <i>pyridostigmine bromide</i> ... | 135 | REZUROCK | 128 |
| PRIMAQUINE | 45 | <i>pyrimethamine</i> | 45 | RHOPRESSA..... | 136 |
| <i>primidone</i> | 32 | Q | | <i>ribavirin</i> | 54 |
| PRIORIX (PF) | 131 | QINLOCK..... | 27 | RIDAURA | 128 |
| PRIVIGEN..... | 128 | QUADRACEL (PF)..... | 131 | <i>rifabutin</i> | 44 |
| PRO COMFORT ALCOHOL PADS..... | 98 | <i>quetiapine</i> | 49 | <i>rifampin</i> | 44 |
| PRO COMFORT INSULIN SYRINGE | 98 | <i>quinapril</i> | 60 | <i>riluzole</i> | 69 |
| PRO COMFORT PEN NEEDLE | 98 | <i>quinapril-hydrochlorothiazide</i> | 60 | <i>rimantadine</i> | 53 |
| PROAIR RESPICLICK | 139 | <i>quinidine gluconate</i> | 60 | RINVOQ | 128 |
| <i>probenecid</i> | 42 | <i>quinidine sulfate</i> | 60 | RINVOQ LQ | 128 |
| <i>probenecid-colchicine</i> | 42 | <i>quinine sulfate</i> | 45 | <i>risedronate</i> | 133, 134 |
| <i>prochlorperazine</i> | 44 | QULIPTA..... | 43 | <i>risperidone</i> | 49 |
| <i>prochlorperazine maleate</i> .. | 44 | R | | <i>ritonavir</i> | 52 |
| <i>proctosol hc</i> | 76 | RABAVERT (PF)..... | 131 | <i>rivastigmine</i> | 34 |
| <i>proctozone-hc</i> | 76 | <i>rabeprazole</i> | 117 | <i>rivastigmine tartrate</i> | 34 |
| PRODIGY INSULIN SYRINGE | 98 | RADICAVA ORS STARTER KIT SUSP | 69 | <i>rizatriptan</i> | 43 |
| <i>progesterone micronized</i> .. | 123 | <i>raloxifene</i> | 121 | <i>r-natal ob</i> | 144 |
| PROGRAF | 128 | <i>ramipril</i> | 60 | ROCKLATAN | 136 |
| PROLASTIN-C | 140 | <i>ranolazine</i> | 62 | <i>roflumilast</i> | 141 |
| PROLIA..... | 133 | <i>rasagiline</i> | 46 | <i>ropinirole</i> | 46 |
| PROMACTA..... | 56 | RAYALDEE | 133 | <i>rosuvastatin</i> | 65 |
| <i>promethazine</i> | 42, 44 | <i>reclipsen (28)</i> | 72 | ROTARIX | 131 |
| | | RECOMBIVAX HB (PF) .. | 131 | ROTATEQ VACCINE | 131 |
| | | REGRANEX..... | 74 | ROZLYTREK..... | 27 |
| | | | | RUBRACA..... | 27 |
| | | | | <i>rufinamide</i> | 32 |
| | | | | RUKOBIA..... | 52 |
| | | | | RYBELSUS | 37 |
| | | | | RYDAPT..... | 27 |

| | | | | | |
|---------------------------------------|-----|-------------------------------------|-----|------------------------------------|----------|
| RYTARY..... | 46 | <i>simvastatin</i> | 65 | <i>sulfacetamide sodium</i> | 114, |
| S | | <i>sirolimus</i> | 128 | 115 | |
| SAFESNAP INSULIN | | SIRTURO | 44 | <i>sulfacetamide sodium (acne)</i> | |
| SYRINGE | 99 | SKY SAFETY PEN NEEDLE | | | 75 |
| SAFETY PEN NEEDLE | 99 | | 100 | <i>sulfacetamide-prednisolone</i> | |
| <i>sajazir</i> | 62 | SKYRIZI | 128 | | 115 |
| SANTYL | 74 | <i>sodium chloride 0.45 %</i> ... | 137 | <i>sulfadiazine</i> | 21 |
| <i>sapropterin</i> | 113 | <i>sodium chloride 0.9 %</i> | 137 | <i>sulfamethoxazole-</i> | |
| SAVELLA | 69 | <i>sodium oxybate</i> | 141 | <i>trimethoprim</i> | 21 |
| SCEMBLIX..... | 27 | <i>sodium phenylbutyrate</i> | 118 | <i>sulfasalazine</i> | 133 |
| <i>scopolamine base</i> | 44 | <i>sodium polystyrene sulfonate</i> | | <i>sulindac</i> | 15 |
| SECUADO | 49 | | 118 | <i>sumatriptan</i> | 43 |
| SECURESAFE INSULIN | | <i>sodium,potassium,mag</i> | | <i>sumatriptan succinate</i> | 43 |
| SYRINGE | 100 | <i>sulfates</i> | 119 | <i>sumatriptan-naproxen</i> | 43 |
| SECURESAFE PEN | | <i>sofosbuvir-velpatasvir</i> | 54 | <i>sunitinib malate</i> | 28 |
| NEEDLE | 100 | <i>solifenacin</i> | 119 | SUNLENCA..... | 52 |
| <i>select-ob</i> | 144 | SOLQUA 100/33 | 39 | SURE COMFORT ALCOHOL | |
| <i>select-ob (folic acid)</i> | 144 | SOLTAMOX | 27 | PREP PADS | 100 |
| <i>selegiline hcl</i> | 46 | SOMAVERT | 123 | SURE COMFORT INS. SYR. | |
| <i>selenium sulfide</i> | 74 | <i>sorafenib</i> | 27 | U-100..... | 100 |
| SELZENTRY | 52 | <i>sorine</i> | 61 | SURE COMFORT INSULIN | |
| SEMGLEE(INSULIN | | <i>sotalol</i> | 61 | SYRINGE | 100, 101 |
| GLARGINE-YFGN)..... | 39 | <i>sotalol af</i> | 61 | SURE COMFORT PEN | |
| SEMGLEE(INSULIN | | SPIRIVA RESPIMAT | 139 | NEEDLE | 100, 101 |
| GLARG-YFGN)PEN | 39 | <i>spironolactone</i> | 63 | SURE COMFORT SAFETY | |
| <i>se-natal 19 chewable</i> | 144 | <i>spironolacton-</i> | | PEN NEEDLE..... | 100 |
| SEREVENT DISKUS | 139 | <i>hydrochlorothiaz</i> | 64 | SURE-FINE PEN NEEDLES | |
| SEROSTIM | 123 | <i>sprintec (28)</i> | 72 | | 101 |
| <i>sertraline</i> | 35 | SPRITAM | 32 | SURE-JECT INSULIN | |
| <i>setlakin</i> | 72 | SPRYCEL | 27 | SYRINGE | 101 |
| <i>sharobel</i> | 72 | <i>sps (with sorbitol)</i> | 118 | SURE-PREP ALCOHOL | |
| SHINGRIX (PF)..... | 131 | <i>sronyx</i> | 72 | PREP PADS | 101 |
| SIGNIFOR..... | 123 | <i>ssd</i> | 74 | SUTAB | 119 |
| <i>sildenafil</i> | 142 | STELARA..... | 128 | <i>syeda</i> | 72 |
| <i>sildenafil (pulm.hypertension)</i> | | STERILE PADS | 100 | SYMDEKO | 141 |
| | 142 | STIOLTO RESPIMAT..... | 139 | SYMPAZAN | 32 |
| <i>silodosin</i> | 119 | STIVARGA | 28 | SYMTUZA | 53 |
| <i>silver sulfadiazine</i> | 74 | <i>streptomycin</i> | 17 | SYNAREL | 123 |
| SIMBRINZA..... | 136 | STRIBILD | 52 | SYNJARDY | 37 |
| SIMLANDI(CF)..... | 128 | STRIVERDI RESPIMAT.. | 139 | SYNJARDY XR | 37 |
| SIMLANDI(CF) | | <i>subvenite</i> | 32 | SYNTHROID | 124 |
| AUTOINJECTOR..... | 128 | <i>sucralfate</i> | 117 | | |

| | | | | | |
|--|---------|---|----------|--|-----------|
| SYRINGE WITH NEEDLE, SAFETY..... | 100 | <i>tenofovir disoproxil fumarate</i> | 53 | <i>tobramycin-dexamethasone</i> | 115 |
| T | | TEPMETKO | 28 | <i>tolterodine</i> | 119 |
| TABLOID..... | 28 | <i>terazosin</i> | 119 | TOPCARE CLICKFINE ... | 103 |
| TABRECTA..... | 28 | <i>terbinafine hcl</i> | 41 | TOPCARE ULTRA COMFORT | 103 |
| <i>tacrolimus</i> | 76, 128 | <i>terbutaline</i> | 139 | <i>topiramate</i> | 32 |
| <i>tadalafil</i> | 142 | <i>terconazole</i> | 42 | <i>toremifene</i> | 28 |
| <i>tadalafil (pulm. hypertension)</i> | 142 | <i>teriflunomide</i> | 69 | <i>torpenz</i> | 28 |
| TAFINLAR..... | 28 | <i>teriparatide</i> | 134 | <i>torseamide</i> | 64 |
| <i>tafluprost (pf)</i> | 136 | TERUMO INSULIN SYRINGE | 102, 103 | TOUJEO MAX U-300 SOLOSTAR | 39 |
| TAGRISSE..... | 28 | <i>testosterone</i> | 120 | TOUJEO SOLOSTAR U-300 INSULIN | 39 |
| TAKHZYRO..... | 135 | <i>testosterone cypionate</i> ... | 120 | TPN ELECTROLYTES ... | 137 |
| TALZENNA | 28 | <i>testosterone enanthate</i> | 120 | TRADJENTA | 37 |
| <i>tamoxifen</i> | 28 | TETANUS,DIPHThERIA TOX PED(PF)..... | 132 | <i>tramadol</i> | 13 |
| <i>tamsulosin</i> | 119 | <i>tetrabenazine</i> | 69 | <i>tramadol-acetaminophen</i> ... | 13 |
| <i>tarina 24 fe</i> | 72 | <i>tetracycline</i> | 22 | <i>trandolapril</i> | 60 |
| <i>tarina fe 1-20 eq (28)</i> | 72 | THALOMID..... | 135 | <i>trandolapril-verapamil</i> | 60 |
| <i>taron-c dha</i> | 144 | <i>theophylline</i> | 139, 140 | <i>tranexamic acid</i> | 57 |
| <i>taron-prex prenatal-dha</i> ... | 144 | THINPRO INSULIN SYRINGE | 103 | <i>tranylcyromine</i> | 35 |
| TASIGNA | 28 | <i>thioridazine</i> | 49 | TRAVASOL 10 % | 58 |
| <i>tasimelteon</i> | 141 | <i>thiothixene</i> | 50 | <i>travoprost</i> | 136 |
| TAVNEOS | 128 | <i>tiadylt er</i> | 62 | <i>trazodone</i> | 36 |
| <i>tazarotene</i> | 77 | <i>tiagabine</i> | 32 | TRECATOR | 44 |
| TAZORAC | 77 | TIBSOVO | 28 | TRELEGY ELLIPTA | 140 |
| TAZVERIK..... | 28 | TICOVAC | 132 | TRELSTAR | 28 |
| TDVAX | 131 | <i>tigecycline</i> | 22 | TREMFYA..... | 128 |
| TECHLITE INSULIN SYRINGE | 102 | <i>timolol maleate</i> | 61, 136 | TREMFYA PEN..... | 128 |
| TECHLITE INSULN SYR(HALF UNIT) 101, 102 | | <i>tinidazole</i> | 45 | <i>tretinoin</i> | 77 |
| TECHLITE PEN NEEDLE 102 | | <i>tiopronin</i> | 120 | <i>tretinoin (antineoplastic)</i> ... | 28 |
| TECHLITE PLUS PEN NEEDLE | 102 | <i>tiotropium bromide</i> | 140 | <i>triamcinolone acetonide</i> ... | 73, 77 |
| TEFLARO..... | 19 | TIROSINT | 124 | <i>triamterene-</i> <i>hydrochlorothiazid</i> | 64 |
| <i>telmisartan</i> | 59 | TIROSINT-SOL | 124 | <i>triazolam</i> | 17 |
| <i>telmisartan-amlodipine</i> | 59 | TIVICAY | 53 | <i>trientine</i> | 120 |
| <i>telmisartan-</i> <i>hydrochlorothiazid</i> | 59 | TIVICAY PD | 53 | <i>tri-estarylla</i> | 72 |
| <i>temazepam</i> | 17 | <i>tizanidine</i> | 141 | <i>trifluoperazine</i> | 50 |
| TENIVAC (PF)..... | 131 | TOBI PODHALER | 17 | <i>trifluridine</i> | 115 |
| | | <i>tobramycin</i> | 115 | <i>trihexyphenidyl</i> | 46 |
| | | <i>tobramycin in 0.225 % nacl</i> | 17 | | |
| | | <i>tobramycin sulfate</i> | 17 | | |

| | | | | | |
|--------------------------------|---------------|-------------------------|------------------|---------------------------------------|----------|
| TRIJARDY XR..... | 38 | TWINRIX (PF)..... | 132 | ULTRACARE PEN NEEDLE | |
| TRIKAFTA..... | 141 | <i>tyblume</i> | 73 | | 109 |
| <i>tri-legest fe</i> | 72 | TYBOST..... | 135 | ULTRA-THIN II (SHORT) INS | |
| <i>tri-lo-estarylla</i> | 72 | TYMLOS | 134 | SYR | 109, 110 |
| <i>tri-lo-sprintec</i> | 72 | TYPHIM VI | 132 | ULTRA-THIN II (SHORT) | |
| <i>trimethoprim</i> | 18 | U | | PEN NDL | 110 |
| <i>tri-mili</i> | 72 | UBRELVY | 43 | ULTRA-THIN II INS PEN | |
| <i>trimipramine</i> | 36 | UDENYCA..... | 56 | NEEDLES | 110 |
| TRINTELLIX..... | 36 | UDENYCA AUTOINJECTOR | | ULTRA-THIN II INSULIN | |
| <i>tri-nymyo</i> | 73 | | 56 | SYRINGE | 109 |
| <i>tri-sprintec (28)</i> | 73 | ULTICARE | 106, 107 | UNIFINE PEN NEEDLE .. | 110 |
| TRIUMEQ..... | 53 | ULTICARE INSULIN | | UNIFINE PENTIPS.... | 97, 110 |
| TRIUMEQ PD..... | 53 | SYRINGE | 106 | UNIFINE PENTIPS | |
| <i>triveen-duo dha</i> | 144 | ULTICARE INSULN | | MAXFLOW | 110 |
| <i>trivora (28)</i> | 73 | SYR(HALF UNIT) | 106 | UNIFINE PENTIPS PLUS | 110 |
| <i>tri-vylibra</i> | 73 | ULTICARE PEN NEEDLE | | UNIFINE PENTIPS PLUS | |
| <i>tri-vylibra lo</i> | 73 | | 106 | MAXFLOW | 110 |
| TROPHAMINE 10 %..... | 58 | ULTICARE SAFETY PEN | | UNIFINE PROTECT | 110, 111 |
| <i>trospium</i> | 119 | NEEDLE | 106 | UNIFINE SAFECONTROL | |
| TRUE COMFORT ALCOHOL | | ULTIGUARD SAFEPACK- | | | 111 |
| PADS..... | 104 | INSULIN SYR | 107 | UNIFINE SAFECONTROL | |
| TRUE COMFORT INSULIN | | ULTIGUARD SAFEPACK- | | PEN NEEDLE | 111 |
| SYRINGE | 104 | PEN NEEDLE | 107 | UNIFINE ULTRA PEN | |
| TRUE COMFORT PEN | | ULTILET ALCOHOL SWAB | | NEEDLE | 111 |
| NEEDLE | 104 | | 107 | UPTRAVI..... | 142 |
| TRUE COMFORT PRO | | ULTILET INSULIN SYRINGE | | <i>ursodiol</i> | 118 |
| ALCOHOL PADS..... | 104 | | 92, 107 | UZEDY | 50 |
| TRUE COMFORT PRO INS | | ULTILET PEN NEEDLE .. | 107 | V | |
| SYRINGE ... | 103, 104, 105 | ULTRA CMFT INS SYR | | <i>valacyclovir</i> | 54 |
| TRUE COMFORT SAFE | | (HALF UNIT)..... | 91, 100 | VALCHLOR..... | 74 |
| INSULIN SYRG ... | 104, 105 | ULTRA COMFORT INSULIN | | <i>valganciclovir</i> | 54 |
| TRUE COMFORT SAFETY | | SYRINGE | 86, 91, 107, 108 | <i>valproic acid</i> | 32 |
| PEN NEEDLE..... | 103 | ULTRA FLO INSUL | | <i>valproic acid (as sodium salt)</i> | |
| TRUEPLUS INSULIN | 105 | SYR(HALF UNIT) | 108 | | 32 |
| TRUEPLUS PEN NEEDLE | | ULTRA FLO INSULIN | | <i>valsartan</i> | 59 |
| | 105 | SYRINGE | 108 | <i>valsartan-hydrochlorothiazide</i> | |
| TRULANCE..... | 118 | ULTRA FLO PEN NEEDLE | | | 59 |
| TRULICITY..... | 38 | | 108 | VALTOCO | 32 |
| TRUMENBA..... | 132 | ULTRA THIN PEN NEEDLE | | <i>vancomycin</i> | 18 |
| TRUQAP | 28 | | 108 | VANFLYTA..... | 28 |
| TUKYSA..... | 28 | ULTRACARE INSULIN | | VANISHPOINT INSULIN | |
| TURALIO..... | 28 | SYRINGE | 108, 109 | SYRINGE | 111 |

| | | |
|---------------------------------------|-------------------------------|--------------------------------------|
| VANISHPOINT SYRINGE | <i>vitafol gummies</i> | XOFLUZA |
| 111 | <i>vitafol nano</i> | 53 |
| VAQTA (PF)..... 132 | <i>vitafol-ob+dha</i> | XOLAIR..... 141 |
| <i>varenicline tartrate</i> 16 | VITRAKVI..... 29 | XOSPATA..... 29 |
| VARIVAX (PF)..... 132 | VIZIMPRO..... 29 | XPOVIO..... 29 |
| VAXCHORA VACCINE ... 132 | VONJO..... 29 | XTAMPZA ER..... 14 |
| <i>velivet triphasic regimen (28)</i> | VORANIGO..... 29 | XTANDI..... 29 |
| 73 | <i>voriconazole</i> 41 | <i>xulane</i> 73 |
| VELTASSA..... 118 | VOSEVI..... 54 | XULTOPHY 100/3.6..... 40 |
| VEMLIDY..... 53 | VOWST..... 135 | Y |
| VENCLEXTA..... 28 | <i>vp-ch-pnv</i> 144 | YF-VAX (PF)..... 132 |
| VENCLEXTA STARTING | <i>vp-pnv-dha</i> 144 | YONSA..... 29 |
| PACK..... 29 | VRAYLAR..... 50 | <i>yuvaferm</i> 121 |
| <i>venlafaxine</i> 36 | VUMERITY..... 69 | Z |
| <i>venlafaxine besylate</i> 36 | <i>vyfemla (28)</i> 73 | <i>zafemy</i> 73 |
| VEOZAH..... 135 | <i>vylibra</i> 73 | <i>zafirlukast</i> 138 |
| <i>verapamil</i> 62 | VYNDAMAX..... 62 | <i>zaleplon</i> 141 |
| VERIFINE INSULIN | VYZULTA..... 136 | ZARXIO..... 57 |
| SYRINGE..... 111, 112 | W | <i>zatean-pn dha</i> 144 |
| VERIFINE PEN NEEDLE 111, | <i>warfarin</i> 55 | <i>zatean-pn plus</i> 144 |
| 112 | WEBCOL..... 112 | ZEGALOGUE |
| VERIFINE PLUS PEN | WELIREG..... 29 | AUTOINJECTOR..... 135 |
| NEEDLE..... 112 | <i>wixela inhub</i> 138 | ZEGALOGUE SYRINGE..... 135 |
| VERIFINE PLUS PEN | X | ZEJULA..... 29 |
| NEEDLE-SHARP..... 112 | XALKORI..... 29 | ZELBORAF..... 29 |
| VERQUVO..... 62 | XARELTO..... 55 | <i>zenatane</i> 74 |
| VERSACLOZ..... 50 | XARELTO DVT-PE TREAT | ZENPEP..... 113 |
| VERSALON..... 112 | 30D START..... 55 | <i>zidovudine</i> 53 |
| VERZENIO..... 29 | XATMEP..... 29 | <i>zingiber</i> 144 |
| <i>vestura (28)</i> 73 | XCOPRI..... 33 | <i>ziprasidone hcl</i> 50 |
| <i>vienva</i> 73 | XCOPRI MAINTENANCE | <i>ziprasidone mesylate</i> 50 |
| <i>vigabatrin</i> 32, 33 | PACK..... 33 | ZIRGAN..... 115 |
| <i>vigadrone</i> 33 | XCOPRI TITRATION PACK | ZOLINZA..... 29 |
| VIGAFYDE..... 33 | 33 | <i>zolmitriptan</i> 43 |
| <i>vigpoder</i> 33 | XDEMVY..... 115 | <i>zolpidem</i> 142 |
| <i>vilazodone</i> 36 | XELJANZ..... 128, 129 | ZONISADE..... 33 |
| VIRACEPT..... 53 | XELJANZ XR..... 129 | <i>zonisamide</i> 33 |
| VIREAD..... 53 | XERMELO..... 118 | <i>zovia 1-35 (28)</i> 73 |
| <i>virt-c dha</i> 144 | XGEVA..... 134 | ZTALMY..... 33 |
| <i>virt-nate dha</i> 144 | XHANCE..... 116 | ZURZUVAE..... 36 |
| <i>virt-pn dha</i> 144 | XIFAXAN..... 18 | ZYDELIG..... 29 |
| <i>virt-pn plus</i> 144 | XIIDRA..... 116 | ZYKADIA..... 29 |
| | | ZYLET..... 115 |

ZYPREXA RELPREVV 50

Multi-Language Insert

Multi-language Interpreter Services

English: We have free interpreter services to answer any questions you may have about our health or drug plan. To get an interpreter, just call us at 1-844-969-5366. Someone who speaks English/Language can help you. This is a free service.

Spanish: Tenemos servicios de intérprete sin costo alguno para responder cualquier pregunta que pueda tener sobre nuestro plan de salud o medicamentos. Para hablar con un intérprete, por favor llame al 1-844-969-5366. Alguien que hable español le podrá ayudar. Este es un servicio gratuito.

Chinese Mandarin: 我们提供免费的翻译服务，帮助您解答关于健康或药物保险的任何疑问。如果您需要此翻译服务，请致电 1-844-969-5366。我们的中文工作人员很乐意帮助您。这是一项免费服务。

Chinese Cantonese: 您對我們的健康或藥物保險可能存有疑問，為此我們提供免費的翻譯服務。如需翻譯服務，請致電 1-844-969-5366。我們講中文的人員將樂意為您提供幫助。這是一項免費服務。

Tagalog: Mayroon kaming libreng serbisyo sa pagsasaling-wika upang masagot ang anumang mga katanungan ninyo hinggil sa aming planong pangkalusugan o panggamot. Upang makakuha ng tagasaling-wika, tawagan lamang kami sa 1-844-969-5366. Maaari kayong tulungan ng isang nakakapagsalita ng Tagalog. Ito ay libreng serbisyo.

French: Nous proposons des services gratuits d'interprétation pour répondre à toutes vos questions relatives à notre régime de santé ou d'assurance-médicaments. Pour accéder au service d'interprétation, il vous suffit de nous appeler au 1-844-969-5366. Un interlocuteur parlant Français pourra vous aider. Ce service est gratuit.

Vietnamese: Chúng tôi có dịch vụ thông dịch miễn phí để trả lời các câu hỏi về chương sức khỏe và chương trình thuốc men. Nếu quý vị cần thông dịch viên xin gọi 1-844-969-5366 sẽ có nhân viên nói tiếng Việt giúp đỡ quý vị. Đây là dịch vụ miễn phí.

German: Unser kostenloser Dolmetscherservice beantwortet Ihren Fragen zu unserem Gesundheits- und Arzneimittelplan. Unsere Dolmetscher erreichen Sie unter 1-844-969-5366. Man wird Ihnen dort auf Deutsch weiterhelfen. Dieser Service ist kostenlos.

Korean: 당사는 의료 보험 또는 약품 보험에 관한 질문에 대해 드리고자 무료 통역 서비스를 제공하고 있습니다. 통역 서비스를 이용하려면 전화 1-844-969-5366 번으로 문의해 주십시오. 한국어를 하는 담당자가 도와 드릴 것입니다. 이 서비스는 무료로 운영됩니다.

Russian: Если у вас возникнут вопросы относительно страхового или медикаментного плана, вы можете воспользоваться нашими бесплатными услугами переводчиков. Чтобы воспользоваться услугами переводчика, позвоните нам по телефону 1-844-969-5366. Вам окажет помощь сотрудник, который говорит по-русски. Данная услуга бесплатная.

Arabic: إننا نقدم خدمات المترجم الفوري المجانية للإجابة عن أي أسئلة تتعلق بالصحة أو جدول الأدوية لدينا. للحصول على مترجم فوري، ليس عليك سوى الاتصال بنا على 1-844-969-5366. سيقوم شخص ما يتحدث العربية بمساعدتك. هذه خدمة مجانية.

Hindi: हमारे स्वास्थ्य या दवा की योजना के बारे में आपके किसी भी प्रश्न के जवाब देने के लिए हमारे पास मुफ्त दुभाषिया सेवाएँ उपलब्ध हैं। एक दुभाषिया प्राप्त करने के लिए, बस हमें 1-844-969-5366 पर फोन करें। कोई व्यक्ति जो हिन्दी बोलता है आपकी मदद कर सकता है। यह एक मुफ्त सेवा है।

Italian: È disponibile un servizio di interpretariato gratuito per rispondere a eventuali domande sul nostro piano sanitario e farmaceutico. Per un interprete, contattare il numero 1-844-969-5366. Un nostro incaricato che parla Italianovi fornirà l'assistenza necessaria. È un servizio gratuito.

Portuguese: Dispomos de serviços de interpretação gratuitos para responder a qualquer questão que tenha acerca do nosso plano de saúde ou de medicação. Para obter um intérprete, contacte-nos através do número 1-844-969-5366. Irá encontrar alguém que fale o idioma Português para o ajudar. Este serviço é gratuito.

French Creole: Nou genyen sèvis entèprèt gratis pou reponn tout kesyon ou ta genyen konsènan plan medikal oswa dwòg nou an. Pou jwenn yon entèprèt, jis rele nou nan 1-844-969-5366. Yon moun ki pale Kreyòl kapab ede w. Sa a se yon sèvis ki gratis.

Polish: Umożliwiamy bezpłatne skorzystanie z usług tłumacza ustnego, który pomoże w uzyskaniu odpowiedzi na temat planu zdrowotnego lub dawkowania leków. Aby skorzystać z pomocy tłumacza znającego język polski, należy zadzwonić pod numer 1-844-969-5366. Ta usługa jest bezpłatna.

Japanese: 当社の健康 健康保険と薬品 処方薬プランに関するご質問にお答えするために、無料の通訳サービスがあります。通訳をご用命になるには、1-844-969-5366 にお電話ください。日本語を話す人者が支援いたします。これは無料のサービスです。